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Abstract 
Many intricate networks are required to work together to regulate two defining characteristics 
of human pluripotent stem cells (hPSCs): the capacity to self-renew, and the potential to 
produce (through differentiation processes) any cell type of the body. The discovery of PSCs 
has provided an invaluable tool for investigating fundamental aspects of developmental 
biology, drug discovery, disease modelling, and tissue-replacement therapies. Master 
regulators of pluripotency have been identified in PSCs including OCT4, NANOG, and 
SOX2. However, the molecular events that drive self-renewal and differentiation currently are 
not completely understood. Previous results from our group identified the retinoblastoma 
(RB)-binding protein 9 (RBBP9) as a novel pluripotency regulator. Small interfering RNA 
(siRNA)-mediated loss of RBBP9 protein in hPSCs decreased expression of pluripotency and 
cell cycle genes, and increased expression of neurogenesis genes. RBBP9 is reported to have 
two potential mechanisms of action: the ability to i) bind RB protein and influence the 
RB/E2F pathway, and ii) serine hydrolase (SH) activity. To investigate the relative 
contribution of these two activities to hPSC maintenance and embryonic development in vitro 
and in vivo, we compared the responses of hPSCs and zebrafish treated with a recently 
identified selective chemical inhibitor of RBBP9 SH activity (ML114), to those treated with 
either RBBP9 siRNA or rbbp9 morpholino. 
 Data presented in this thesis show the requirement of RBBP9, including RBBP9 SH 
activity, in hPSC maintenance in vitro, and possibly its requirement in early embryogenesis in 
vivo. In Chapter 2, selective loss of RBBP9 SH activity was investigated in hPSCs via 
ML114. This treatment resulted in the decoupling of hPSC self-renewal from differentiation, 
xxii 
 
as seen by a significant reduction in hPSC proliferation without any observable decrease in 
pluripotency marker expression or morphological change. Chapter 3 then investigated 
effectors which could potentially be responsible for this unusual decoupling effect. Promoter 
analyses identified the Nuclear transcription factor Y subunit A (NFYA) as a highly-ranked 
candidate effector of RBBP9 SH activity through analyses of gene expression changes arising 
from ML114 treatment of hPSCs. The up-regulation of NFYA was hypothesised to mediate 
the changes in cell proliferation seen whilst maintaining pluripotency in hPSCs. Chapter 4 
began to explore the impacts of RBBP9 and its activities in vivo. Rbbp9 is expressed in a 
large range of zebrafish tissues, and the data presented here is consistent with the idea that 
Rbbp9 and its activities are required for zebrafish embryogenesis. However, the complexity of 
the observed phenotypes suggests that toxicity might be an alternate explanation of the data. 
Further investigation into the role of RBBP9 activities during hPSC generation, 
maintenance and differentiation, as well as the early stages of embryonic development, is 
required to better understand the mechanisms behind developmental abnormalities resulting 
from Rbbp9 losses. A better understanding of RBBP9 activities and its role throughout 
embryonic development in vitro and in vivo will help us better understand the molecular 
networks required to: maintain hPSCs; generate hPSCs via somatic reprograming; and also 
drive or facilitate normal embryogenesis and cancer progression. 
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CHAPTER 1: General Introduction 
  
2 
 
1.1. Retinoblastoma-binding protein 9: a putative regulator of 
pluripotency. 
The retinoblastoma (RB) binding protein 9 (RBBP9) has been shown to be expressed in 
human pluripotent stem cells (hPSCs), and in a large number of cells throughout embryonic 
development such as the eye, heart, brain and digestive tract (Bastian et al., 2008). RBBP9 
has also been found expressed in a range of human cancer cells (Shields et al., 2010, Woitach 
et al., 1998). Despite its broad expression, little is known of the roles RBBP9 plays in normal 
development or cancer progression. The few published studies of RBBP9 suggest it might 
control cell cycle progression either by regulating the activity of RB protein (which itself 
regulates E2F transcription factors whose activity is critical for cell proliferation) (Woitach et 
al., 1998) or by acting as a serine hydrolase (SH) (Shields et al., 2010) on as yet undefined 
target proteins. 
In a study aimed at better understanding the molecular circuitry of hPSC maintenance, 
O’Connor and colleagues (2011) identified RBBP9 as a novel pluripotency regulator. This 
study showed small interfering RNA (siRNA)-mediated loss of RBBP9 expression in hPSCs 
resulted in a specific loss of pluripotent cells (as detected by the colony forming cell assay), 
decreased FOXD3 expression, decreased cell cycle gene expression, and increased expression 
of neural differentiation genes. These data suggested that RBBP9 plays a role in maintaining 
molecular networks required for pluripotency. However, decreased RBBP9 protein expression 
in this study via siRNA did not enable determination of the relative contribution of RB-
binding activity and/or SH activity to hPSC maintenance. More detailed analysis of the role of 
RBBP9 in hPSCs and during development could provide important information on how 
3 
 
pluripotent cells are generated/maintained, and how normal development and cancers 
progress. 
1.2. Models of embryonic development. 
1.2.1. Human pluripotent stem cells. 
The discovery of PSCs has unlocked a new generation of cells which possess unique 
properties such as the ability to self-renew indefinitely, and to differentiate into all cells of the 
body (Martin, 1981, Thomson et al., 1998). These properties, unique to PSCs such as human 
embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) amongst 
others, have made these cells an invaluable tool for investigating fundamental aspects of 
developmental biology, drug discovery, disease modelling and cell therapies (Park et al., 
2008, Takahashi et al., 2007b, Yu et al., 2007, Reubinoff et al., 2000, Thomson et al., 1998) 
(Figure 1.1). hESCs share similarities with mouse embryonic stem cells (mESCs), however 
differences between these two embryonic cell types are known to exist (Hanna et al., 2010). It 
has been shown that hESCs are more equivalent to mouse epiblast stem cells, which 
represents a later stage of development than mESCs (Tesar et al., 2007). By expanding our 
understanding of the molecular events that drive self-renewal and differentiation, including 
the molecular networks regulated by RBBP9, it is anticipated that the potential benefits 
offered by hPSCs will become closer to reality.  
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Figure 1.1 The origin and cell fate of hESCs. hESCs are obtained from the ICM of surplus 
IVF blastocysts, and hiPSCs are obtained from reprogrammed somatic cells. Once hPSC lines 
are generated they can be maintained in culture for long periods, or differentiated into cell 
types derived from the endoderm, mesoderm, and ectoderm. hPSCs open doors for drug 
discovery, cell replacement therapies, and investigations into disease mechanisms. Adapted 
from (Irion et al., 2008). 
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1.2.1.1. Origin of hESCs.  
hESCs are derived from the inner cell mass (ICM) obtained from pre-implantation human 
blastocysts approximately 6-7 days post fertilisation (Mitalipova et al., 2003, Reubinoff et al., 
2000, Thomson et al., 1998). Blastocysts are composed of two cell types which are 
responsible for different cell fates. The outer layer of the blastocyst consists of: i) the 
trophoectoderm layer which is essential for generating the placenta and extra-embryonic yolk 
sac; and ii) the ICM (Fleming, 1987, Gardner and Rossant, 1979, Adjaye et al., 2005). For 
hESC derivation, the trophoectoderm layer is typically removed from surplus blastocysts 
donated from IVF programs after informed consent (Cowan et al., 2004, Heins et al., 2004). 
The ICM is then placed in cell culture and propagated. With appropriate conditions, the cells 
that grow out into the culture dish can be maintained in an undifferentiated state in long term 
cultures (Thomson et al., 1998, Amit et al., 2000, Ludwig et al., 2006), or be induced to 
follow differentiation programs that appear to mimic aspects of normal embryonic 
development (Schuldiner et al., 2000). Examples of differentiated cells that can be generated 
include derivatives of: i) the endoderm, such as the stomach lining, gastrointestinal tract, and 
epithelium and glands of the lungs; ii) the mesoderm, such as muscle, bone, and blood; and 
iii) ectodermal derivatives, such as epidermal and neural tissues (Thomson et al., 1998, 
Shamblott et al., 1998, Amit et al., 2000, Itskovitz-Eldor et al., 2000, Heins et al., 2004). The 
capacity of hPSCs to self-renew and differentiate into any cell type has been correlated with 
specific phenotypic and/or functional markers that have been shown to provide reliable assays 
for pluripotency. These assays include detection of alkaline phosphatase (AP) activity, 
assessment of ‘pluripotency antigen’ expression such as the stage specific embryonic antigens 
as well asTRA-1-60 and TRA-1-81 (O'Connor et al., 2008, Lensch et al., 2007, Thomson et 
al., 1995, Draper et al., 2002), and also teratoma formation.  
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1.2.1.2 Core regulatory factors controlling pluripotency in hESCs.  
The regulation of self-renewal within hPSCs is inadequately understood at present. Current 
knowledge suggests that certain transcription factors act as molecular switches to either 
activate or repress specific gene expression programs which ultimately determine the overall 
fate of each cell. The transcription factors OCT4 (i.e., POU5F1), NANOG, and SOX2 are 
amongst the most highly studied pluripotency factors and have been shown to be key 
regulators of hPSC maintenance (Boyer et al., 2005, Loh et al., 2006, Masui et al., 2007, 
Niwa et al., 2000, Rodda et al., 2005, Xu et al., 2008). 
 
1.2.1.2.1. OCT4. 
The homeodomain protein OCT4 is a transcription factor encoded by the gene POU5F1 
(Boyer et al., 2005, Niwa et al., 2000, Rodda et al., 2005, Xu et al., 2008). Studies in mESCs 
have shown that imbalanced expression of Oct4 results in differentiation of mESCs and 
hESCs into different cell lineages (Hay et al., 2004, Hough et al., 2006, Nichols et al., 1998, 
Niwa et al., 1998). Decreased Oct4 expression results in the failure to maintain pluripotency 
and has been shown to stimulate differentiation into trophoectoderm and endoderm lineages 
(Hay et al., 2004, Nichols et al., 1998). Interestingly, over-expression of Oct4 can initiate 
differentiation into primitive mesoderm and ectoderm in mESCs (Niwa et al., 2000) (Figure 
1.2). In hESCs increased expression of OCT4 in hESCs results in differentiation towards 
endodermal and mesodermal lineages, whereas decreased expression results in endodermal 
differentiation (Rodriguez et al., 2007). Together, these studies demonstrate a requirement for 
tight regulation of OCT4 expression levels within a specific range in order to maintain 
pluripotency, indicating that OCT4 is a master regulator of pluripotency.  
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Figure 1.2 Relative expression levels of Oct4 control the pluripotent state.  High levels of 
Oct4 expression induce ESC differentiation into primitive endoderm and mesoderm. Low 
levels of Oct4 expression induce formation of trophoectoderm. Controlled levels of Oct4 
expression between these two extremes allow the cell to remain pluripotent (Niwa et al., 
2000). 
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1.2.1.2.2. NANOG.  
Another highly studied regulator of pluripotency is Nanog, a member of the homeobox family 
of DNA binding factors. Nanog has been shown to play a key role in the maintenance of 
pluripotency in mESCs and hESCs (Hart et al., 2004). Nanog was first identified as a 
regulator of pluripotency in mouse embryos, where mRNA transcripts were detected within 
the ICM of the blastocyst that were lost with differentiation into trophoectoderm. Nanog 
expression was also enriched in multiple pluripotent cell lines such as embryonic stem, 
embryonic germ, and embryonic carcinoma cells, however not detected in adult tissues 
(Chambers et al., 2003, Mitsui et al., 2003). Loss of both Nanog gene and protein expression 
was shown to induce differentiation into extra-embryonic lineages in both mESCs and hESCs 
(Chambers et al., 2007, Hatano et al., 2005, Hough et al., 2006, Hyslop et al., 2005, Ivanova 
et al., 2006, Lin et al., 2005, Pan and Pei, 2005, Xu et al., 2008). Concomitantly, stable 
expression of NANOG in hESCs has been shown to repress the differentiation of hESCs into 
extra-embryonic endoderm derivatives (Masui et al., 2007). Together, these findings 
demonstrate NANOG is key to the maintenance of pluripotency within hESCs.  
 
1.2.1.2.3. SOX2. 
SOX2 is also an essential element of pluripotency as loss of Sox2 has been shown to affect 
self-renewal and result in differentiation (Avilion et al., 2003, Masui et al., 2007, Ivanova et 
al., 2006). SOX2 is thought to function by maintaining expression of OCT4 and, similar to 
OCT4, SOX2 expression needs to be maintained within specific limits to maintain 
pluripotency and avoid differentiation (Kopp et al., 2008, Masui et al., 2007). Over-
expression of Sox2 protein has been associated with neural differentiation in mESCs, where 
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up-regulation of Sox2 was found to down-regulate several developmentally regulated genes 
including Nanog (Kopp et al., 2008). In addition, studies in hESCs have shown that loss of 
SOX2 expression results in differentiation into trophoectoderm-like cells (Fong et al., 2008, 
Wang et al., 2012). Together, these studies show Sox2 acts as a key molecular switch to aid in 
the regulation of other genes that are critically required for maintaining self-renewal or 
differentiation or PSCs.  
 
1.2.1.2.4. FOXD3.  
The transcription factor FOXD3 is highly expressed in hESCs and has been shown to be 
essential for maintaining pluripotency within early mouse embryos (Guo et al., 2002, Liu and 
Labosky, 2008). In mouse embryos, Foxd3 was shown to contribute to the establishment of an 
epiblast-like state (a pluripotent state which is thought to be equivalent to hESCs), due to the 
dramatic loss of cells within mouse epiblasts as a result of Foxd3 loss of function (Hanna et 
al., 2002). Additionally, Foxd3 expression was shown to lead to a slight up-regulation of 
known regulators of pluripotency Oct4, Sox2, Nanog, Esrrb, Tbx3, Klf4, and C-myc. This 
change suggests that Foxd3 may act downstream or in parallel to these pluripotency factors to 
regulate self-renewal and induce stem-cell like properties (Liu and Labosky, 2008). This up-
regulation of Foxd3 in the maintenance of self-renewal in ESCs indicates that Foxd3 may act 
as a gatekeeper by preventing pluripotent cells from undergoing inappropriate differentiation 
(Hanna et al., 2002, Liu and Labosky, 2008, Zhu et al., 2014) (Figure 1.3). FOXD3 has also 
been shown to act as a transcriptional repressor that blocks mesodermal differentiation from 
occurring (Steiner et al., 2006). The proposed mechanisms of action for Foxd3 as either a  
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Figure 1.3 Model of Foxd3 functions in mESCs. The expression of Foxd3 appears to 
repress differentiation within mESCs. This repression allows mESCs to retain self-renewal 
potential, thus allowing ESCs to survive in a pluripotent state (Liu and Labosky, 2008).  
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repressor or activator could indicate a role for Foxd3 as a convergent point for multiple 
pathways within pluripotent cells (Liu and Labosky, 2008).  
 
1.1.1.3. Regulation of pluripotency in hESCs. 
Regulation and integration of the above transcription factors into pluripotency networks is 
tightly controlled in order to maintain self-renewal and pluripotent differentiation capacity. 
Alterations to the expression of key pluripotency regulators and the associated genes they 
regulate results in differentiation or even cell death (Hanna et al., 2002). Studies have 
identified strong interaction between core regulators of pluripotency in ESCs. For example, 
OCT4, NANOG, and SOX2 have been shown to contribute to ESC pluripotency through a 
positive feedback loop whereby they each regulate the expression of each other (Boyer et al., 
2005, Chen et al., 2008, Cole et al., 2008, Kim et al., 2008, Kuroda et al., 2005). OCT4, 
NANOG and SOX2 were identified to co-occupy promoters of at least 353 genes in hESCs 
and were shown to work together to form an interconnected auto-regulatory feedback loop to 
control and maintain embryonic stem cell transcriptional circuitry, and to repress genes 
essential for embryonic development (Boyer et al., 2005) (Figure 1.4). 
 The activity of Oct4 and Sox2 has been shown to be linked, with Sox2 found to play a 
large role in assembling key target regulatory elements of Oct4 to maintain ESC self-renewal 
(Avilion et al., 2003, Chambers et al., 2003, Mitsui et al., 2003). Targeted loss of Sox2 was 
found to replicate differentiation events seen with loss of Oct4 expression in ESCs (Masui et 
al., 2007, Niwa et al., 2000). Additionally, a positive feedback loop has been identified 
between Oct4, Nanog, and Sox2 interactions. In order to maintain a pluripotent state within 
embryonic stem cells, Nanog has been shown to promote the expression of Oct3/4 and Sox2, 
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which are also required for transcriptional regulation of Nanog gene expression (Boyer et al., 
2005, Kuroda et al., 2005, Loh et al., 2006, Wang et al., 2006).  
As described above, tight regulation of Oct4, Nanog and Sox2 expression is required 
for ESCs to remain in an undifferentiated state (Chambers et al., 2003, Mitsui et al., 2003, 
Niwa et al., 2000). Interestingly, Foxd3 was shown to act as a transcriptional activator 
through its binding interactions with Oct4, which in turn activates osteopontin enhancers 
expressed in hESCs (Guo et al., 2002). An immunoprecipitation study has also shown Oct4 
can interact with the DNA-binding domain of Foxd3, suggesting Oct4 might regulate Foxd3 
transcriptional activity. Overexpression of Oct4 has also been shown to repress both Nanog, 
and Oct4 expression, ultimately resulting in differentiation of ESCs. However, Foxd3 can 
function as a positive activator of Nanog in ESCs, overcoming repression induced by Oct4 
and therefore resulting in retention of pluripotent ESCs (Pan et al., 2006). This study 
suggested that the negative feedback loop created from the interactions of Foxd3, Nanog, and 
Oct4 leads to an interdependent network of transcription factors as part of the complex 
regulation involved in ESC pluripotency (Figure 1.5). This proposed model may function in a 
similar manner to the OCT4/NANOG/SOX2 transcriptional regulatory network proposed by 
Boyer and colleagues (Boyer et al., 2005). More recent studies have also shown that FOXD3 
simultaneously acts as a transcriptional activator and repressor to maintain pluripotency in 
ESCs (Krishnakumar et al., 2016). In this context it is interesting to note that RBBP9 
expression is required for maintenance of pluripotency, and that loss of RBBP9 in hESCs 
rapidly led to a significant reduction in FOXD3 expression. 
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1.1.1.4. Consequences of pluripotency networks. 
The auto-regulatory feedback loop responsible for regulating pluripotency within embryonic 
stem cells is thought to be advantageous as it could reduce the cellular response time to 
environmental stimuli. This would allow the pluripotent cells in vivo to respond appropriately 
to developmental cues as well as increasing the stability of gene expression (Alon, 2007). 
This auto-regulatory feedback loop would be compromised if the expression of the above 
transcription factors were to be altered, thus resulting in either loss of pluripotency or priming 
for loss of pluripotency. Together, appropriate regulation of expression of these core 
pluripotency regulators is required to repress differentiation and retain pluripotency, although 
the full mechanisms controlling how they act, including pathways regulated by RBBP9, are 
not known. 
Accompanying these core regulatory pluripotency factors are many other known or 
suspected factors that are though to contribute to long term maintenance of ESCs. For 
example Klf4, c-myc, Stat3, Sall4, β-catenin, Esrrb and RBBP9 have all been found to 
contribute to the maintenance of ESCs (Li et al., 2005, Cartwright et al., 2005, Matsuda et al., 
1999, Niwa et al., 1998, Wu et al., 2006, Zhang et al., 2006, Loh et al., 2006, Qiu et al., 2010, 
Richards et al., 2004, Sperger et al., 2003, O'Connor et al., 2011). The requirement for at least 
some of these pluripotent factors in the maintenance of ESCs across species is variable, as 
shown by known discrepancies between hESCs and mESCs. For example in hESCs the 
requirement of STAT3 is not critical in maintenance of self-renewal (Daheron et al., 2004, 
Humphrey et al., 2004). Nevertheless, these studies show that pluripotent factors other than 
the quartet of OCT4, SOX2, NANOG and FOXD3 help sustain the transcriptional regulatory 
network required for the regulation of pluripotency and self-renewal. 
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Figure 1.4 A core transcriptional regulatory network model for maintenance of 
pluripotency. In this model OCT4, NANOG, SOX2 co-occupy a range of mutual target 
genes to either promote or repress expression of the target genes. Adapted from (Boyer et al., 
2005). 
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Figure 1.5 Proposed model for Foxd3-Nanog-Oct4 negative feedback loop. This model 
proposes the interaction of Foxd3 with Nanog to ensure the optimal expression of Nanog in 
PSCs and ultimately aid in obtaining the appropriate level of Oct4 expression needed to 
maintain pluripotency (Pan et al., 2006). 
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1.1.2. hiPSCs: advancements in cell reprogramming and disease modelling.  
The identification of Oct4, Nanog and Sox2 as key pluripotency regulators, as well as other 
pluripotency regulators such as Klf4 and Lin28, led to ground-breaking pluripotency factor 
over-expression experiments that identified approaches to reprogramming somatic cells to a 
pluripotent state. This process generates disease-specific and/or patient-specific mouse (m) 
iPSCs and hiPSCs (Park et al., 2008, Takahashi et al., 2007b, Takahashi and Yamanaka, 
2006, Yu et al., 2007). These iPSCs have become an invaluable tool for modelling normal 
develop and diseases, and potentially also providing patient-specific cells for transplantation. 
Two general reprogramming gene cocktails have been established, consisting of the 
original miPSC and hiPSC reprogramming cocktail of Oct4/Sox2/Klf4 (+/- c-myc), and an 
alternate cocktail of Oct4/Nanog/Sox2/Lin28 (Park et al., 2008, Takahashi et al., 2007b, 
Takahashi and Yamanaka, 2006, Yu et al., 2007). The original reprogramming cocktail was 
derived from a list of 24 genes selected based on i) their high expression in ESCs (Takahashi 
and Yamanaka, 2006), and ii) the finding that nuclei transplanted from a somatic cell to an 
oocyte could be reprogrammed back to a pluripotent state (Gurdon, 1962). Re-expression of 
these ‘reprogramming genes’ in somatic cells is typically achieved using retro-viral vectors 
(Takahashi et al., 2014). The resulting iPSCs possess the ability to be integrated into 
organisms when transplanted into embryos (only ethically possible with miPSCs), and also to 
generate teratomas containing derivatives of endoderm, mesoderm and ectoderm when 
transplanted typically into immunocompromised mice (Lensch et al., 2007, Thomson et al., 
1998) (Figure 1.6). Reprogramming gene cocktails originally contained the oncogene c-myc, 
however, in 2007 Takahashi and colleagues demonstrated reprogramming can occur in the 
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absence of c-myc, and in doing so reduced the tumorigenicity of the reprogrammed cells 
(Takahashi et al., 2007a). 
 Originally, hiPSC production required the use of viruses to re-introduce expression of 
pluripotency genes, resulting in viral integration within the genome of the reprogrammed 
cells. Due to the simplicity of this method it is often still used today. To avoid this viral 
integration a number of groups have investigated reprogramming methods that either excise 
the integrated viral DNA, or that do not require viruses to insert cDNA into the genome such 
as the piggyBac transposon approach (Jia et al., 2010, Narsinh et al., 2011, Okita et al., 2008, 
Stadtfeld et al., 2008, Woltjen et al., 2009). Unfortunately these methods tend to result in a 
significant decrease in iPSC formation (Takahashi et al., 2007b). In an attempt to overcome 
this issue, small molecules have been tested to both increase reprogramming efficiency, and 
decrease the number of genes required for the reprogramming cocktail. For instance Huangfu 
and colleagues identified that the addition of valporic acid (a histone deacetylase inhibitor) 
increased the efficiency for human fibroblast reprogramming (Huangfu et al., 2008). 
Nevertheless, significant time and effort is still required to generate hiPSCs. Efforts are 
therefore being made to better understand the molecular mechanisms of pluripotency and the 
reprogramming process, so the time and expense of this technology can be sufficiently 
reduced to make it feasible for the investigation for patient specific stem cell-based 
transplantation therapies.  
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Figure 1.6 Reprogramming of differentiated somatic cells using retroviral transduction. 
A schematic of iPSC generation and downstream analyses. Once expression of the exogenous 
pluripotency factors has been achieved (e.g., via retroviral transduction), re-organisation of 
the genome occurs to re-activate expression of the endogenous pluripotency genes. As a 
result, an iPSC is generated that can be maintained indefinitely in culture, or induced to 
differentiate, e.g., via teratoma formation. Adapted from (Rodolfa and Eggan, 2006). 
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Various studies have suggested that hiPSCs and hESCs are almost identical in terms 
of morphology, pluripotency antigen expression, and gene expression profiles (Takahashi et 
al., 2007b, Chin et al., 2009). However, subtle differences have been seen and it is not yet 
clear how significant these are (i.e., whether they significantly change the properties of iPSCs 
compared to ESCs). One concern is the potential for mutations to arise during the 
reprogramming process that then lead to the potential for tumors in any transplanted hiPSC-
derived cells. Indeed, the first ever hiPSC-based clinical trial (that aimed to treat macular 
degeneration with patient-specific retinal pigment epithelial cells) was recently put on hold 
due to mutations found in the cells prior to transplantation (Scudellari, 2016). In addition to 
using hESCs and hiPSCs as models of development, a clearer understanding of the molecular 
mechanisms that govern pluripotent cells is a high priority for the field to enable continued 
improvements to reprogramming technology.  
 
1.1.3. Zebrafish as an in vivo model of embryonic development.  
1.1.3.1. Unique properties of zebrafish embryogenesis. 
Zebrafish (Danio rerio) have been increasing in popularity as an in vivo model for embryonic 
development (Kimmel et al., 1995, Chen et al., 2015a, Chen et al., 2015b, Zou et al., 2015, 
Behra et al., 2004, Ekker and Larson, 2001, Langheinrich et al., 2002, Parng et al., 2002, 
Robles et al., 2011). Compared to other animal models, zebrafish models possess unique 
properties making them ideal for studying the early stages of embryonic development. 
Zebrafish embryos are fertilised and continue to develop rapidly outside the mother’s body, 
with hatching within three to four days. In addition to this, developmental changes can easily 
be tracked as zebrafish embryos are optically transparent, thus allowing simple microscopic 
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visualisation of clearly defined, stage-specific phenotypes of zebrafish embryos (Kimmel et 
al., 1995, Streisinger et al., 1981). Zebrafish are able to produce large numbers of fertilised 
embryos (approximately 200-300) at any one time, making them ideal candidates for high 
throughput screens. This also results in relatively low cost maintenance compared to other 
animal models (e.g., mice) (Parng, 2005, Parng et al., 2004).  
 
1.1.3.2. Molecular similarities of zebrafish and hPSC models.  
Developmental and molecular similarities are present between hPSCs and zebrafish. As 
described above, hPSCs express high levels of the core pluripotency regulator OCT4 (Boyer 
et al., 2005, Masui et al., 2007, Niwa et al., 2000). Similarly, high levels of oct4 have been 
detected in early blastomeres of zebrafish embryos (Kotkamp et al., 2014, Robles et al., 2011) 
which are equivalent to the ICM from which hESCs are derived (Mitalipova et al., 2003, 
Reubinoff et al., 2000, Thomson et al., 1998). Not surprisingly, zebrafish PSCs have been 
successfully generated from zebrafish embryos (Fan et al., 2004, Ghosh and Collodi, 1994) 
approximately 2.25 hours post fertilisation (hpf) (blastula stage) and 5.5 hpf (gastrula stage) 
(Kimmel et al., 1995). Cells derived from zebrafish embryos between the blastula and gastrula 
stages have the potential to generate a variety of cell lineages (Kimmel and Warga, 1986) 
similarly to hPSCs (Thomson et al., 1998). These similarities between zebrafish and hPSCs 
make zebrafish ideal candidates for in vivo modelling of general embryonic development. 
In 2013, sequencing of the zebrafish genome was completed and revealed a significant 
(~70%) genetic similarity between zebrafish and humans (Howe et al., 2013) (Figure 1.7). 
Earlier studies identified thousands of mutants in early zebrafish development through genetic 
screens (Amsterdam et al., 1999, Driever et al., 1996, Haffter et al., 1996). Similarities 
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observed between human and zebrafish genomes enable the use of zebrafish to model 
developmental phenotypes and offer the potential to provide a greater understanding of 
factors which control specification of cell types and organ systems relevant to some human 
diseases. Despite obvious physiological differences apparent between humans and zebrafish, 
the availability of screens to select for developmental mutants coupled with the complete 
sequencing of the zebrafish genome is advantageous. This provides the opportunity for a 
greater understanding of cell and biological processes behind disease phenotypes at specific 
early developmental time points which are difficult to obtain using other animal models.  
 
1.1.3.3. Morpholino oligonucleotides: A gene knockdown approach in vertebrate 
development. 
Zebrafish have been utilised in many gene knockdown studies due to the unique 
developmental properties they possess. The identification of antisense morpholino 
oligonucleotides (MOs) provided a tool for transient gene knockdown in animal models by 
developmental biologists since its first identification in 2000 (Heasman et al., 2000, Ekker 
and Larson, 2001, Nasevicius and Ekker, 2000). MOs are chemically modified synthetic 
oligonucleotides composed of chains of approximately 25 subunits, and are highly similar to 
DNA and RNA oligonucleotides. MOs have a modification where a morpholine ring replaces 
the ribose ring, allowing MOs to still undergo Watson-Crick base pairing (Summerton and 
Weller, 1997) (Figure 1.8 B).  
First generation antisense MOs were developed as DNA oligonucleotides between 18-
22 subunits in length (Summerton and Bartlett, 1978, Zamecnik and Stephenson, 1978) 
(Figure 1.8 A). These MOs were designed to form RNA-DNA hybrids with target mRNA to 
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then act as a substrate where the target mRNA could be degraded by RNase H (Cazenave et 
al., 1989). However, it was later shown that these DNA oligonucleotides were not ideal in 
developmental studies due to non-specific toxic side effects. Also, the knockdown effect was 
temporary due to degraded mRNA transcripts being replenished with new transcription 
(Woolf et al., 1990).  
 To overcome these limitations, MOs were re-developed as DNA analogs to block 
mRNA translation. Re-design of MO structure offered greater advantages over conventional 
oligonucleotides, including greater stability. Rather than inhibiting protein translation through 
RNAse H-mediated degradation of the mRNA (Cazenave et al., 1989), the redesigned MOs 
specifically target the initiation codon of the target mRNA, inhibiting translation of mRNA 
both in vitro and in vivo without the need for RNAse H (Summerton, 1999). These MOs can 
only block translation when designed to be complementary to the 5’ leader sequences, or 
designed to the first 25 bases 3’ to the AUG translational start site (where it is hypothesised 
ribosomes are inhibited from binding). Generally, MOs are designed to be the exact antisense 
match against the region surrounding the first translated ATG to successfully block translation 
(Figure 1.8 C). This MO redesign also decreased the likelihood of toxicity and non-specific 
binding with other components of the cell as they do not have a negatively charged backbone, 
unlike previous oligonucleotide structures. These translation blocking MOs can be injected 
into zebrafish embryos at the 1-2 cell stage to determine the role of particular genes during 
development (Nasevicius and Ekker, 2000, Draper et al., 2001). 
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Figure 1.7 Genome comparisons between in vivo developmental models. Shows 
orthologue genes shared between human, mouse, chicken, and zebrafish (Howe et al., 2013).  
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Figure 1.8 MO structure. Structures of MOs where; A) shows the structure of 
phosphodiester DNA oligonucleotide, and B) shows the structure of the widely used MO, 
where R’ represent continuation of the oligomer chain in the 5’ or 3’ direction (Corey and 
Abrams, 2001). C) Representative diagram of mRNA inhibition via MO, where the MO is 
targeted to a sequence 5’ of the translation start site and inhibits the initiation complex from 
completing mRNA translation (Eisen and Smith, 2008). 
A B 
C 
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1.1.3.4. Effectiveness of MO mediated gene knockdown. 
To minimise the potential for off-target effects arising from MOs, a range of controls are 
routinely implemented (Robu et al., 2007, Eisen and Smith, 2008, Kok et al., 2015, Stainier et 
al., 2015). A key control is the co-injection of MO targeting p53 together with the MO 
targeting the gene of interest. This is done to determine whether any phenotype seen as a 
result of the test MO is due to activation of the p53 pathway - if the phenotype remains even 
in the presence of the p53 MO then the effect is most likely due to specific loss of expression 
of the target gene (Robu et al., 2007). Thus MO technology provides a useful tool for 
investigating the role of particular genes of interest during embryonic development in a way 
that both parallels and complements hPSC technology.  
 
1.2. Role of the RB/E2F pathway in cell cycle regulation. 
Appropriate regulation of cell cycle progression, self-renewal of stem cells and cell 
differentiation are key aspects of normal and cancer development. These processes are 
regulated by many networks, one of those being controlled by interaction between the RB and 
E2F transcription factors (Woitach et al., 1998). The highly studied RB protein has been 
identified as a negative regulator of cell proliferation when hypo-phosphorylated; as a result 
RB is a key tumor suppressor that acts at the ‘G1 checkpoint’ that regulates progression into 
the S (i.e., DNA synthesis) phase of the cell cycle (Woitach et al., 1998, Boyer et al., 1996). 
By binding and sequestering E2F transcription factors, Rb inhibits transcription of E2F target 
genes that are required for cell cycle progression by forming a repressor domain in G1/G0 
(Boyer et al., 1996). Absence of hypo-phosphorylated Rb is thought to contribute to high 
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proliferation rates observed in ESCs (Savatier et al., 1994, Fluckiger et al., 2006). 
Phosphorylation of RB was found to inactivate the protein, and this event was shown to 
reinstate E2F transcriptional activity (Chellappan et al., 1991, Vandel et al., 2001). A crucial 
balance of RB and E2F expression is required within hESCs to maintain the optimal balance 
necessary between cell proliferation and survival (Conklin et al., 2012). In the context of 
pluripotency in hESCs, it has been shown that accumulation of hypo-phosphorylated RB in 
G1 of the cell cycle coincides with loss of hESC markers such as OCT4, and also with hESC 
differentiation (Filipczyk et al., 2007). RB activity can also be regulated by RB-binding 
proteins. Importantly, loss of control of the RB-mediated G1 checkpoint is a key step in 
cancer formation.  
As mentioned above, RBBP9 has been shown to bind to RB in both non-pluripotent 
cells and in hPSCs (O'Connor et al., 2011, Woitach et al., 1998). Moreover, siRNA-mediated 
knockdown of RBBP9 resulted in loss of pluripotent cells, decreased expression of cell cycle 
and some pluripotency genes, as well as increased expression of neurogenesis genes 
(O'Connor et al., 2011). However, the relative contribution of RBBP9’s RB-binding and SH 
activities to hPSC maintenance remains unknown. Further investigation of the RB-binding 
and SH activities of RBBP9 in hPSCs could therefore yield valuable new information on cell 
proliferation and differentiation relevant to both hPSCs and cancer. 
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1.3. Proposed activities of RBBP9: RB-binding and SH activity.  
1.3.1. Identification of RBBP9 SH activity.  
The first identification of RBBP9 demonstrated it to be able to bind RB protein and thus 
release active E2F1 transcription factors. Consistent with this, overexpression of RBBP9 
promoted cell proliferation by overcoming growth inhibitory effects. These data suggested 
that RBBP9 might be involved in oncogenic transformation. Since then, RBBP9 transcripts 
have been detected throughout normal development and also in a range of cancer cells 
(Woitach et al., 1998). As mentioned above, RBBP9 has also been shown to bind RB in 
hPSCs and to be required for maintenance of hPSCs (O'Connor et al., 2011). However, 
RBBP9 has also been suggested to be a SH (Shields et al., 2010, Vorobiev et al., 2012). 
Notably, SHs are central effectors of the proliferative, invasive, and migratory properties of 
tumours. Studies have shown SH transcript and protein levels are elevated in many cancer cell 
lines such as human breast and melanoma and primary tumours (Jessani et al., 2002, Chiang 
et al., 2006). Additionally, serine proteases have been implicated in Drosophila gastrulation, 
with loss of function due to mutations of serine proteases resulting in incomplete neural 
development during early embryogenesis (Han et al., 2000). Also, the serine protease Furin 
has been shown to be essential for the formation of key tissues derived from endoderm, 
mesoderm and ectoderm. Disruption of this enzymatic activity was shown to result in 
malformation of epiblast derivatives such as the primitive heart, gut, and extraembryonic 
mesoderm (Constam and Robertson, 2000, Roebroek et al., 1998).  
 DNA sequence analysis shows that RBBP9 contains GXSXG residues that suggest a 
putative SH nucleophilic serine. These residues are conserved across RBBP9 orthologs in 
human, mouse and zebrafish sequences amongst other species, suggesting an evolutionarily-
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important function for these residues (Figure 1.9) (Shields et al., 2010, Vorobiev et al., 2009). 
Elucidation of the crystal structure of human RBBP9 revealed an α/β fold common to SHs. 
Within this domain lies serine 75 (Ser75) and other amino acids of the putative RBBP9 SH 
catalytic triad (His165-Ser75-Asp138), suggesting an enzymatic role for RBBP9 (Vorobiev et 
al., 2009, Ollis et al., 1992) (Figure 1.10).  
 
1.3.2. RBBP9 SH activity in cancer.  
A study by Shields and colleagues identified for the first time SH activity in RBBP9, and its 
specific involvement in pancreatic cancer progression (Shields et al., 2010). Over-expression 
of normal RBBP9 promoted cellular proliferation in human pancreatic carcinoma cells, with 
over-expression of a mutant and catalytically inactive version of RBBP9 resulting in 
decreased proliferation. Fortuitously, a highly selective inhibitor of RBBP9 SH activity called 
[1-(1,3-thiazol-2-yl)ethylideneamino] cyclohexanecarboxylate (or ML114), was recently 
reported (Bachovchin et al., 2010b). Activity-based protein profiling (ABPP) was used to test 
RBBP9 SH activity against a library of putative chemical SH inhibitors. This analysis showed 
that only ML114 was able to specifically and selectively inactivate RBBP9 SH activity by 
modifying the active site (Ser75). Furthermore, Bachovchin and colleagues also showed that 
this inhibitor acts by covalently modifying the active site Ser75, whist simultaneously 
releasing a soluble fragment during RBBP9-mediated hydrolysis (Bachovchin et al., 2010b) 
(Figure 1.11). The identification of this highly selective chemical inhibitor of RBBP9 SH 
activity offers a useful tool to further define the relative contributions of RB-binding and SH 
activities in both pluripotent cells and in development. The information gained through such 
studies will be relevant to our understanding of how pluripotent cells are maintained and  
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Figure 1.9 Primary sequence alignment of RBBP9 orthologues shows a conserved 
GXSXG motif common to SHs. Alignment of RBBP9 amino acid sequences shows a 
conserved serine residue within a GXSXG motif across a variety of species including Homo 
sapiens, Mus musculus, Danio rerio and others. This motif is known from analysis of 
confirmed SHs to contain the active site serine (Shields et al., 2010). 
  
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Crystal structure of RBBP9 identified a putative SH catalytic triad. A) 
Ribbon structure of RBBP9. The secondary structure of RBBP9 is depicted as red for α-
helixes, yellow for β-strands and green for connecting loops. B) Space-filling model shows 
Ser75 is the predicted active serine of RBBP9 (Vorobiev et al., 2009). 
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Figure 1.11 The RBBP9 SH inhibitor ML114. A) Chemical structure of ML114. B) 
Hydrolysis of ML114 by RBBP9 Ser75 leads to covalent modification of Ser75, resulting in 
an increased mass of +110.09 Da. C) The soluble ML114 fragment released upon ML114 
hydrolysis by RBBP9 SH activity. Adapted from (Bachovchin et al., 2010b). 
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possibly generated, and also to our understanding of development and/or progression of 
cancer  
 
1.4. Hypothesis and Aims.  
1.4.1. Hypothesis. 
That targeted loss of RBBP9 SH activity within hPSCs and zebrafish embryos will identify 
candidate molecular networks regulated by the two putative RBBP9 activities. These data will 
then provide new leads for future investigations aimed at improving the efficiency of somatic 
cell reprogramming and/or better understanding cancer cell behaviour.  
 
1.4.2. Aims.  
The work undertaken for this thesis therefore aimed to:  
1) Investigate the consequences of chemically-mediated inhibition of RBBP9 SH activity 
in hPSCs.  
2) Identify putative effectors of RBBP9 SH activity in hPSCs.  
3) Investigate the consequences of chemically-mediated inhibition of RBBP9 SH activity 
during early development in vivo using zebrafish embryos.  
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CHAPTER 2: RBBP9 SH inhibitor 
ML114 decouples hPSC proliferation and 
differentiation 
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2.1. INTRODUCTION 
Analysis of published gene expression data shows RBBP9 is expressed in hPSCs, and in a 
range of human cancer cells, as well as during developmental time points of different species 
such as rats and zebrafish (Bastian et al., 2008, Hirst et al., 2007, O'Connor et al., 2011, 
Woitach et al., 1998, Vorobiev et al., 2009). Despite this very broad expression little is known 
of the roles RBBP9 plays in normal development or cancer progression. The few published 
RBBP9 studies available have suggested RBBP9 has two different activities: i) the ability to 
bind RB protein and regulate the activity of the RB/E2F cell cycle pathway (Woitach et al., 
1998), and ii) the ability to act as a SH on as yet undefined target proteins (Shields et al., 
2010). 
The RB-binding activity of RBBP9 was first described in 1998 when it was shown to 
displace E2F1 from RB/E2F1complexes, thus allowing expression of cell cycle-related genes. 
This interaction has been shown to occur through interactions of a LXCXE RB-binding motif; 
a base-pair change of leucine to glutamine of the LXCXE RB-binding motif abolishes the 
ability of RBBP9 to bind to RB and displace E2F1 (Woitach et al., 1998). More recently, 
RBBP9 SH activity was first suspected by sequence similarity. It has been suggested that 
RBBP9 belongs to the Domain of unknown function (DUF1234) superfamily of serine 
proteases (Vorobiev et al., 2009). Comparison of protein sequences identified a conserved 
serine residue hypothesised to be the putative nucleophilic serine (Ser75) within a GXSXG 
motif (Shields et al., 2010, Vorobiev et al., 2009). This motif is contained within known SHs 
such as seprase, a serine protease expressed in human malignant melanoma cells (Aoyama 
and Chen, 1990, Goldstein et al., 1997). Overexpression of the catalytically inactive mutant 
RBBP-S75A in human carcinoma cells demonstrated that loss of RBBP9 SH activity led to a 
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decrease in cell proliferation (Shields et al., 2010). More recently, high throughput screening 
for inhibitors of enzymes with poorly characterised biochemical activity identified a potent 
and specific chemical inhibitor of RBBP9 SH activity (Bachovchin et al., 2010b). This 
chemical, ML114, has an IC50 of 0.63 μM on cell-free recombinant RBBP9. At 20 μM to 100 
μM ML114 is capable of blocking the SH activity of recombinant RBBP9 in human 
embryonic kidney 293T (HEK) cells, or RBBP9 doped into mouse brain membrane proteome. 
The selectivity of ML114 is shown by its IC50 for 30 other serine hydrolases being >100 μM. 
ML114 also showed low cytotoxicity, with its CC50 being >100 μM in HEK cells 
(Bachovchin et al., 2010a).  
To date, only one study has investigated the activity of endogenously-expressed 
RBBP9 (O'Connor et al., 2011). In this study, RBBP9 RNA and protein expression was 
shown in a range of hPSCs including human embryonic stem cells, human induced 
pluripotent stem cells, and human embryonal carcinoma cells. Co-immunoprecipitation 
showed RBBP9 interacts with RB protein in hPSCs. siRNA-mediated knockdown of 
endogenous RBBP9 protein (i.e., loss of both RB-binding and SH activities) resulted in: i) 
decreased population growth rate; ii) decreased expression of cell cycle genes; iii) decreased 
expression of some pluripotency genes; and iv) increased expression of genes involved in 
neurogenesis. While this study demonstrated a requirement for RBBP9 in hPSC maintenance, 
the use of siRNA did not allow the identification of the relative contributions of RB-binding 
and SH activity to be established.  
To obtain insights into the relative importance of RBBP9 SH activity to hPSC 
maintenance, the present study used ML114 to identify the consequences of inhibiting only 
RBBP9 SH activity in hPSCs. The findings showed that ML114-mediated loss of RBBP9 SH 
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activity partially phenocopied the published effects of siRNA-mediated loss of RBBP9 
protein (O'Connor et al., 2011) though with a key difference. ML114 treatment of hPSCs 
resulted in reduced population growth rate and altered cell proliferation patterns, but with 
retention of pluripotency markers and teratoma-forming ability. These data suggest that 
ML114 decouples initiation of hPSC differentiation from inhibition of hPSC proliferation - an 
unusual, though not unprecedented, phenomena. Further investigation and clarification of 
RBBP9 and its activities will enable a greater understanding of its role in the maintenance of 
hPSCs, in development, and in progression of cancer.  
 
 
2.2. METHODS 
2.2.1. General reagents and consumables. 
Reagents used for cell culture including mTeSR1™, Dispase and Trypan Blue were acquired 
from StemCell Technologies (Melbourne, Australia). Reagents used in cell harvesting and 
antibody staining, including TryPLE™ Express, Dulbecco’s Modified Eagles Medium 
(DMEM), and Dulbecco’s Phosphate Buffered Saline (PBS), were acquired from Thermo 
Fisher Scientific (Scoresby, Australia) unless stated otherwise. Matrigel used to coat tissue 
culture plates for cell adherence was acquired from Corning, Falcon-Discovery Labware 
(Clayton, Australia).  All tissue culture plates (6-well, 96-well, 35 mm and 60 mm) and 
pipette tips used for general cell culture were acquired from Interpath Services (Heidelberg 
West, Australia). All consumables used for electrophoresis, including acrylamide, tris-
glycine, and sodium dodecyl sulfate (SDS) buffer were of electrophoresis grade or higher 
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quality and were obtained from Ameresco Inc. distributed by Astral Scientific Pty Ltd., 
Sydney, Australia. 
 
2.2.2. General equipment. 
2.2.2.1. General cell culture. 
All cell culture was conducted within a Gelaire BH-EN 2000 D Series Class II Biological 
Safety Cabinet (Seven Hills, Australia). All surfaces were disinfected using isopropanol both 
prior to and upon completion of use. All cell cultures were incubated in a Heracell 150 CO2 
incubator at 37 °C, 5% CO2 (Thermo Fisher Scientific). All non-sterile pipette tips, tubes and 
glassware were sterilised by autoclaving at 121 °C for 20 minutes with a 5 minute drying time 
using a benchtop Tuttnauer 3150EL autoclave (Tuttnauer, Breda, Netherlands) prior to cell 
culture use. All waste cell culture media was disinfected with bleach prior to disposal.  Used 
pipette tips, tissue culture plates and tubes were sterilised using a Getinge HS 6610 AM-2 
autoclave (Getinge AB, Getinge, Sweden). 
 
2.2.2.2. Light microscopy. 
Prior to routine tissue culture (including daily medium changes), all cultures were visually 
inspected for any differentiation or abnormalities using an Olympus CKX41 inverted 
microscope and accompanying digital camera (Olympus, Macquarie Park, Australia). Light 
microscopy images were captured using the imaging software Q Capture Pro v6 (Q Imaging, 
Brisbane, Australia).   
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2.2.2.3. Centrifugation. 
All centrifugation with volumes higher than 1.5 mL was conducted using a Beckman and 
Coulter Allegra® X-15R Centrifuge (Gladesville, Australia). All centrifugation with volumes 
lower than 1.5 mL was conducted using a Beckman and Coulter Microfuge® 22R Centrifuge 
or QikSpin Personal Microfuge (Edwards Instrument Co., Narellan, Australia).  
2.2.2.4. Storage of samples. 
All protein and RNA samples were stored at -80 °C in an ultra-low temperature freezer 
(Thermo Fisher Scientific). 
 
2.2.3. General cell culture.  
The hPSC line used in this study was the CA1 human embryonic stem cell line. hPSCs were 
obtained from Prof. Andras Nagy of The University of Toronto, Canada (Adewumi et al., 
2007) and seeded either as aggregates or single cells. Use of hPSCs complied with national 
guidelines with oversight by Western Sydney University Human Research Committee 
(approval H10950) and Biosafety and Radiation Committee (approval B8022 and B10355). 
All hPSCs were cultured using the defined, feeder cell-free medium mTeSR1™ (Ludwig et 
al., 2006) and the extracellular matrix product Matrigel (0.08 mg/mL Matrigel in DMEM) to 
aid cell attachment. The tissue culture plates were coated with Matrigel for a minimum time 
of 30 minutes at room temperature. Prior to seeding of cells the Matrigel was removed, 
leaving a coating for cell attachment.  
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2.2.3.1. Aggregate cell seeding. 
Confluent hPSCs were passaged every 7 days using previously optimised hPSC culture 
conditions (O'Connor et al., 2008). hPSCs were first washed with 1 X PBS, and were 
incubated in 1 X Dispase (3 minutes at 37 C, 5% CO2). Dispase was removed and hPSCs 
were washed with 1X PBS. Following this, DMEM was added and hPSCs were harvested 
using a cell scraper and collected, followed by a 1 X PBS wash to collect any residual hPSCs 
remaining on the tissue culture dish. hPSCs were then centrifuged (300  g, 5 minutes), 
supernatant was removed and the pellet was resuspended with mTesR1
™
 by gentle trituration. 
A clump count was performed by adding 5 L of triturated hPSCs to 20 L of 1 X PBS to 
create a 1/5 dilution; clumps were then counted using a light microscope. The average 
concentration of clumps was calculated and the desired number of clumps then seeded into 
Matrigel-coated tissue culture plates with mTeSR1
™
 and incubated (37 C, 5% CO2) until 
required.  
 
2.2.3.2. Single-cell seeding and ML114 treatment conditions.  
Confluent hPSC cultures were washed with 1 X PBS, then incubated in TrypLE
™
 to generate 
single cells (7 minutes at 37 C, 5% CO2). Single cells were collected and the culture dishes 
washed with 1 X PBS to collect remaining hPSCs. Supernatant was removed and the cell 
pellet was resuspended with mTesR1
™ 
with 10 M Rho-Kinase Inhibitor (ROCK inhibitor, 
Ri) (Merk, Kilsyth, Australia). A single cell count was performed by adding 10 L of the 
single cell mixture to 40 L of 0.4% (w/v) Trypan blue to create a 1/5 dilution for each cell 
sample in a well of a 96-well tissue culture plate. The mixture of cell sample and Trypan Blue 
was then placed into a hemocytometer (Bright-Line; Hausser Scientific, Pennsylvania, USA) 
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and a cell count was performed using a light microscope. Two counts on the same sample 
were performed, counting live (unstained) cells present within the neubauer grid of the 
hemocytometer (the frequency of dead - i.e., stained - cells was also determined). This count 
was then averaged and divided by 0.1 μL (the volume of cells contained on the 
hemocytometer), and multiplied by 5 (for the dilution factor used). This enabled 
determination of the total cell number present within each sample. The desired number of 
single cells were then seeded into a Matrigel-coated tissue culture dish with mTesR1™ and 
10 M of Ri and incubated (37 C, 5% CO2). The mTeSR1™ medium was replaced the 
following day without Ri and both control and ML114 treatments were added after this time-
point. For ML114-based experiments, cells were treated either with 0.25% DMSO (Sigma 
Aldrich, Castle Hill, Australia) as a vehicle-only control, the ML114 soluble fragment (Key 
Organics) made up in 0.25% DMSO as an additional control, or the RBBP9 SH inhibitor 
ML114 (Key Organics, Cornwall, UK) made up in 0.25% DMSO (Figure 1.11). Unless 
otherwise stated, treatments were added 72 hours after cell seeding to ensure maximal cell 
yield of treated hPSCs for downstream assays. In all cases, final DMSO concentration was 
0.25%. 
2.2.4. ML114 dose response using hPSCs plated as single cells.  
hPSCs were plated (see section 2.2.3.2), and treatment was added 24 hours after initial cell 
seeding. Each well of the 6-well tissue culture plate was treated with different doses of 
ML114 (5, 50, and 100 µM) for 7 days of culture. Colonies present within the tissue culture 
dish were counted with a light microscope 1, 2, and 5 days after treatment. Colony numbers 
were averaged and all 0 µM bars were set to 100% to compare the changes in magnitude due 
to ML114 treatment. A student’s t-Test verified statistical significance of the data. 
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2.2.5. hPSC post-ML114 recovery treatment. 
Treated hPSCs were harvested at day 7 of treatment and re-seeded into optimal hPSC 
maintenance conditions and maintained via standard passaging for up to 12 weeks. Cells 
counts were recorded at each passage prior to hPSC re-seeding.  
 
2.2.6. Colony forming cell (CFC) assay. 
Treated hPSCs were assessed using the alkaline phosphatase (AP) CFC assay (O'Connor et 
al., 2008). The CFC assay was performed using reagents obtained from the Alkaline 
Phosphatase (AP) Leukocyte kit (Sigma Aldrich) with adjustments to the protocol as follows: 
hPSCs were cultured (see section 2.2.4) and at the appropriate time point culture media was 
removed and cells were washed with PBS and fixed with AP fixative (25 mL Citrate Solution, 
65 mL Acetone and 8 mL 37% Formaldehyde) for 30 seconds. The fixative was then removed 
and the cells washed with PBS. Sufficient AP stain was made for each 35 mm tissue culture to 
be analysed by adding 22 µL/well of Sodium Nitrate solution to 22 µL/well of FBB-Alkaline 
Solution. This was allowed to sit for 2 minutes before1 mL/well of distilled water (dH2O) and 
22 µL/well of Napthol AS-BI Alkaline Solution was added. Each well was then stained with 1 
mL of AP stain for 15 minutes in the dark before being washed with PBS. Fresh PBS was 
added for storage purposes and to maintain the integrity of stains for analysis. 
 
2.2.6.1. CFC analysis. 
Representative light micrographs of AP-stained colonies were captured using the Olympus 
CKX41 inverted microscope/camera and Q Capture Pro v6. The cell number per colony was 
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determined by approximating the plate area occupied by each colony. These sizes were based 
on the estimated average colony diameters as well as the assumption that each 
undifferentiated hESC colony had an approximate diameter of 30 μM after fixation. To 
determine the diameter of the colonies, the average length of the longest colony axis was 
estimated as well as the colony axis length that was perpendicular to this. The diameter of 
colonies was estimated using a linear (mm) graph paper printed on a transparent sheet then 
placed on an inverted microscope (O'Connor et al., 2011). 
 
2.2.7. Flow cytometry analysis. 
Cells were harvested as single cells (see section 2.2.3.2) and cell counts performed to ensure 
appropriate numbers were used for analysis. The cells were then centrifuged (300 × g, 5 
minutes), the supernatant removed, and the residual supernatant used to re-suspend the cell 
pellet. Cells were fixed in 100 L of 2% para-formaldehyde and placed on ice for 15 minutes. 
After incubation 1 mL of PBS was added to the suspension before centrifugation (300 × g, 5 
minutes). The supernatant was removed and the pellet re-suspended in 10% fetal bovine 
serum (FBS) in PBS. The cell suspension was kept on ice during all subsequent antibody 
staining procedures.  
 
2.2.7.1 Extracellular and Intracellular Antigen Staining.  
Extracellular staining for the antigens TRA-1-60 and TRA-1-81 used 1  105 cells, and 
intracellular staining for the antigen OCT4 used 2  105 cells. Samples for extracellular 
staining were placed in the QikSpin microfuge (2000 × g, 1 minute), after which the 
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supernatant was removed and the cell pellet re-suspended in 10% FBS in PBS then placed on 
ice. Samples designated for intracellular staining were centrifuged using the QikSpin 
Microfuge (2000 × g, 1 minute), the supernatant was removed and the cells re-suspended in 
500 µL of 0.1% Saponin permeabilisation buffer (100 mg Saponin, 100 mL PBS and 10% 
bovine serum albumin, BSA) for 15 minutes on ice. The intracellular staining samples were 
then placed in the QikSpin microfuge (2000 × g, 1 minute), after which 400 µL of supernatant 
was removed from each sample.  
To each tube test sample, 1 µL of titrated primary antibody was added to the cells, i.e. 
2 μg/μL anti- TRA-1-60 and 2 μg/μL anti-TRA-1-81 antibodies (Abcam, Cambridge, UK); 
and 0.25 μg/μL anti-OCT4 antibody (BD Biosciences). All samples stained with primary 
antibody were placed on ice for 20 minutes then washed with 1 mL of 10% FBS in PBS for 
extracellular stained samples and 1 mL of 0.1% Saponin/10% FBS in PBS for intracellular 
stained samples. Samples were centrifuged using a QikSpin microfuge (2000 × g, 1 minute) 
followed by removal of 1 mL of supernatant. All samples were stained with 1 L of 1 in 10 
diluted secondary antibody for 20 minutes on ice (control samples were stained with 
secondary antibody without primary antibody). The secondary antibody used for extracellular 
samples was Alexa Fluor-488 anti-mouse IgM secondary antibody (Thermo Fisher 
Scientific), and Alexa Fluor-488 anti-mouse IgG antibody (Thermo Fisher Scientific) was 
used for intracellular staining. After incubation, 1 mL of 10% FBS in PBS was added to the 
extracellular staining samples and 1 mL of 0.1% Saponin/10% FBS in PBS was added to the 
intracellular samples. All samples were centrifuged in the QikSpin microfuge (2000 × g, 1 
minute), followed by the removal of 1 mL supernatant. Sample volumes were adjusted to 300 
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µL with either 10% FBS in PBS for extracellular samples or 0.1% Saponin/10% FBS in PBS 
for intracellular samples. The samples were then kept on ice until analysis. 
 
2.2.7.2. Flow cytometry data acquisition and analysis. 
The antibody-stained samples were analysed using a MACSQuant® Analyser Flow 
Cytometer (Miltenyi Biotec, North Ryde, Australia). During flow cytometry data acquisition, 
cells were visualized using the following parameters:  
1) Plot 1: Forward scatter-area (FSC-A) vs. side scatter-area (SSC-A) plot. Cells within 
this plot were then gated to define the main cell population.  
2) Plot 2: The main cell population was gated using FSC-A vs. FSC-height (FSC-H) to 
ensure that only single cells were subsequently analyzed.  
3) Plot 3: The fluorescence detector most suited to the emission and excitation profiles of 
the secondary antibody fluorophores was used to detect secondary antibody 
fluorescence  
Appropriate instrument settings were configured by analyzing control stained samples (i.e. 
secondary antibody only), and setting a gating control to capture 99.9% of these stained cells 
as negative events (Figure 2.1 A). Test (primary and secondary antibody) stained samples 
were then analysed using the gating control obtained previously, and the number of positive 
events were recorded Figures 2.1 B-C). Biological replicates for each sample were then 
recorded and averaged, with comparisons made using the student’s t-Test.  
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Figure 2.1 Flow cytometry data acquisition. Representative flow cytometry plots used for 
data acquisition and analysis for: A) unstained control samples. B) 0 µM control-treated 
hPSCs and C) 100 µM ML114-treated hPSCs. 
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2.2.8. Cell proliferation assay. 
hPSCs were treated with DMSO and ML114 as previously described (see section 2.3.2). Prior 
to confluency (generally after 5 days of treatment) 10 µM of EdU label (Thermo Fisher 
Scientific) was added to the cell culture for 2 and 6 hours of incubation. Following this, cells 
were then harvested as a single cell suspension as previously described (see section 2.3.2) and 
1  106 cells were collected from each condition and fixed with 4% para–formaldehyde in 
PBS for 15 minutes on ice in the dark. Samples were then washed with 1% BSA in PBS, 
centrifuged (300  g, 1 minute), and supernatant removed. The cell pellet was then processed 
using the Click-iT EdU detection kit (Thermo Fisher Scientific) as per the manufacturer’s 
instructions. The EdU labelled samples were then analysed via flow cytometry as described in 
2.2.6.2, however, plot 3 was adjusted to detect PI and Alexa Fluor 647 within the samples. 
The plot parameters were set at FL6-A (to detect Alexa Fluor 647 positive events) and FL4-A 
(to detect PI positive events as a negative control). Populations of cells present in each phase 
of the cell cycle were measured by dividing Plot 3 into quadrants that clearly separated each 
phase of the cell cycle. The values within each quadrant were recorded for each biological 
replicate and averaged, with comparisons made using the student’s t-Test.  
 
2.2.9. Teratoma and karyoptyping analyses. 
hPSCs were treated with 100 M ML114 in 0.25% DMSO for 7 days. The cells were then 
harvested and re-seeded as single cell suspensions in mTeSR1™ and passaged for a further 11 
weeks. Teratoma formation was performed externally by the StemCore Facility, University of 
Queensland, with histological analysis via an expert pathologist. Karyotyping (i.e. G-banding) 
was also performed by the StemCore Facility. 
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2.3. RESULTS 
2.3.1. ML114 reduces population growth rates.  
To investigate whether RBBP9 SH activity is required for the maintenance of pluripotency, 
hSPCs were cultured with the highly selective chemical inhibitor of RBBP9 SH activity, 
ML114 (Bachovchin et al., 2010b). A dose-response curve was established to find the 
effective concentration of ML114 in hPSCs (Figure 2.2 A), comparing vehicle control (0.25% 
DMSO) with various concentrations of ML114 up to 100 μM - the highest reported 
concentration enabling inhibition with minimal cell death due to toxicity (Bachovchin et al., 
2010b). This dose response study showed that all concentrations of ML114 tested (i.e., 5-100 
μM) significantly reduced hPSC population growth rate after 7 days of culture compared to 
control treatment (Figure 2.2 B), with the greatest effect seen with the highest concentrations. 
These data suggest that ML114 treatment decreased hPSC proliferation and/or induced hPSC 
death. hPSCs were also cultured with ML114 fragment to test whether the effect of ML114 on 
hPSC number was due to the presence of the ML114 fragment released after RBBP9 SH 
activity (Figure 2.2 A). Notably, the hPSC yield was not significantly reduced by treatment 
with ML114 soluble fragment even when the fragment was used at 100 μM (Figure. 2.2 B; p 
= 0.124).  
 
2.3.2. Exposure to ML114 does not induce hPSC differentiation.  
As inhibition of hPSC proliferation has been correlated with hPSC differentiation (O'Connor 
et al., 2011, Becker et al., 2006, Calder et al., 2013), a number of pluripotency assays were 
performed to investigate whether ML114 treatment induced differentiation in addition to its 
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effect on hPSC population growth rate. These assays included the CFC assay and flow 
cytometric analysis for known pluripotency-associated antigens.  
The AP-based CFC assay showed a decrease in colony number within the initial 24 
hours (Figure 2.3 A), suggesting that ML114 might impair hPSC attachment and/or cause cell 
death within the initial cell-seeding phase of the assay. A small decrease was noted in colony 
number within each treatment over the 5 days (day 1 vs day 5; approximately 3-fold for 
control treatment and 16-fold for 100 µM-treated hPSCs). However, comparison of control- 
and 100 µM consistently showed a much higher fold change (75-fold change at day 5), 
indicating that inhibitor had a larger effect than the DMSO in the treatment. Consistent with 
the population growth rate data described above, the ML114-treated colonies were much 
smaller than the control-treated colonies - suggesting that ML114 decreased cell proliferation 
and/or caused cell death (Figure 2.3 B). At the end of the assay the colonies derived from all 
ML114 treatments remained AP positive, suggesting they remained pluripotent (Figure 2.3 
B). Overall, increasing concentrations of ML114 decreased both the CFC frequency and size 
of colonies (Figure 2.4). 
 Next, control- and ML114-treated hPSCs were assessed via flow cytometry to look for 
changes in expression of the pluripotency antigens OCT4, TRA-1-60, and TRA-1-81. This 
analysis showed detection of equally high levels of all 3 pluripotency-associated antigens in 
both control- and ML114-treated hPSCs even after 7 days of treatment with 100 μM of 
ML114, with no statistically significant difference between each treatment (Figure 2.5). 
2.3.3. ML114 slows hPSC proliferation. 
To test whether the reduced hPSC population growth rate and reduced CFC colony growth 
rate that resulted from ML114 treatment were due to changes in the cell cycle, both control-  
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Figure 2.2 ML114 reduces hPSC population growth rate. A) Dose response showing all 
concentrations of ML114 used decrease hPSC growth rate after 7 days of treatment, with 
greater effects seen with concentrations. (n = 3; * p < 0.05). B) hPSC population size is 
significantly reduced after 7 days of ML114 treatment, with no significant changes in hPSC 
population size when treated with ML114 soluble fragment. (n = 3). 
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Figure 2.3 hPSC colony survival after ML114 treatment. A) Colonies that remain attached 
after ML114 treatment were counted 1, 2, and 5 days post ML114 treatment. The initial 
reduction in hPSC colony number by day 1 remained relatively stable throughout the duration 
of culture. (n = 5; * p = 0.05, ** p = 0.001, *** p = 0.0001). B) CFC assay data showing CFC 
colony size decreases with increasing ML114 concentration, but that AP expression is 
maintained at all ML114 concentrations tested. (n = 5). 
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Figure 2.4 ML114 treatment decreases CFC frequency and colony size. CFC assay data 
showing that: A) increasing concentrations of ML114, reduce CFC colony frequency; and B) 
increasing concentrations of ML114 reduce CFC colony size, as shown by the reduction in 
cell number estimated within each CFC colony. (n = 5; * p = 0.05, ** p = 0.001, *** p = 
0.0001) 
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Figure 2.5 ML114-treated hPSCs retain high expression of pluripotency associated 
antigens. Flow cytometry revealed control- and ML114-treated hPSCs express similarly high 
levels of pluripotency associated antigens OCT4, TRA-1-60, and TRA-1-81 with no 
significant differences in expression levels. (n = 3; OCT4 * p = 0.16, TRA-1-60 * p = 0.35, 
and TRA-1-81 * p = 0.26).  
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and ML114-treated cells were assessed via the EdU cell proliferation assay. This analysis 
showed a significantly larger number of ML114-treated hPSCs remained in G0/G1, while 
fewer hPSCs had progressed to S-phase and G2/M compared to control-treated hPSCs (Figure 
2.6 A). After 2 hours of EdU exposure approximately 55% of control-treated hPSCs had 
entered S-phase (Figure 2.6 A). In contrast, it took 6 hours for the same percentage of hPSCs 
to enter S-phase after ML114 treatment (Figure 2.6 B). These data suggest that ML114-
treated hPSCs progressed through the cell cycle approximately three times slower than the 
control-treated hPSCs.  
2.3.4. ML114 effects are not permanent.  
To test whether the effects of ML114 treatment were permanent or reversible, hPSCs were 
subject to either control- or ML114-treatment for 7 days, and then re-seeded into optimal 
hPSC maintenance conditions without further ML114 treatment for 7 weeks. Consistent with 
earlier findings, these data showed that ML114 treatment resulted in a dramatic and 
statistically-significant reduction in cell number as a result of the initial 7 day treatment 
period relative to the control treatment. However, after removal of ML114, the hPSC 
population growth rate of the ML114-treated cultures increased, becoming indistinguishable 
from that of the control cultures within approximately 2 weeks (Figure 2.7 A). In addition, the 
CFC assay showed that the colony size and colony/cell morphology from both control- and 
ML114-treated cells were identical after 7 weeks of culture in optimal hPSC maintenance 
conditions (Figure 2.7 B).  
 A teratoma assay was then performed to assess whether the hPSCs previously treated 
with ML114 retained functional pluripotency, i.e., the ability to form derivatives of all 3 germ 
layers of the body. This analysis showed that hPSCs previously treated with ML114 for 1 
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week before expansion in standard pluripotency-maintenance conditions retained the ability to 
form teratomas containing cell types representative of endoderm, mesoderm, and ectoderm 
(Figure 2.8). A karyotyping assay was also performed to investigate whether the hPSCs 
previously treated with ML114 had developed significant chromosomal damage. These data 
indicated that both the control- and ML114-treated hPSCs had normal karyotypes (Figure 
2.9).  
 
 
2.4. DISCUSSION  
Various studies have implicated RBBP9 in normal development (O'Connor et al., 2011, 
Woitach et al., 1998), and progression of cancer (Shields et al., 2010, Woitach et al., 1998). 
These studies have suggested two possible mechanisms of RBBP9 activity: i) the ability to 
bind RB protein and regulate the activity of the RB/E2F cell cycle pathway (Woitach et al., 
1998), and ii) the ability to act as a SH (Shields et al., 2010). RBBP9 has been shown to be 
required for maintenance of hPSCs (O'Connor et al., 2011). RBBP9 protein is expressed in 
hPSCs, and siRNA-mediated loss of RBBP9 protein results in decreased CFC frequency, 
decreased expression of pluripotency and cell cycle genes, and increased expression of genes 
involved in neurogenesis (O'Connor et al., 2011). However, the mechanism(s) by which it 
controls cell behaviour in hPSCs is currently unknown. 
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Figure 2.6 ML114 slows hPSC progression through the cell cycle. EdU-based flow 
cytometry assessment of cell distribution across different phases of the cell cycle for control- 
and ML114-treated hPSCs after A) 2 hours, and B) 6 hours of EdU exposure. Comparison of 
the data shows it took 2 hours EdU exposure for ~55% of control-treated hPSCs to enter S-
phase (A), whereas it took 6 hours EdU exposure for 55% of hPSCs treated with 100 µM 
ML114 to enter S-phase (B). (n = 4; * p < 0.05).  
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Figure 2.7 The effects of ML114 are not permanent once removed from hPSC culture. 
A) ML114 treatment of hESCs results in significantly fewer cells after 7 days. However, after 
removal of ML114 treatment followed by 7 weeks culture in optimal hPSC maintenance 
conditions, the population growth rate increased to be indistinguishable from the control-
treated cells. (n = 4; *p < 0.05). B) hESCs previously treated with ML114 display identical 
cell morphology, colony size and AP staining as control-treated hESCs. 
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Figure 2.8 hPSCs treated with ML114 retain teratoma-forming ability. Histological 
analysis of teratomas derived from hPSCs treated for 7 days with 100 mM ML114, and then 
cultured re-seeded in mTeSR1 for an additional 11 weeks. All 3 germ layers are present in the 
teratomas including: A) ectoderm (e.g. neuroepithelium, arrow head); B) mesoderm (e.g. 
stroma; cartilage, arrowhead; and smooth muscle); and C) endoderm (e.g. glandular 
epithelium, arrow head). 
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Figure 2.9 G-banding analysis of hPSCs revealed ML114 does not induce large-scale 
DNA rearrangements. Karyotype data shows hPSCs exposed to 100 μM ML114, followed 
by a further 11 weeks of culture in hPSC maintenance conditions, do not possess abnormal 
chromosomes at a resolution of 400 bands per haploid set.  
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2.4.1. Use of ML114 decouples hPSC proliferation from differentiation.  
In the present study, loss of RBBP9 SH activity was investigated using ML114, the newly 
identified and selective chemical inhibitor of RBBP9 SH activity. Upon cleavage by RBBP9, 
a fragment of ML114 has been shown to covalently bind to the catalytically active Ser75 of 
RBBP9 and thus inhibit RBBP9 activity, while the remaining RBBP9 fragment is released. In 
complex cell and protein assays, ML114 inhibits RBBP9 at concentrations between 20 and 
100 µM – concentrations at which it does not affect the activity of 30 other serine proteases. 
ML114 is also reported to have very low cytotoxicity up to at least 100 M (Bachovchin et 
al., 2010a). In this chapter it was shown that ML114, but not its soluble cleavage product, 
decreased hPSC growth rate regardless of whether the hPSCs were passaged as aggregates or 
plated as single cells in the CFC assay. Some effect on hPSC attachment and/or cell death was 
evident from the CFC assay, and an apoptosis assay such as the TUNEL assay could be used 
to distinguish whether the effects of ML114 resulted in apoptosis or prohibited a high 
frequency of cell attachment (Watanabe et al., 2007). However from the work presented here 
it was clear that ML114 had an inhibitory effect on hPSC proliferation by: i) decreasing the 
population and CFC colony growth rates; ii) increasing the number of hPSCs in G0/G1; and 
iii) decreasing the number of cells in S/G2/M (equating to a 3-fold decrease in progression 
through the cell cycle). After removal of ML114 the cells were shown to recover their growth 
rate, consistent with newly transcribed/translated RBBP9 replenished the RBBP9 covalently 
inactivated by ML114 treatment.  
Data from the CFC assay, flow cytometry analyses and teratoma assay all indicated 
that ML114-treatment did not induce differentiation. Interestingly, literature reports show that 
addition of potent differentiation agents such as retinoic acid result in significant changes in 
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cell morphology within 5 days of treatment, as well as a large reduction in CFC frequency 
(~80 fold) and a significant decrease in expression of pluripotency markers such as OCT4 (~5 
fold) in that same timeframe (Bain et al., 1996, Schuldiner et al., 2000, O'Connor et al., 2008). 
In comparison, ML114-treated hPSCs did not show morphological changes during the 7 days 
of treatment, and retained cells which expressed equally high levels of pluripotency-
associated antigens as control-treated cells. While the size and number of CFC-derived 
colonies were reduced by ML114 treatment, the cells still had typical hPSC morphology and 
AP activity suggesting retention of a pluripotent phenotype. The pluripotent potential of the 
ML114-treated hPSCs was supported by the teratoma-forming ability of hPSCs previously 
treated with 100 M ML114. These data suggest that the 7 day ML114 treatment did not 
induce differentiation, although it is still possible that subtle differentiation events might be 
initiated that need a longer ML114 treatment to manifest themselves. Genomic expression of 
both early differentiation and pluripotency marker levels could be assessed during the 7 day 
ML114 treatment to determine whether longer exposure to ML114 during and beyond 7 days 
would drive hPSCs towards differentiation. Alternatively, agents such as retinoic acid can be 
used to induce differentiation of hPSCs, such as the embryonal carcinoma cell line NTeraD2 
and induced PSC line iPSC65, during ML114 treatment (O'Connor et al., 2008). This would 
determine whether selective loss of RBBP9 SH activity has the capacity to accelerate, delay 
or have no effect on differentiation of hPSCs and reprogramming. Overall, the hPSC growth 
rate, cell cycle and pluripotency assay data indicate that in ML114-treated hPSCs inhibition of 
proliferation does not lead to and is not coupled with initiation of hPSC differentiation. 
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2.4.2. Evidence for coupling of proliferation and differentiation in 
pluripotent cells.  
Numerous studies of pluripotent cells have suggested that differentiation of pluripotent cells is 
coupled with decreased proliferation (Becker et al., 2006, O'Connor et al., 2011, Calder et al., 
2013, Singh et al., 2013, Savatier et al., 1996). Rapid transition from G1 phase to S-phase has 
been used as an indicator of pluripotency, where cells undergoing differentiation were found 
to accumulate in the G1 phase of the cell cycle with fewer cells present in S-phase (Becker et 
al., 2006, Calder et al., 2013, Pauklin and Vallier, 2013). Furthermore, treatment with the 
differentiation agent retinoic acid in embryonal carcinoma cells for 2-4 hours was enough 
time to lengthen G1 phase of the cell cycle and rapidly induce differentiation (Mummery et 
al., 1987, Berg and McBurney, 1990). 
 More recently though, a number of studies have suggested that hPSC proliferation and 
differentiation can be decoupled, and that decreased hPSC proliferation does not always 
determine their differentiation. For example, E2F2 is a gene that encodes a transcription 
factor with important functions in control of embryonic development, differentiation, 
proliferation, and apoptosis (Muller and Helin, 2000). Knockdown of E2F2 expression in 
hESCs led to a reduction in proliferation, reduced numbers of CFCs, and an accumulation of 
cells in G1. Yet these same cells maintained expression of pluripotency markers and also the 
ability to form differentiating embryoid bodies (Suzuki et al., 2014). Similarly, depletion of 
the protein arginine methyltransferase 5 enzyme, PRMT5, was found to decrease hPSC 
proliferation, to increase the number of hPSCs in G0/G1, and reduce the number of cells in 
G2M (Gkountela et al., 2014). However, this decrease in hPSC proliferation did not affect 
expression of pluripotency markers such as OCT4, NANOG, TRA-1-60, and SSEA4, nor did 
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it remove the capacity for multi-lineage differentiation in embryoid bodies. In light of these 
studies, the observed decoupling of hPSC proliferation and differentiation is consistent with 
an emerging understanding of hPSC biology. Notably, the effectors involved in this de-
coupling of hPSC differentiation and proliferation due to ML114 treatment are currently 
unknown.  
2.4.3. ML114 slows down progression of hPSCs through the cell cycle.  
Proliferation of pancreatic cancer cells has been shown to be mediated by RBBP9 SH activity 
(Shields et al., 2010). Overexpression of wildtype RBBP9, but not the enzymatically inactive 
S75A mutant RBBP9, was able to overcome the anti-proliferative effects of TGF- on 
pancreatic cancer cells in vitro. Interestingly, TGF- signalling is known to regulate PSC 
proliferation. For example, specific inhibition of TGF-β signalling in mESCs results in a 
significant decrease of cell proliferation, but does not affect pluripotency (Ogawa et al., 
2007). Other studies have shown TGF-β signalling to be a major contributor to the 
maintenance of pluripotency in hPSCs. TGF-β signalling has been shown to enable 
expression of master regulators of pluripotency such as OCT4, NANOG, and SOX2, while 
supressing expression of BMP4, a known inducer of differentiation (James et al., 2005, 
Vallier et al., 2009, Wei et al., 2005, Xu et al., 2008, Greber et al., 2007). Further 
investigating the impact of RBBP9 SH activity and TGF- signalling in hPSCs might provide 
a molecular framework for understanding how both pluripotent cells and cancer cells regulate 
proliferative signalling.  
 
 In summary, the data presented in this chapter has shown ML114 treatment of hPSCs 
(at concentrations known to have low cytotoxicity and high specificity for RBBP9 SH) results 
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in the de-coupling of cellular proliferation from pluripotency, thereby indicating RBBP9 SH 
activity is required for hPSC proliferation. These data also show that inhibition of RBBP9 SH 
activity does not completely phenocopy the effects of siRNA-mediated RBBP9 protein loss in 
hPSCs (O'Connor et al., 2011). In turn, this suggests that both the SH and RB-binding/E2F 
regulating activities of RBBP9 are required for hPSC proliferation, and that RBBP9-mediated 
regulation of the RB/E2F pathway is also involved in regulating differentiation towards the 
neural lineage. This later conclusion is consistent with the known role for RB/E2F in 
neurogenesis in mouse models (Callaghan et al., 1999, Ghanem et al., 2012). Further analyses 
to identify potential effectors of RBBP9 SH activity could help decipher the molecular 
pathways through which RBBP9 SH inhibition regulates hPSC proliferation. Understanding 
these mechanisms will give insights into the role of RBBP9 in hPSC maintenance and 
differentiation, tissue development, and progression of numerous cancers. 
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CHAPTER 3: Identification of putative 
effectors of RBBP9 SH activity 
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3.1. INTRODUCTION 
The originally identified mechanism of action for RBBP9 involved regulation of cell cycle 
progression through its interactions with RB. This led to the hypothesis that RBBP9 was 
involved in various cancers and tumours such as colorectal adenocarcinoma, lymphoblastic 
leukaemia, lung carcinoma, and melanoma cell lines (Woitach et al., 1998). RBBP9 has been 
implicated in the progression of pancreatic cancers through its poorly described role as a SH 
(Shields et al., 2010). More recently, our group has identified RBBP9 as a putative regulator 
of pluripotency in hPSCs. siRNA-mediated loss of RBBP9 protein resulted in decreased 
CFCs, cell cycle and pluripotency gene expression, with an increase in expression of genes 
involved in neurogenesis (O'Connor et al., 2011). However, this study did not determine 
whether these changes resulted from the loss of RB/RBBP9-binding interactions and/or the 
loss of SH activity. Moreover, the effectors of RBBP9 SH activity are currently unknown. 
Thus investigation that define the effectors of RBBP9 SH activity will enable further 
understanding of the role of RBBP9 in maintenance in hPSCs, tissue-specific stem cells and 
in the progression of various cancers.  
 
 The data presented in Chapter 2 shows that ML114 treatment of hPSCs resulted in a 
significant reduction in population growth rate, reduced frequency and size of CFCs, 
decreased progression through the cell cycle, and decoupling of differentiation from reduced 
proliferation. In the study described here, a bioinformatics approach was taken to identify 
candidate RBBP9 SH effectors in hPSCs. Gene expression profiles generated from control- 
and ML114-treated hPSCs described in the previous chapter were compared. This data was 
also compared with previously published gene expression profiles from hPSCs treated with 
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RBBP9 siRNA. Gene ontology (GO) analyses were then used to identify gene categories 
affected by ML114-induced loss of RBBP9 SH activity. Subsequent promoter analyses were 
used to predict putative effectors of RBBP9 SH activity, with PCR and Western blotting used 
to further investigate two predicted RBBP9 effectors, Nuclear transcription factor Y subunit 
A (NFYA) and Deformed epidermal auto-regulatory factor-1 (DEAF1). 
 
 
3.2. METHODS 
3.2.1. Treatment of hPSCs with ML114. 
Refer to (Chapter 2 sections; 2.2.1, 2.2.2, and 2.2.3) for general reagents and consumables, 
general equipment, and general cell culture. CA1 hESCs were treated with 0.25% DMSO, and 
100 μM ML114 chemical inhibitor 72 h post initial cell seeding and cultured for a further 7 
days.  
 
3.2.2. Reverse-Transcription Polymerase Chain Reaction (RT-PCR).  
3.2.2.1. RNA harvest.  
After treatment 1 × 10
6
 hPSCs were collected as a single cell suspension with TryPLE, 
centrifuged at 300 × g for 5 minutes and the supernatant removed. RNA was extracted and 
purified using the Bioline Isolate II RNA purification kit as per the manufacturer’s 
instructions (Bioline, Eveleigh, Australia). The concentration and purity of RNA samples was 
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assessed using triplicate A260/A280 absorbance readings via an Implen nanophotometer 
(Implen, München, Germany). RNA was stored at – 80 °C for downstream applications. 
3.2.2.2. cDNA synthesis via reverse transcription. 
Each RNA sample was analysed using a combination of 3 cDNA reactions: i) RNA with 
Reverse Transcriptase (+RT); ii) RNA without Reverse Transcriptase (-RT) to test for 
genomic contamination; and iii) a non-template control (NTC) without RNA to test for DNA 
contamination of PCR reagents. For  cDNA production, 500 ng of purified RNA, 2 μL of 25 
μg random hexamer primers (Bioline) and RNase/DNase free water for a final volume of 15 
μL were mixed briefly with a QikSpin personal centrifuge (2000 × g, 1 minute). Samples 
were placed in the Mastercycler
™ 
(70 °C, 5 minutes), then 6 μL of 5 X Reverse Transcriptase 
(RT) buffer, 1.5 μL 10 mM dNTPs, 1.5 μL U/μL RNase inhibitor and 6 μL RNase/DNase free 
water were added to a final volume of 15 μL. To the +RT and NTC samples, 0.4 μL of 200 
U/μL Bioscript enzyme (Bioline) was added. Samples were mixed briefly with a QikSpin 
personal centrifuge (2000 × g, 1 minute) before being placed in the Mastercycler ™ for 
cDNA production using the following cycles: cycle 1 (42 °C, 60 minutes), and cycle 2 (70 °C, 
10 minutes).  
3.2.2.3. Primer design. 
Forward and reverse primers for specific genes were designed using the Primer3Plus web 
page (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). Exon sequences for 
specific genes of interest were obtained using the Ensembl genome browser 
(http://asia.ensembl.org/index.html) noting known splice variants or mutations. Sequences 
covering the 3’ end of an exon to the 5’ end of the next exon were copied into Primer3Plus 
and primer design initiated using 60 °C melting temperature and 80-200 base amplicon 
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length. The specificity of output primers was assessed by searching the sequences against the 
entire known human genome and transcriptome using the National Centre of Biotechnology 
Information BLAST nucleotide web page 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch). Primers were 
considered unique if they generated a high BLAST score coupled with a low expect (E) value. 
Primers were synthesised by GeneWorks (Table 3.1) (Thebarton, Australia).  
Table 3.1 hPSC primer sequences (5’ to 3’) 
Gene Forward primer sequence Reverse primer sequence 
NFYA GCACGGAGTGTACCTCACAG TGCTGTATACTGCTCCATGGTC 
GAPDH ATTGCCCTCAACGACCACT ATGAGGTCCACCACCCTGT 
 
3.2.2.4. PCR amplification of mRNA transcripts.  
Each PCR primer was tested with trial PCR reactions at temperatures ranging between 55-60 
°C. Each PCR reaction consisted of 5 μL 5 X Go-Taq flexi PCR buffer, 1.5 μL 25 mM 
MgCl2, 1 μL 10 mM dNTPs, 2 μL 12.5 μM forward and reverse primers, 14 μL RNase/DNase 
free water, 0.5 μL Go-Taq flexi buffer, and 1 μL of cDNA (+RT, -RT, and NTC). Samples 
were placed into the Mastercycler® using the test temperatures for cDNA amplification 
starting at 60 °C. Each PCR reaction consisted of 3 steps: denaturation (95 °C, 5 minutes and 
30 seconds); annealing of primers to cDNA (55-60 °C, 20 seconds); and extension (72 °C, 2 
minutes and 30 seconds). PCR products were assessed via gel electrophoresis using 2% 
agarose gels containing 5 μL of 10, 000 X Gel Red Nucleic Acid (Bioline) and a 100 bp DNA 
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ladder (4 μL of 50 μg/μL). Electrophoresis was performed at 100 V, 300 mA, and 50 W for 
40 minutes. Gels were imaged using a Gel Dock Transilumminator (Fisher Biotec, Wembley, 
Australia) and E-box software. 
 
3.2.3. Quantitative PCR (qPCR).  
qPCR was performed in triplicate using the optimal primer temperatures identified as 
described above. The RT-PCR efficiency of each primer was determined using a standard 
curve for all primers for all genes of interest (GOI), including the housekeeping gene 
GAPDH. Primer pairs were kept if their amplification efficiency was between 90%-110%. 
RT-PCR reaction mixture consisted of 5 μL of SYBR® Green PCR Master Mix (Thermo 
Fisher Scientific), 1 μL of 12.5 μM forward and reverse primer mixture, and 4 μL of sample 
cDNA (+RT, -RT, and NTC). Triplicates technical replicates were performed per test sample 
in a flat top low profile 96-well plate (Scientific Specialties, Inc., California, USA). Plates 
were centrifuged (1,000 × g, 1 minute) and RT-PCR performed using an Mx3005P qPCR 
system (Aligent Technologies, Sydney, Australia), MxPro software, a polymerase activation 
cycle (50 °C, 2 minutes) followed by 40 cycles of: denaturation (95 °C, 5 minutes and 30 
seconds); annealing of primers to target sequences (optimal temperature identified between 
55-60 °C, 20 seconds); and extension (72 °C, 2 minutes and 30 seconds) Triplicate cycle 
threshold (Ct) values for each primer/sample set were averaged and the quantification (Q) 
value obtained based on:  
Q value = Efficiency of Gene of Interest (GOI)
(Sample 1-Sample 2 Ct values). 
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The Q value of the GOI was then normalised against the Q value of the housekeeping gene 
GAPDH.  
𝑄 𝐺𝑂𝐼
𝑄 𝐻𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝑔𝑒𝑛𝑒
 
A students t-Test was then performed to determine whether the change seen in gene 
expression levels were statistically-significant (i.e., p < 0.05).  
 
3.2.4. Affymetrix gene expression profiling.  
3.2.2.1. Sample preparation for Affymetrix analysis. 
Affymetrix profiling was performed on 6 samples (3 × DMSO control-treated and 3 × 100 
µM ML114 treated hPSCs), with each sample harvested after 7 days of treatment.  
 
3.2.4.2. RNA extraction, purification, and quantification for Affymetrix analyses. 
Treated hPSCs were harvested at confluency for RNA, purified, and then quantified (see 
section 3.2.2.1). Following this, separate samples containing 500 ng of purified RNA were 
analysed using HuGene-1.0-st-v1 arrays (Affymetrix, Santa Clara, CA, USA) at the 
Ramaciotti Centre for Gene Function Analysis (University of New South Wales, Sydney, 
Australia) as per manufacturer’s instructions. Analysis of Affymetrix profiling data was 
performed using the GenePattern software suite (Reich et al., 2006) as described below.  
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3.2.4.3 Identifying present and absent calls in microarray data. 
As a method of validation, Affymetrix gene expression profiling data was analysed to identify 
which transcripts were present (P) or absent (A) across all 3 Affymetrix profiling arrays for 
each treatment. Transcripts were considered for further analysis if they were found present 
across all 3 Affymetrix profiling arrays for their respective treatments (i.e., ‘3P’). After 
identifying 3P genes, a .RES file containing unique identifiers relating to particular transcripts 
was used to generate P and A calls via the GenePattern module 
‘AffySTExpressionFileCreator’. Transcript identifiers from the sample array data were then 
sorted based on 3P and 3A calls for each transcript using the ‘Sort’ function embedded within 
Microsoft Excel. Once genes in both treatments were identified as 3P, they were saved in a 
Microsoft Excel document for future reference.  
 
3.2.4.4. Identifying statistically significant gene expression differences between control- and 
ML114-treatments. 
Affymetrix microarray data was initially analysed using the GenePattern module 
‘NormalizeAffymetrixST’, together with a .CLS file which defined the treatment type and 
order for each Affymetrix sample to be analysed. This generated a .GCT file which described 
the expression dataset of control- and ML114-treated hPSCs. An additional pre-processing 
step was performed to identify interesting trends present within Affymetrix data, such as 
differential expression between DMSO-control, and ML114-treatment, as well as remove 
platform noise and transcripts whose probe did not emit a signal. The .GCT and .CLS files 
were input into to a log-base 2 filter to further increase signal-to-noise, thus creating the pre-
processed .GCT file. In this step, up- and down-regulated genes were brought to the same 
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scale and allowed the identification of gene expression signatures unique to ML114 treatment. 
This pre-processed output was input into the ‘ComparativeMarkerSelection’ module of 
GenePattern, and results were viewed and extracted using the 
‘ComparativeMarkerSelectionViewer’ module.  
In order to identify candidate genes statistically significantly up-regulated by ML114 
treatment, the ‘ComparativeMarkerSelectionViewer’ data was partitioned to identify 
transcripts with differential expression p values <0.05 and associated false discovery rate 
values (FDR-value) <0.05. The FDR-value was included as a consideration for statistical-
significance to reduce the probability of a false-positive result due to random chance that can 
occur with analysis of large datasets. Once transcripts were classed as statistically-
significantly affected by ML114 treatment, they were then compared against the 
corresponding 3P list from 3.2.4.1 to generate a high confidence list of genes affected by 
ML114 treatment. This guaranteed that the transcripts found statistically-significantly 
differentially expressed by ML114 treatment were expressed in all 3 Affymetrix profiling 
arrays for either the control- or ML114-treated samples. This final gene list was used for 
downstream analyses. As a number of genes had multiple Affymetrix probes due to different 
potential gene transcripts, genes were considered expressed if at least 1 transcript probe was 
identified as 3P in either control- or ML114-treated samples.  
 
3.2.5. Gene Ontology (GO) analysis.  
Genes whose expression was statistically-significantly affected by ML114 treatment were 
input into the Database for Annotation, Visualisation and Integrated Discovery (DAVID) 
online bioinformatics database suite (https://david.ncifcrf.gov/). Selected genes were 
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uploaded into the ‘Functional Annotation Tool’ as ‘Official Gene Symbols’. The GO terms of 
genes categorised under ‘Homo sapiens’ were selected for further analysis. The GO term 
category of level 5 or higher was used for the Biological processes category to provide a 
useful balance between breadth and specificity of the output GO term groupings. Selection of 
GO terms within this category with stringent parameters (kappa statistics based on score 
distribution of all human genes to reported human protein-protein interaction pairs, and p < 
0.05) enabled broad GO class identifications in order to understand biological roles of 
selected genes and gene products (Huang et al., 2007).  
 
3.2.6. Promotor analyses. 
Putative transcription factor binding sites common to genes affected by ML114 treatment 
were identified using the PASTAA (Predicting associated transcription factors from annotated 
affinities) online suite (Roider et al., 2009). The list of unique ENSEMBL identifiers for 
genes affected by ML114-treatment were obtained using the DAVID webpage were input into 
the PASTAA online suite. Proximal promoter analyses (i.e. +400 base pairs (bp) either side of 
the transcription start sites) and distal analyses (i.e. -10,000 kilo bases (kb) upstream from the 
transcription start sites) were performed. Candidate regulator transcription factors motifs were 
identified by having a reported PASTAA p value < 0.05. 
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3.2.7. Gene expression comparisons between hPSCs treated with ML114 
and RBBP9 siRNA.  
To identify genes expressed by hPSCs and commonly affected by ML114 treatment and 
RBBP9 siRNA, Affymetrix datasets produced in Chapter 2 (for ML114) or previously 
published by our group (for RBBP9 siRNA) were processed in the same way as described 
above (see sections 3.2.4.2 and 3.2.4.3). Gene lists which were found significantly affected by 
loss of RBBP9 activities were compared using the following equation in Microsoft Excel:  
=IF(ISNA(VLOOKUP(LIST,LIST2!A:A,1,FALSE)),’NO’,’YES’) 
This formula identified genes which were commonly up-regulated by the loss of both RBBP9 
activities. Gene ontology and promoter analyses were performed as described above (see 
sections 3.2.5 and 3.2).  
 
3.2.8. Proteomics.  
3.2.8.1. Protein collection.  
Treated hPSCs were harvested as a single cell suspension (see section 2.2.3.2), centrifuged 
(300 × g, 5 minutes), the supernatant removed and the cell pellet resuspended in 500 μL of 
lysis buffer (25 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X 100, 1 
mM Na Vanadate, 1 mM PMSF, 5 μg Aprotinin, 1 X Protease inhibitor (PI), pH 7.4). 
Samples were incubated on ice for 5 minutes with occasional vortexing, then centrifuged (300 
× g, 5 minutes, 4 °C), and the supernatant collected. Samples underwent a urea exchange 
purification and concentration step using a 3,000 Da molecular weight cut-off filter (Merck 
Millipore, Bayswater, Australia) and three consecutive wash steps using 1 mL exchange 
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buffer (4 M urea, 1 X protease inhibitors) and centrifugation (4,000 × g, 20 minutes, 4 °C). 
Sample protein concentration was quantified against a BSA standard using the EZQ
®
 protein 
quantification kit (Molecular probes, Oregon, USA). To a clean filter paper, 2 μL aliquots of 
all protein standards and samples were blotted in triplicate and allowed to air dry. The blot 
was then fixed with 100% MeOH for 5 minutes and allowed to air dry. The blot was then 
stained with EZQ protein stain for 30 minutes with agitation, whilst protected from light. All 
proceeding steps were consequently performed in the dark. Following this, the blot was de-
stained with 3 × 25 second washes using 10% MeOH/7% HAc. The blot was then imaged 
using the LAS-4000 imager (Fuji Film, Brookvale, Australia) using densitrometry and 
quantification analysis via Multi Gauge v3.0 software (Fuji Film).  
 
3.2.8.2. 1-Dimensional electrophoresis (1-DE) and Western Blotting.  
For each sample, 25 μg of isolated protein was diluted 1:1 with 1-D sample buffer containing 
2% SDS, 25 mM Tris pH 8.8, 12.5 mM Dithiothretretiol (DTT), and 5% glycerol. Prior to 
electrophoresis samples were heated at 100 °C for 5 minutes, cooled to room temperature, and 
loaded into 12 % Mini Protean
®
 TGX, long shelf life pre-cast gels (Bio-Rad Laboratories, 
Gladesville, Australia). Electrophoresis was carried out using 150 V during initial migration 
through the stacking gel, and then protein separation using 90 V at 4 °C. Gels were either 
stained for total protein or analysed via Western Blotting. For total protein staining, gels were 
fixed with 10% MeOH/7%HAc and stained with Neuhoff Coomassie stain (0.1% CBB-G250, 
2% Phosphoric acid, 10% Ammonium sulfate, and 20% MeOH) for 20 hours. Gels were de-
stained with 5 × 5 minute washes of 0.5 M NaCl. Gels and imaged using a FLA-9000 imager 
(Fuji Film). For Western blotting proteins were transferred from the 1-DE gel onto a 0.2 µM 
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pore-size polyvinylidene difluoride (PVDF) membrane (Merck Millipore) that had been pre-
soaked in western transfer buffer (25 mM Tris, 192 mM Glycine, 20% MeOH, 0.025% SDS). 
Electro-blotting of the PVDF membrane was carried out at 120 V at 4 °C for 1 hour using a 
Mini Trans-Blot
® 
Cell apparatus (Bio-Rad Laboratories). After transfer, the membrane was 
placed in blocking buffer (1 X PBS, 0.1% Tween-20, 1% PVP40, 5% skim milk) for 1 hour at 
room temperature. The blocked membrane then underwent 2 × 15 minute washes with 0.1% 
PBST (1 X PBS, 0.1% Tween-20) before being exposed to a 1/500 dilution of antibody. 
Antibodies used were: anti-DEAF-1 monoclonal antibody (Sapphire Bioscience, Redfern, 
Australia); anti-NFYA monoclonal antibody (Sapphire Bioscience); and anti-GAPDH 
polyclonal antibody (Sapphire Bioscience). Membranes were incubated with their respective 
antibodies overnight at 4 °C, with constant agitation. The following day, the membrane 
underwent 2 × 15 minute washes with 0.1% PBST before being treated with a 1/2,500 
dilution of peroxidase-conjugated goat anti-mouse IgG antibody (Sigma Aldrich) for 
membranes treated with DEAF1 primary antibody, or peroxidase-conjugated goat anti-rabbit 
IgG antibody (Sigma Aldrich) for membranes treated with NFYA and GAPDH primary 
antibodies. Membranes were incubated in secondary antibody for 1 hour at room temperature 
with constant agitation. The membrane then underwent 2 × 15 minute washes with 0.1% 
PBST followed by 1 × 15 minute wash with 1 X PBS. The membrane was then exposed to 1 
mL of the Luminata Cresendo Western HRP Substrate (Merck Millipore) for 1 minute in the 
dark and imaged using a LAS-4000 (Fuji Film) and Multi-Gauge v3.0 software (Fuji Film). 
Entire western blot images were imported into Adobe Photoshop to visualise bands for 
analysis with ImageJ software. Arbitrary units obtained from bands of predicted size for 
proteins of interest were normalised against those of the housekeeping protein GAPDH. 
Statistical-significance was determined with a paired one-tail student’s t-Test.  
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3.3. RESULTS 
3.3.1. ML114-mediated loss of RBBP9 SH activity alters hPSC gene 
expression. 
To begin investigating the molecular consequences of ML114-mediated RBBP9 SH 
inhibition, Affymetrix gene expression analysis was performed on DMSO- and ML114-
treated hPSCs. This analysis revealed 2208 genes that were significantly up-regulated with 
ML114 treatment and expressed in all 3 ML114-treated samples (Figure 3.1 A, B), based on a 
p value < 0.002 and false-discovery rate of 0.021. Comparison of these 2208 genes with 
published gene expression data from RBBP9 siRNA-treated hPSCs (O'Connor et al., 2011) 
identified 152 genes commonly up-regulated by loss of both RBBP9 activities (Figure 3.1 C).  
 
3.3.2. ML114 up-regulates genes involved in protein modification processes.  
Gene ontology (GO) analysis of the 2208 genes up-regulated by ML114 identified ‘protein 
modification processes’ as the only significantly enriched GO term after testing for the 
likelihood of false-positive discoveries due to the size of the dataset (Table 3.2). As shown in 
Tables 3.3 to 3.5, this GO term category included genes involved in regulating: i) the cell 
cycle; ii) proteolysis; and iii) apoptosis. Notably, a number of these genes altered by ML114 
treatment are known targets of transcription factors involved in regulation of proliferation and 
PSC maintenance. For example, CDC25C, CCNB2, and SOX9 are targets of NFYA (Manni et 
al., 2001, Shi et al., 2015) (Appendix 1).  
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Figure 3.1 Affymetrix analysis revealed an up-regulation of genes in hPSCs treated with 
ML114. A) Affymetrix comparison of DMSO- control and ML114-treated hPSCs revealed a 
significant up-regulation of 2,726 genes in hPSCs treated with ML114. B) Identification of 
2,208 genes affected by ML114 treatment in hPSCs were shown in all 3 Affymetrix profiling 
arrays. C) Comparison of genes show 152 genes significantly up-regulated by ML114 
mediated loss of RBBP9 SH activity, and siRNA mediated loss of RBBP9 protein.  
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Table 3.2 Top 30 Biological Process (level 5) GO 
terms enriched by genes up-regulated in ML114-
treated hPSCs 
p-value Benjamini 
protein modification process 1.20E-05 2.50E-02 
hexose metabolic process 1.30E-04 1.30E-01 
regulation of Wnt receptor signaling pathway 3.10E-04 2.00E-01 
endoderm development 3.60E-04 1.70E-01 
formation of primary germ layer 9.60E-04 3.40E-01 
lipid modification 1.20E-03 3.40E-01 
glucose metabolic process 1.30E-03 2.70E-01 
Wnt receptor signaling pathway 1.30E-03 3.00E-01 
fatty acid catabolic process 1.30E-03 3.30E-01 
protein transport 1.40E-03 2.70E-01 
intracellular signaling cascade 1.50E-03 2.60E-01 
protein import into peroxisome matrix 2.60E-03 3.70E-01 
fatty acid oxidation 2.70E-03 3.40E-01 
lipid oxidation 2.70E-03 3.40E-01 
regulation of small GTPase mediated signal transduction 2.70E-03 3.60E-01 
gastrulation 3.60E-03 4.00E-01 
peroxisomal transport 3.80E-03 4.00E-01 
tissue morphogenesis 4.70E-03 4.50E-01 
positive regulation of RNA metabolic process 5.00E-03 4.50E-01 
epithelial tube morphogenesis 5.80E-03 4.80E-01 
positive regulation of transcription, DNA-dependent 5.90E-03 4.70E-01 
mesoderm morphogenesis 7.10E-03 5.20E-01 
hippocampus development 7.80E-03 5.30E-01 
cellular lipid catabolic process 8.40E-03 5.40E-01 
cellular protein metabolic process 8.60E-03 5.40E-01 
carboxylic acid catabolic process 1.00E-02 5.80E-01 
pallium development 1.00E-02 5.80E-01 
anterior/posterior pattern formation 1.10E-02 5.80E-01 
development of secondary sexual characteristics 1.10E-02 5.90E-01 
embryonic placenta development 1.30E-02 6.20E-01 
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Table 3.3 Genes affected by ML114-treatment are involved in 
the ‘regulation of cell cycle process’  
HECTD3  HECT domain containing E3 ubiquitin protein ligase 3  
APBB1 Amyloid beta precursor protein binding family B member 1   
CAMK2D Calcium/calmodulin-dependent protein kinase II delta  
CDC25C Cell division cycle 25 homolog C (S. pombe) [Gorilla gorilla]  
CDC7 Cell cycle division 7   
HERC2 HECT and RLD domain containing E3 ubiquitin protein 
ligase 2  
PRKCQ Protein kinase C theta   
ATM ATM serine/threonine kinase  
TGFA Transforming growth factor alpha  
TGFB1 Transforming growth factor 1  
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Table 3.4 Genes affected by ML114-treatment are involved in 
‘proteolysis’ 
ATG10 Auophagy related 10   
ATG7 Autophagy related 7  
BAP1 BRCA1 associated protein 1   
DZIP3 DAZ interacting zinc finger protein 3  
FBXL5 F-box and leucine-rich repeat protein 5  
FBXO11 F-box protein 11   
FBXO25 F-box protein 25  
FBXO4 F-box protein 4  
HERC2 HECT and RLD domain containing E3 ubiquitin protein ligase 2 
HERC3 HECT domain containing E3 ubiquitin protein ligase 3 
HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2  
KEL Kell blood group, metallo-endopeptidase 
MYSM1 Myb-like, SWIRM and MPN domains 1 
PCNP PEST proteolytic signal containing nuclear protein 
SENP7 SUMO1/sentrin specific peptidase 7  
UEVLD UEV and lactate/malate dehydrogenase domains  
CHFR Checkpoint with forkhead and ring finger domains,E3 ubiquitin protein 
ligase 
C3 Complement component 3   
DDB1 Damage specific DNA binding protein 1  
HERC2 HECT and RLD domain containing E3 ubiquitin protein ligase 2  
HECTD3 HECT domain containing E3 ubiquitin protein ligase 3  
HERC6 HECT and RLD domain containing E3 ubiquitin ligase family member 6  
HGF Hepatocyte growth factor   
HDAC6 Histone deacetylase 6  
LNX1 Ligand of numb-protein X 1, E3 ubiquitin protein ligase   
MAPK1 Mitogen-activated protein kinase 1   
PRKCQ Protein kinase C theta   
RING1 Ring finger protein 1   
RNF14 Ring finger protein 14   
RNF19A Ring finger protein 19A  
UBE3B Ubiquitin protein ligase E3B  
USP20 Ubiquitin specific peptidase 20  
UBE2H Ubiquitin conjugating enzyme E2H 
UBA1 Ubiquitin like modifier activating enzyme 1   
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Table 3.5  Genes affected by ML114-treatment are involved in the 
‘regulation of apoptosis’ 
FASTK Fas activated serine/threonine kinase  
STRADB STE20-related kinase adaptor beta  
B4GALT1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
ACVR1C Activin A receptor type IC 
APP Amyloid beta precursor protein   
APBB1 Amyloid beta precursor protein binding family B member 1 
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase 
CCL2 chemokine (C-C motif) ligand 2  
CDK5 cyclin-dependent kinase 5 
ERCC6 excision repair cross-complementation group 6 
GRM4 glutamate receptor, metabotropic 4 
GSK3B glycogen synthase kinase 3 beta 
HGF Hepatocyte growth factor   
HDAC3 Histone deacetylase 3 
HDAC6 Histone deacetylase 6  
ING4 Inhibitor of growth family member 4 
LCK LCK proto-oncogene, Src family tyrosine kinase for  
MAPK1 Mitogen-activated protein kinase 1   
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
PRLR prolactin receptor 
CHEK2 Checkpoint kinase 2 
PPP2R1A protein phosphatase 2 regulatory subunit A, alpha 
STK17B Serine/threonine kinase 17b 
STAT5A Signal transducer and activator of transcription 5A 
ATM ATM serine/threonine kinase   
TGFB1 Transforming growth factor 1  
TGFB2 Transforming growth factor 2 
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3.3.2. NFYA is a predicted effector of RBBP9 SH activity.  
Promoter analyses were used to identify transcription factor binding motifs common to genes 
whose expression was altered by ML114 treatment, as a way of identifying candidate 
transcription factors responsible for the gene expression changes caused by ML114. Two 
separate promoter analyses were performed: i) a distal analysis interrogated a region 
extending 10 kb upstream from the transcription start site of each genes promoter, and ii) a 
proximal analysis interrogated a region situated ± 400 bp either side of the transcription start 
site for each gene affected by ML114 treatment. Using this approach a number of 
transcription factors were found to be highly ranked predicted regulators of the genes up-
regulated by ML114 treatment in both the proximal and distal analyses (Tables 3.6 and 3.7). 
This included ELF-1 and SP1, previously implicated in tumorigenesis and cell cycle 
regulation (Gerloff et al., 2011, Davie et al., 2008, Chuang et al., 2009), with SP1 also 
implicated in regulation of NANOG expression in murine embryonic carcinoma cells (Wu 
and Yao, 2006). Interestingly NFYA and DEAF1 were identified as the top, or close to top, 
predicted transcriptional regulators of the ML114-affected genes in both the proximal and 
distal analyses. These two transcription factors have been implicated in proliferation, PSC 
maintenance, and early embryo development (Bhattacharya et al., 2003, Dolfini et al., 2012, 
Gu et al., 2010, Manni et al., 2001). Similar promoter analyses of the genes commonly 
affected by both ML114 treatment and RBBP9 siRNA also predicted DEAF1 and NFYA 
(through its alternate name CBF_01) as putative candidate regulators of RBBP9 activities 
(Tables 3.8 and 3.9).  
 To test whether NFYA and DEAF1 might be effectors of RBBP9 SH activity, a 
variety of gene and protein expression analyses were performed. A small fold change in 
84 
 
transcripts was observed (less than 2-fold change), with fold change increases ranging from 
24.7% to 0.05%. Firstly, analysis of Affymetrix gene expression data showed a small but 
significant increase in NFYA transcript levels (fold change = 1.005218, p = 0.001996), but no 
significant changes with DEAF1 expression (fold change = 1.000845, p = 0.469062) between 
DMSO- and ML114-treated hPSCs. Additional analysis via qPCR revealed no difference in 
NFYA transcript levels resulting from ML114 treatment (Figure 3.2 A). Western blotting was 
then used to determine whether NFYA and/or DEAF1 protein might be targets of RBBP9 SH 
activity. Analysis of hPSCs treated with DMSO, 100 μM ML114 soluble fragment, or 100 
μM ML114 showed DEAF1 protein expression in all three conditions, with no significant 
difference in expression between the different treatments (Figure 3.2 A-D). In contrast, 
NFYA protein expression increased by ~50% in the ML114-treated cells relative to GAPDH 
expression, p = 0.04 (Figure 3.3 B-D). 
 
 
3.4. DISCUSSION  
The molecular networks regulated by RBBP9 SH activity are currently unknown, but are of 
significant interest given the demonstrated roles RBBP9 plays in hPSC maintenance and 
proliferation of cancer cells (O'Connor et al., 2011, Woitach et al., 1998, Shields et al., 2010). 
In an attempt to identify effectors of RBBP9 SH activity, this chapter used a variety of 
complementary approaches including gene expression profiling, promoter analyses and 
Western blotting.  
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Table 3.6 Proximal analysis using PASTAA: Top 20 predicted regulators of 
genes up-regulated in hPSCs treated with ML114. 
 
Candidate mediators of genes affected by ML114 (Proximal Analysis ± 
400 bp) 
Matrix 
Transcription 
Factor Association Score P-Value 
ARNT_02 Arnt 10.876 0.00E+00 
STRA13_01 Stra13 9.882 0.00E+00 
NFY_01 N/A 7.035 5.00E-06 
TFIII_Q6 Tfii-i 6.654 1.70E-05 
MAZR_01 Mazr 6.294 4.20E-05 
NFKAPPAB65_01 Rela 6.156 5.40E-05 
USF_Q6 Usf1 , Usf2a 6.139 5.40E-05 
MZF1_01 Mzf-1 6.09 6.70E-05 
DEAF1_01 Deaf-1 5.999 8.00E-05 
USF_Q6_01 Usf-1 , Usf1 5.802 1.27E-04 
ATF1_Q6 Atf-1 5.652 1.63E-04 
NERF_Q2 Nerf-1a 5.422 2.79E-04 
DEAF1_02 Deaf-1 5.354 3.16E-04 
MTF1_Q4 Mtf-1 5.266 3.98E-04 
MOVOB_01 Movo-b 5.161 4.91E-04 
EGR2_01 Egr-2 5.155 4.94E-04 
CETS1P54_03 C-ets-1 4.928 8.23E-04 
NRF2_01 N/A 4.768 1.17E-03 
ARNT_01 Arnt 4.584 1.72E-03 
EGR3_01 Egr-3 4.565 1.80E-03 
YY1_Q6_02 Yy1 4.563 1.80E-03 
 
  
86 
 
Table 3.7 Distal analysis using PASTAA: Top 20 predicted regulators of 
genes up-regulated in hPSCs treated with ML114. 
 
Candidate mediators of genes affected by ML114 (Distal Analysis 
- 10 kb) 
Matrix 
Transcription 
Factor 
Association 
Score P-Value 
NFY_01 N/A 4.681 1.37E-03 
ETS_Q4 Erf , Elf-1 4.194 3.76E-03 
NFKAPPAB50_01 N/A 4.147 4.05E-03 
PR_02 N/A 4.059 4.91E-03 
NFY_Q6 Cbf-a , Cbf-b 3.616 1.21E-02 
SZF11_01 N/A 3.597 1.26E-02 
NFY_Q6_01 Cbf-a , Cbf-b 3.515 1.47E-02 
DEAF1_02 Deaf-1 3.393 1.88E-02 
NFY_C Cbf-a , Cbf-b 3.314 2.15E-02 
CRX_Q4 Crx , Rx 3.311 2.17E-02 
ETS2_B C-ets-1 , C-ets-2 3.293 2.27E-02 
MAZR_01 Mazr 3.288 2.34E-02 
OCT1_01 Pou2f1 , Pou2f1a 3.19 2.82E-02 
E2F_Q4_01 Dp-1 , E2f-1 3.149 3.07E-02 
CDP_02 Cutl1 3.037 3.71E-02 
CLOX_01 Cutl 3.037 3.71E-02 
YY1_02 Yy1 3.014 3.98E-02 
HNF4_Q6_02 Hnf-4 , Hnf-4alpha 2.98 4.20E-02 
HSF1_Q6 Hsf1 , Hsf1long 2.898 4.81E-02 
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Table 3.8 Proximal analysis using PASTAA: Top 20 predicted regulators of 
genes up-regulated in hPSCs treated with both ML114- and RBB9 siRNA. 
 
Candidate mediators of genes affected by loss of both RBBP9 activities 
(Proximal Analysis ± 400 bp) 
Matrix Transcription Factor Association Score P-Value 
LBP1_Q6 N/A 5.55 1.12E-04 
PAX4_03 Pax-4a 4.392 1.32E-03 
MAZR_01 Mazr 4.348 1.43E-03 
HEN1_01 N/A 4.133 2.10E-03 
PAX9_B Pax-9a 4.133 2.10E-03 
ETF_Q6 N/A 4.132 2.10E-03 
HEB_Q6 Heb 3.898 3.45E-03 
E2_Q6 N/A 3.806 4.25E-03 
AP4_Q6_01 Ap-4 3.804 4.25E-03 
GC_01 N/A 3.556 7.05E-03 
DEAF1_01 Deaf-1 3.535 7.34E-03 
SP1_Q4_01 Sp1 , Sp2 3.468 8.12E-03 
SP1_Q6 Sp1 3.468 8.12E-03 
SP1_Q6_01 Sp1 , Sp3 3.468 8.12E-03 
PAX5_01 Pax-5 3.425 9.26E-03 
SP1_01 Sp1 3.357 1.03E-02 
MYB_Q6 C-myb 3.352 1.03E-02 
GATA1_01 Gata-1 3.349 1.03E-02 
E2_01 N/A 3.259 1.25E-02 
CHCH_01 Chch 3.126 1.62E-02 
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Table 3.9 Distal analysis using PASTAA: Top 20 predicted regulators of 
genes up-regulated in hPSCs treated with both ML114- and RBB9 siRNA. 
 
Candidate mediators of genes affected by loss of both RBBP9 activities 
(Distal Analysis - 10 kb) 
Matrix 
Transcription 
Factor 
Association 
Score P-Value 
POU1F1_Q6 Pou1f1 , Pou1f1a 4.809 5.41E-04 
YY1_02 Yy1 3.697 5.30E-03 
AHR_01 Ahr 3.413 9.58E-03 
PU1_Q6 Pu.1 3.365 1.01E-02 
LXR_DR4_Q3 N/A 3.153 1.55E-02 
CDP_02 Cutl1 3.061 1.83E-02 
GATA3_03 Gata-3 3.043 1.92E-02 
NFKAPPAB50_01 N/A 3.017 2.07E-02 
STAT3_02 Stat3 2.99 2.20E-02 
ROAZ_01 Roaz 2.967 2.27E-02 
COUP_DR1_Q6 
Coup-tf1 , Coup-
tf2 2.931 2.41E-02 
GATA1_02 Gata-1 2.893 2.59E-02 
NFE2_01 Nf-e2 2.799 3.09E-02 
OLF1_01 Olf-1 2.772 3.23E-02 
HFH4_01 Foxf1 , Foxj1 2.75 3.34E-02 
LYF1_01 N/A 2.748 3.35E-02 
E2_Q6 N/A 2.72 3.67E-02 
NFMUE1_Q6 N/A 2.699 3.83E-02 
PBX1_02 Pbx1a 2.646 4.14E-02 
CBF_01 N/A 2.645 4.14E-02 
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Figure 3.2 DEAF1 is not significantly increased in treated hPSCs A) Coomassie stained 1-
DE gel of samples run in hPSCs treated with DMSO-control, ML114-soluble fragment 
treated, and ML114. B) Western blot detection of DEAF1 protein across all treatments. C) 
Analysis of western blots identified no significant changes in DEAF1 protein levels between 
DMSO-control, (n = 3), 100 μM ML114-soluble fragment (n = 2), and ML114-treated hPSCs 
(n = 3).  
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Figure 3.3 NFYA expression in hPSCs treated with ML114. A) qPCR revealed no 
significant increases in NFYA transcript levels in hPSCs treated with ML114. B) Coomassie 
stained 1DE gel of samples run with hPSCs treated with DMSO-control, ML114-soluble 
fragment treated, and ML114. C) Western blot detection of NFYA protein across all 
treatments. D). Analysis of western blots identified a significant increase in NFYA protein 
levels between DMSO-control, 100 μM ML114-soluble fragment, and ML114-treated hPSCs 
(n = 3).  
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3.4.1. DEAF1 & NFYA: pluripotency regulators as candidate RBBP9 SH 
effectors. 
Affymetrix profiling revealed 2208 genes up-regulated as a result of ML114 treatment. The 
promoters of many of these differentially regulated genes contained a range of known and 
novel pluripotency-related transcription factors. DEAF1 and NFYA were selected for further 
investigation as they were high-confidence predicted regulators in both the distal and 
proximal promoter analyses of genes affected by both ML114 and RBBP9 siRNA treatments. 
DEAF1 and NFYA are reported to have roles in embryonic development and self-renewal in 
ESCs (Bolognese et al., 1999, Dolfini et al., 2012, Gu et al., 2010, Veraksa et al., 2002). For 
instance, a reduction of DEAF1 protein has been shown to induce embryonic arrest in the 
early stages of Drosophila development (Veraksa et al., 2002). Additionally, differentiation of 
mESCs and hESCs was found to decrease levels of DEAF1 similarly to OCT4 and NANOG. 
This decrease led the authors to conclude that DEAF1 has a role in self-renewal of both 
mESCs and hESCs (Gu et al., 2010). The lack of any decrease in OCT4, NANOG and 
DEAF1 transcript levels seen in this chapter provides further support for the idea that ML114 
treatment did not induce hPSC differentiation.  
NFYA has been shown to be a bifunctional transcription factor, where it has dual 
functions in transcriptional regulation by acting as either an activator or repressor (Ceribelli et 
al., 2008, Peng and Jahroudi, 2002, Deng et al., 2007, Peng and Jahroudi, 2003). For NFYA 
to act either as an activator or repressor of NFY targets there must be an active NFY trimer 
(NFYA, NFYB, or NFYC) present. These NFY subunits possess histone like properties, 
which enables specific binding to the CCAAT box, a common eukaryotic promoter element 
(Ceribelli et al., 2008). A study has shown subunits of NFY function in a cell-specific 
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manner, where recruitment of histone deacetylases to the von Willebrand factor endothelial-
specific promoter were found to repress promoter activity in non-endothelial cells and activate 
promoter activity in endothelial cells (Peng and Jahroudi, 2002). 
Loss of NFYA in early embryogenesis was shown to result in early embryonic 
lethality, supporting the requirement of NFYA in early embryogenesis and ESCs 
(Bhattacharya et al., 2003). Chromatin immunoprecipitation data has shown NFY binds to the 
CCAAT-containing regions of Cdc25c, Sall4, and Zic3, which are highly expressed in 
pluripotent cells (Grskovic et al., 2007). The Affymetrix analyses showed here revealed up-
regulation of CDC25C and NANOG with ML114 treatment. Compared with analysis of the 
published RBBP9 siRNA data showed increased ZIC3 expression with RBBP9 siRNA 
treatment (O'Connor et al., 2011). During differentiation events in ESCs NFYA expression 
was shown to be significantly down-regulated, suggesting NFYA is required for assisting 
maintenance of pluripotency in ESCs (Grskovic et al., 2007). This suggests the up-regulation 
of NFYA might be a cellular consequence responsible for maintaining pluripotency in hESCs 
after selective inhibition of RBBP9 SH activity. In support of this idea, genes involved in 
differentiation were not significantly expressed with ML114 treatment; in contrast 
neurogenesis genes were upregulated with complete loss of RBBP9 protein. 
The CCAAT binding motif bound by NFY has been shown to be part of the ESC 
transcription factor circuitry, promoting binding of master transcription factors such as OCT4, 
NANOG and SOX2 (Dolfini et al., 2012, Oldfield et al., 2014). Oldfield and colleagues 
showed silencing of NFYA resulted in significant loss of mESC Nanog protein, and gene 
expression analyses identifying depletion of NFY subunits resulted in down-regulation of 
pluripotency genes such as Nanog concomitantly with up-regulation of differentiation genes 
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(Oldfield et al., 2014). The Affymetrix data presented here also showed a small but significant 
increase in expression of NANOG, SMAD1 and TGF-β1. High expression of NANOG is 
associated with pluripotency in hPSCs (Hart et al., 2004). Additionally, Nanog has been 
shown to bind to Smad1 and inhibit differentiation induced by bone morphogenic protein 
(BMP) signalling in mESCs (Suzuki et al., 2006). Thus ML114-treated hPSCs might retain 
pluripotency due to at least maintained, if not increased, levels of NANOG gene expression. 
Furthermore, NFYA expression has been shown to be regulated both at a transcriptional and 
translational level, with significant losses of NFYA identified in differentiated cells (Farina et 
al., 1999). Chromatin immunoprecipitation experiments performed in another study had also 
identified a high percentage of NFY motifs are present in the promoters of genes that are 
regulated by well-known regulators of pluripotency such as NANOG (47%), and SOX2 
(43%), with addition of NFYA resulting in up-regulation of Nanog in mESCs (Dolfini et al., 
2012). Curiously, this also increased proliferation of the mESCs, opposite to the effect seen 
with ML114 on hPSCs. As NFYA can act as a transcriptional activator or repressor, the 
different effect of increased NFYA protein on hESCs (used here) compared to the Dolfini 
mESC study could be due to the known and quite large differences in chromatin between 
these 2 different pluripotent states. In support of this idea, overexpression of the short isoform 
NFYA via protein transduction in the pluripotent NT2/D1 human embryonal carcinoma cells 
was shown to significantly reduce growth rates by 50-60% (Mojsin et al., 2015). Also, 
siRNA-mediated loss of RBBP9 protein in NT2/D1 cells resulted in reduced proliferation but 
also initiation of neural differentiation (O'Connor et al., 2011). 
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3.4.2. Potential mechanisms for effect of ML114 on hPSCs mediated by 
DEAF1. 
Both DEAF1 and NFYA have reported roles in the regulation of proliferation in other, non-
pluripotent cell types. Increased proliferation was shown with overexpression of DEAF1 in 
human breast epithelial cells in vitro, and mouse epithelial cells in vivo (Barker et al., 2008). 
In contrast, up-regulation of NFYA resulted in reduced proliferation in cell types including 
human embryonal carcinoma cells, and mouse erythroleukemia cells (Mojsin et al., 2015, 
Bolognese et al., 1999). However, depletion of various subunits of NFY trimers have also 
been shown to result in reduced proliferation of human carcinoma cells (Benatti et al., 2011). 
These differences may be due to the dual role of NFY trimers, more specifically NFYA to act 
as both a transcriptional activator and repressor in a cell-type specific manner (Peng and 
Jahroudi, 2002, Mojsin et al., 2015). 
The lack of any increase in DEAF1 transcript or protein levels suggests that DEAF1 is 
unlikely to be a direct target of RBBP9 SH activity and thus may be an indirect proteolysis 
target (e.g., through RBBP9 SH-mediated proteolysis of kinases, phosphatases or other 
proteins that post-translationally regulate DEAF1). In contrast, the combination of no 
consistent increase in NFYA transcript between the Affymetrix and PCR analyses, together 
with the increased NFYA protein levels seen by Western blotting, suggests NFYA may be a 
direct target of RBBP9 SH proteolytic activity. In support of this conclusion, NFYA has 
previously been reported as a putative target of SH activity through mass spectrometry 
analyses in HIV-1 cells (Impens et al., 2012).  
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3.4.3. Potential mechanisms for NFYA-mediated effect of ML114 on hPSCs. 
NFYA has been shown to have a role in cellular proliferation in many cell types. For 
example, loss of NFYA in hematopoietic stem cells resulted in cells accumulating in G2/M 
and apoptosis (Bungartz et al., 2012). Additionally, it has been reported that in a mouse 
erythroleukemia cell line, the mRNA and protein levels of NFYB and NFYC do not vary 
during the cell cycle. In contrast, i) NFYA protein but not mRNA is maximal in mid-S phase 
and decreased in G2/M, and ii) CCAAT-binding activity follows NFYA protein levels. Based 
on this it has been suggested that NFYA is the limiting subunit within the NFY complex, and 
that post-transcriptional mechanisms regulate NFYA levels (Bolognese et al., 1999). These 
published findings therefore suggest that the increase in NFYA protein seen here after ML114 
treatment is consistent with the conclusion that NFYA protein levels are regulated post-
translationally by RBBP9 SH activity. 
NFYA has been shown to regulate many cell cycle regulatory genes such as SOX9, 
CCNB1, CCNB2, CDK1, and TOP2A that are enriched with the CCAAT binding motif of 
NFY (Shi et al., 2015). Overexpression of the NFYA target gene SOX9 has been reported to 
decrease proliferation of prostate tumor cells (Drivdahl et al., 2004), and cyclin B is reported 
to be the only cell cycle-regulated cyclin in hPSCs (Stead et al., 2002). The Affymetrix 
analyses presented here revealed a small but significant increase in expression of particular 
NFYA target genes (as a result of both ML114 and RBBP9 siRNA) involved in cell cycle 
regulation including CCNB2 and SOX9. Thus the Affymetrix data supports the idea that 
altered expression of NFYA target genes plays a role in the reduced hPSC proliferation and 
population growth rates that resulted from ML14 treatment. 
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The Affymetrix analysis of ML114-treated hPSCs also revealed a small but significant 
up-regulation of CDC25C and CDK5 expression. This is interesting as CDC25C has 
previously been associated with NFYA and cell cycle regulation (Lucibello et al., 1995, 
Zwicker et al., 1995, Manni et al., 2001). Members of the CDC family, including Cdc25c 
have been identified as direct targets of Cdk5 in mouse brain lysates (Chang et al., 2012). 
Both CDC25C and CDK5 have been reported to work together to create a proliferative block 
in DU145 androgen-independent prostate cancer cells. Up-regulation of CDK5 resulted in an 
accumulation of cells in G1 phase, similar to the effects seen in hPSCs treated with ML114 
(Lin et al., 2014). Thus in ML114-treated hPSCs, up-regulation of both CDC25C and CDK5 
expression as a result of increased NFYA protein levels could account for the temporary 
proliferative changes observed. 
 
Overall, the data presented here suggests that the decreased proliferation seen in 
Chapter 2 is due to loss of RBBP9 SH activity resulting in increased levels of NFYA protein. 
This then leads to small but statistically-significant changes in gene expression for a range of 
genes known to regulate the cell cycle in pluripotent cells. The observed increase in NFYA 
protein levels as a result of ML114 treatment is consistent with published reports that NFYA 
is a known target of SH (Impens et al., 2012), and that NFYA activity is regulated by post-
translational modification (Manni et al., 2008, Bolognese et al., 1999). As a note of caution, 
the small fold changes seen with the differentially-expressed genes suggest that further 
investigation into the molecular mechanisms of RBBP9 SH activity in hPSCs would benefit 
from proteomic approaches to look at protein levels and/or protein activity - both global 
proteomic analyses and specific analyses targeting NFYA and DEAF1. Given that RBBP9 
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and NFYA are both involved in hPSC maintenance and are both expressed during embryonic 
development, further investigation into the consequences of RBBP9 SH inhibition during 
development is also of interest. Other transcription factors affected by ML114 might also be 
worth investigating such as YY1 which has also been reported to be an essential regulator of 
stem cell maintenance and associated with cancer (Gangaraju and Lin, 2009, Kaufhold et al., 
2016). The relationship of YY1 and RBBP9 SH activity loss could be investigated via gene 
expression and western blot analyses similarly to the assessment of NFYA and DEAF1. 
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CHAPTER 4: Investigating the role of 
Rbbp9 in embryonic zebrafish 
development 
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4.1. INTRODUCTION  
Data presented in Chapter 2 showed ML114 treatment decoupled hPSC proliferation and 
differentiation capabilities, i.e., ML114 reduced hPSC proliferation but the treated cells 
retained pluripotency markers and the capacity to form tri-lineage teratomas after treatment 
was removed. Having an appropriate balance between stem cell maintenance, proliferation, 
and differentiation is essential for normal embryonic development. For example, published 
studies have shown that loss of key regulators of proliferation such as cyclins results in 
developmental abnormalities in mouse embryogenesis (Kozar et al., 2004). Serine proteases 
have previously been implicated in Drosophila gastrulation, with loss of serine protease 
function due to mutations seen to result in incomplete neural development during early 
embryogenesis (Han et al., 2000). In addition, the serine protease Furin: has been shown to be 
essential for the formation of key tissues derived from all three cell lineages. Disruption of 
this enzymatic activity has been shown to result in malformation of epiblast derivatives such 
as the primitive heart, gut, and extraembryonic mesoderm in mouse models (Roebroek et al., 
1998).  
To understand the role of Rbbp9 SH activity during embryonic development in vivo, 
zebrafish embryos were treated with ML114. Zebrafish are a useful model of vertebrate 
embryonic development as they are fertilised and develop outside the mother’s body, have 
rapid development (i.e., a well-developed body and organ systems within three to four days), 
and are optically transparent so their development can be followed via simple microscopy 
(Streisinger et al., 1981, Kimmel et al., 1995). Zebrafish also display molecular similarities to 
human and hPSC development. This includes high levels of oct4 in blastomeres of zebrafish 
embryos (Robles et al., 2011) – cells equivalent to the source of hESCs derived from the 
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blastocyst of the inner cell mass. Other studies have successfully generated PSCs from 
zebrafish embryos at the mid-blastula stage (~2.25 hpf) and gastrula stage (~5.5 hpf) that have 
the potential to generate tissue specific cell lineages, similarly to hPSCs (Fan et al., 2004, 
Ghosh and Collodi, 1994).  
 Investigation via the Bgee gene expression browser shows rbbp9 transcripts are 
expressed in at least 10 zebrafish organs at 40 different stages. This includes in the eye, heart, 
brain, and digestive tract, from fertilisation through to adult stages (Bastian et al., 2008). 
ML114-treated zebrafish were assessed for developmental changes via live animal imaging, 
PCR and histology. These studies confirmed rbbp9 transcripts were expressed throughout the 
early stages of zebrafish development. ML114 treatment resulted in phenotypic changes to 
zebrafish eye, heart, brain and digestive tract morphology. To assess how these changes 
compared to the loss of entire Rbbp9 protein during zebrafish development, rbbp9 
morpholino (i.e., gene expression knockdown via blocking translation) experiments were 
performed. The changes seen were similar, though not identical, to those seen with ML114-
treated zebrafish. The combined ML114 and rbbp9 morpholino data presented here suggests 
Rbbp9 activities might be required for normal embryonic development in zebrafish, thus 
raising the possibility that RBBP9 SH activity plays a role in normal human tissue 
development.  
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4.2. METHODS 
4.2.1. Zebrafish husbandry and housekeeping. 
Tübingen/AB (TAB) strain zebrafish were maintained under standard housing conditions 
(Westerfield, 2000). Briefly, zebrafish were fed twice daily and kept at 28 °C, pH 7.4, and 
average conductance of 800 μS maintained by a ZebTEC automated zebrafish housing system 
(Techniplast, Buguggiate, Italy). An automated 14 hour light and 10 hour dark photoperiod 
cycle was used, with 1 hour of dim light used to mimic sunrise and 1 hour of dim light used to 
mimic sunset. All zebrafish protocols were approved by the Western Sydney University 
Animal Ethics Committee (approval number A9713).  
 
4.2.1.1. Zebrafish embryo production.  
Female and male zebrafish aged between 4-10 months were selected and placed in a breeding 
tank comprised of an outer tank (to hold water) and an inner tank (a smaller tank with small 
grooves for eggs to pass through) with a divider separating the two fish overnight 
(Techniplast). Spawning was carried out upon the start of the light cycle (Kimmel et al., 
1995). The divider was removed from the breeding tank, and eggs released from the female 
were fertilised within the first 30 minutes upon removal of the divider. Fertilised embryos 
were then collected and maintained in 1 X E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM 
CaCl2, 0.33 mM MgSO4, pH 7.4) at 28 °C for the duration of the experiment (i.e. up to 7 
days).  
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4.2.2. Treatment of zebrafish embryos with ML114 chemical inhibitor.  
At the 1-cell stage post-fertilisation, 15-20 embryos were collected and maintained in 1 X E3 
medium in 35 mm Petri dishes (Corning). Embryos were immediately treated with either: 
vehicle-only control consisting of 0.25% DMSO (Sigma Aldrich), a concentration known to 
not affect zebrafish development (Parng et al., 2002, Milan et al., 2003); or with up to 100 μM 
of ML114 or ML114 soluble fragment dissolved in 0.25% DMSO. Treatments were 
replenished daily for 7 days. Zebrafish embryos were counted 24 hours post treatment to 
determine the survival rate of treated embryos. Live embryos were imaged as described in 
4.2.3, before being fixed with 4% PFA at 4 °C for 1 week for downstream applications.  
 
4.2.3. Live imaging of zebrafish.  
Phenotypic changes of zebrafish larvae were documented with live imaging at 24 hpf and 7 
days post-fertilisation (dpf). Zebrafish larvae at 24 hpf were carefully manually dechorinated 
individually using Dumostar #5 fine point tweezers (Electron Microscopy Sciences, 
Pennsylvania, USA) to enable orientation for live imaging. Prior to imaging, zebrafish larvae 
were anesthetised with 0.4 mg/mL tricaine (Sigma Aldrich) and embedded in cooled, 1% low 
melting point agarose (Thermo Fisher Scientific) in a 35 mm glass bottom petri dish (14 mm 
micro-well, and #0 glass thickness) (MatTek Corporation, Massachusetts, USA). Images of 
anesthetised fish were captured using an Olympus MVX10 Stereomicroscope (Olympus), a 
Q-Imaging Retiga-4000 DC Fast 1394 camera (Q-Imaging, Brisbane, Australia), and Q 
Capture Pro 7 software. Images of morpholino-injected zebrafish were also imaged using a 
FITC-filter and visualised with the aid of an external light source provided by an X-cite
®
 
120Q fluorescence illuminator (Excelitas Technologies, Waltham, MA, USA). Zebrafish 
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measurements were obtained from images using ImageJ software (Schneider et al., 2012). 
Measurement parameters were input into ImageJ based on the objective lens magnification 
used to capture the image. Length measurements were taken for the body, yolk sac, 
gastrointestinal space, pericardial cavity as well as the area of the eye. Body length was 
measured from tip of the head to the end of the tail following the contours of the body. Eye 
area was calculated for each eye by placing a circle on the outer perimeter of the eye and 
using ImageJ to calculate the area within. Width of the gastrointestinal space was determined 
by measuring a line from the outer gastrointestinal wall to the swim bladder at the widest 
point between the two tissues. Pericardial cavity was determined by measuring a line from the 
junction of the ear and start of the yolk sac to the apex of the pericardial cavity. Statistical-
significance was determined with a paired one-tail student’s t-Test. 
 
4.2.4. Extraction and purification of zebrafish DNA.  
Healthy adult zebrafish (6-8 months) were euthanized with 8 mg/mL of tricaine (Sigma 
Aldrich). Zebrafish DNA was then extracted using the Purelink Genomic DNA Mini Kit 
(Thermo Fisher Scientific) following the manufacturer’s instructions. Purified DNA samples 
were stored at -20 °C for downstream applications.  
 
4.2.5. Zebrafish primer design for DNA sequencing.  
Forward and reverse primers for specific genes were designed using Primer3Plus online 
software (Untergasser et al., 2007). Exon and intron sequences were obtained using the 
Ensembl online genome browser (http://asia.ensembl.org/index.html). Intronic gene 
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sequences were selected for primer design if they displayed identical sequence across all four 
different mRNA isoforms of available rbbp9 transcripts provided from different databases for 
zebrafish DNA sequence. DNA sequences derived from the 3’ region of one exon and the 5’ 
region of the next exon were input into Primer3Plus. Primer design was then initiated using 
parameters including 60 °C melting temperature, and 300-600 base amplicon pair (bp) length. 
To check whether the predicted primers bound anywhere else in the genome, the predicted 
primers were searched against the entire zebrafish genome and transcriptome using the 
BLAST nucleotide browser 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=OGP__
7955__9557). In the event primers were predicted to bind to other locations in the genome, 
the primer design process was repeated until unique primers were obtained. Primers were 
synthesised by GeneWorks (Sydney Australia).  
Rbbp9 forward primer for DNA sequencing: aacttcagctcgtttgcag 
Rbbp9 reverse primer for DNA sequencing: tgtgcgaataaaagcttcacc 
Optimal working temperatures for each PCR primer set were obtained by performing a trial 
PCR reaction at temperatures ranging between 55-60 °C. Each PCR reaction consisted of 5 
μL of 5 X Go-Taq Flexi PCR Buffer, 1.5 μL 25 mM MgCl2, 1 μL 10 mM dNTPs, 2 μL 12.5 
μM forward and reverse primers, 14 μL RNase/DNase free water, 0.5 μL Go-Taq Flexi, and 1 
μL of cDNA. Samples were placed into an Eppendorf Mastercycler® (Eppendorf, North 
Ryde, Australia) using appropriate temperature profiles to determine the optimal temperature 
of each primer starting at 60 °C. The PCR reaction consisted of a 3 step process: denaturation 
(95 °C, 5 minutes and 30 seconds); followed by annealing of primers to target regions of 
DNA (55-60 °C, 20 seconds); and finally extension (72 °C, 2 minutes and 30 seconds). PCR 
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products were loaded into a 2% agarose gel with 5 μL of 10, 000 X Gel Red Nucleic Acid 
(Bioline) as was a 100 bp DNA ladder (4 μL of 50 μg/μL) (FisherBiotec, Wembley, 
Australia). PCR products were separated using 100 V, 300 mA, and 50 W for 40 minutes. The 
gel was then imaged using a Gel Dock Transilumminator (Fisher Biotec) and E-box software. 
 
4.2.5.1. DNA sequencing.  
PCR products were excised from the agarose gel, extracted using the PureLink® Quick Gel 
Extraction Kit (Thermo Fisher Scientific), and 18 ng per sample was sequenced by the 
Australian Genome Research Facility using both the forward and reverse primers. The 
resulting sequences were compared against the entire zebrafish genome using the NCBI 
BLAST browser.  
 
4.2.6. qPCR analysis of developing zebrafish larvae.  
Zebrafish embryos pooled into respective treatment groups were homogenised on ice using a 
glass tissue homogeniser before being resuspended in RNA lysis buffer. RNA samples were 
then purified as described in section 3.2.2.1 and cDNA synthesis performed as described in 
section 3.2.2.2. Primer design was performed using exonic zebrafish sequences obtained 
using the Ensembl genome browser, and following the steps outlined in section 3.2.2.3. 
Primer sequences used are shown in Table 4.1. PCR amplification of zebrafish mRNA 
transcripts was performed as described in section 3.2.2.4 and quantification of zebrafish target 
transcripts were performed via qPCR as described in section 3.2.3.  
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Table 4.1 Zebrafish primer sequences (5’ to 3’) 
Gene Forward primer sequence Reverse primer sequence 
rbbp9 CCTGTAACGGCCAGAGAGAG GTCCGATGATGAGCGTTTCT 
tp53 GCGAGCAAATTACAGGGAAG CAGTTGTCCATTCAGCACCA 
actb1 CCCAGACATCAGGGAGTGAT CACAATACCGTGCTCAATGG 
eef1a1 GATGGCACGGTGACAACAT ACCGCTAGCATTACCCTCCT 
 
4.2.7. Western blot detection of Rbbp9 protein in zebrafish.  
Untreated zebrafish embryos at 24 hpf were resuspended in calcium free Ringers solution 
(116 mM NaCl, 2.9 mM KCl, and 5 mM HEPES, pH 7.2) on ice to isolate the yolk sac from 
the embryo. Samples were centrifuged (500 × g, 5 minutes, 4 °C) and the supernatant 
(containing the yolk sac) was removed leaving the pellet containing the zebrafish larvae. The 
pellet was washed with 1 X PBS on ice, centrifuged (500 × g, 5 minutes, 4 °C), the 
supernatant removed and the remaining pellet resuspended in RIPA buffer containing 50 mM 
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton-X-100, 1% sodium deoxycholate, 0.1% 
SDS, and protease inhibitors (Promega). Lysed samples were then centrifuged at 18,000 × g, 
20 minutes, 4 °C.  
 Protein estimations were performed as described in section 3.2.8.1; 1-DE and Western 
blotting performed as described in section 3.2.8.2. Transferred membranes were probed 
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overnight with a 1/1,000 dilution of either an anti-RBBP9 rabbit polyclonal antibody 
(Proteintech, Chicago IL, USA), or an anti-alpha tubulin [EP1332Y] rabbit monoclonal 
antibody (Abcam, Massachusetts, USA). Membranes were then washed twice with 1 X PBST 
for 15 minutes and probed with a 1/2,500 dilution of anti-rabbit IgG peroxidase raised in goat 
HRP (Sigma Aldrich) secondary antibody for 1 hour at room temperature. Membranes were 
then washed twice with 1 X PBST for 15 minutes, followed by 1 X PBS wash for 15 minutes 
before exposure to the Luminata Cresendo Western HRP Substrate (Merck Millipore) and 
imaging as detailed in section 3.2.8.6.  
 
4.2.8. Histology. 
4.2.8.1. Paraffin embedding.  
Treated zebrafish larvae were fixed in 4% PFA for 1 week, then washed twice in 1 X PBS and 
embedded and secured in a 1% agarose block to prevent loss of zebrafish during automated 
processing. The 1% agarose block with zebrafish underwent dehydration and paraffin 
infiltration using a Ziess Microm STP120 Automated Tissue Processor (Ziess, North Ryde, 
Australia) and the following settings: 50% EtOH, 3 hours; 70% EtOH, 1 hour; 80% EtOH, 1 
hour; 95% EtOH,  1 hour (twice); 100% EtOH, 1 hour (twice); Xylene, 1 hour; Xylene, 2 
hours (twice); and paraffin at 60 °C, 2 hours (twice). The paraffin-infiltrated samples were 
then embedded into a paraffin block and solidified with a minimum time of 2 hours at -9 °C. 
Serial sections of 8 μM thickness were produced from the paraffin block using a microtome 
(Thermo Scientific). Paraffin ribbons were placed into a water bath held at 30 °C and captured 
using a glass slide (Sail, Wetherill Park, Australia). Slides were dried overnight at 30 °C in an 
oven prior to staining procedures.  
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4.2.8.2. Haemotoxylin and Eosin (H & E) staining and imaging.  
Slides with sectioned material were rehydrated using the following procedure adapted from 
(Sabaliauskas et al., 2006): xylene, 15 minutes (twice); 100% EtOH, 2 minutes (twice); 95% 
EtOH, 3 minutes; and 70% EtOH, 2 minutes. Slides were then rinsed in dH2O and stained 
with Haematoxylin for 3 minutes, rinsed with cool running tap water for 2 minutes, then 
dipped into acid alcohol (0.5% HCl in 70% EtOH) 4 times to de-stain the slides. Slides were 
further developed by brief exposure to Scott’s bluing solution for 30 seconds, stained with 
Eosin for 40 seconds, and then dipped in dH2O until all excess Eosin was removed. Slides 
were then dehydrated with 10 × dips in 70% EtOH, 10 × dips in 95% EtOH, equilibrated in 
100% EtOH for 2 minutes, and finally briefly exposed to Xylene twice. Slides were then 
dried, and coverslips were applied to the slides using DPX as an adhering agent. Slides were 
imaged using a Ziess Apo Tome Microscope (Ziess), and virtual tissue images captured using 
Stereo Investigator version 11 software (MBF Biosciences, Williston, USA). Images were 
then compared at similar sections for morphological similarities and differences brought upon 
by ML114 treatment. Histological images of the acellular space surrounding the brain were 
determined by measuring 3 lines from the border of the brain (near the white matter, as 
indicated by pink staining) to the outer margin of the head at 3 separate landmarks and 
measuring 3 lines from landmarks near the white matter (parallel to lower body anatomy of 
zebrafish marked by chondrocraniumm and gastrointestinal tract) to cells of the 
chondrocranium (indicated by purple stain) then averaged. Statistical-significance was 
determined using a paired student’s t-Test. 
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4.2.9. Morpholino targeted gene knockdown.  
4.2.9.1. Morpholino oligonucleotide preparation.  
Translation-blocking morpholino oligonucleotides were generated by Gene Tools (Oregon, 
USA) based on the specific rbbp9 sequence obtained as described above, and resuspended in 
dH2O.  
rbbp9 (5’ TCACAACTCTCTTCA GAGGCATTAT 3’) 
tp53 (5’ GCGCCATTTGCTTTGC AAGAATTG 3’) 
 
4.2.9.2. Preparation and calibration of microinjection pipettes.  
Borosilicate glass pipette needles were freshly pulled prior to each microinjection. To do this, 
10 cm long (1.0 mm OD, 0.78 mm ID), thin-wall borosilicate glass capillaries (Sutter 
Instrument Co., Novato, CA, USA) were placed into a Flaming/Brown micropipette puller, 
Model P-97 (Sutter Instrument Co.) and pulled under the following parameters: heat = 645; 
pull = 60; and velocity = 80 (Dean, 2006). Prior to use microinjection pipettes were broken at 
the tip with Dumostar #5 fine point tweezers (Electron Microscopy Sciences). Pipettes were 
then backfilled with 0.05% phenol red or 0.3 X Danieau Buffer and the volume delivered 
from them calibrated using an Olympus stereomicroscope SZ61 (Olympus), a MP-285 
micromanipulator (Sutter Instrument Co.), and injection pressure controlled by a PLI-100 
Picoinjector microinjection system (Harvard Apparatus, Massachusetts, USA). Injection 
pressure was adjusted to obtain a consistent injection volume of 4 nL calculated by measuring 
droplet size in mineral oil over a micrometer (Rosen et al., 2009). This volume was selected 
based on the total volume of zebrafish embryo at the 1-2 cell stage (Leung et al., 1998).  
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4.2.9.4. Morpholino injection and observations.  
To determine optimal working concentration, morpholino’s at a stock concentration of 1 mM 
were resuspended into working concentrations ranging from 8-16 ng. Prepared micropipettes 
were backfilled with 0.05% phenol red as a control, or morpholino in 0.3 X Danieau Buffer 
containing 17.4 mM NaCl, 0.21 mM KCl, 0.12 mM MgSO4·7H2O, 0.18 mM Ca(NO3)2, 1.5 
mM HEPES, pH 7.4 (Timme-Laragy et al., 2012). Fertilised zebrafish embryos at the 1-2 cell 
stage were injected with rbbp9 and/or tp53 morpholino. Injected embryos were maintained 
for 7 days as described in 4.2.1 with daily E3 medium changes. Zebrafish imaged at 24 hpf 
and 7 dpf as described in 4.2.3 before being fixed with 4% PFA for 1 week for downstream 
applications.  
 
 
4.3. RESULTS  
4.3.1. rbbp9 is expressed by TAB zebrafish.  
As a first step towards determining whether Rbbp9 SH is required during embryonic 
development of TAB strain zebrafish, embryos at various stages of early development were 
tested for rbbp9 expression. Due to known differences in genomic sequences between 
different zebrafish strains (Coe et al., 2009), the precise genomic rbbp9 sequence for the TAB 
strain used here was obtained through DNA sequencing (Figure 4.1). Based on this sequence, 
PCR analysis of rbbp9 expression was performed across various stages of zebrafish 
embryonic development. These analyses confirmed expression of rbbp9 transcripts during the 
early stages of zebrafish development from the 1-2 cell stage through to 7 dpf (Figure 4.2).  
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Figure 4.1 Rbbp9 DNA sequence is conserved in TAB strain zebrafish. A) Rbbp9 
transcripts detected in genomic DNA (gDNA) of adult zebrafish. B) DNA sequencing 
revealed a match for Rbbp9 sequences from online databases (National Centre for 
Biotechnology Information, NCBI) for B) forward (5’-3’) and C) reverse primer (3’-5’). 
Where ‘Query’ = primer sequences input to verify detection of gene primer has been designed 
to detect by comparing with ‘Sbjct’ = annotated mRNA sequences.  
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Figure 4.2 Early-stage zebrafish larvae express rbbp9 and tp53 transcripts. Zebrafish 
larvae express rbbp9 and tp53 genes as well as the housekeeping genes actb1 and eef1a1 from 
the 1-2 cell stage immediately post fertilisation through to 72 hpf. (n = 3). 
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To investigate expression of Rbbp9 protein in developing zebrafish, Western blot analysis 
was performed using an antibody previously shown by our group to detect human RBBP9 
protein (O'Connor et al., 2011). Comparison of human and zebrafish Rbbp9 protein sequences 
identified 67% of residues fully conserved across the entire protein sequence between the two 
species. Within the N-terminal region detected by the Rbbp9 antibody 55% of the sequence 
contained conserved residues between human and zebrafish (Figure 4.3 A). Despite this 
similarity, Western blotting of 24 hpf zebrafish embryos using the validated anti-human 
RBBP9 antibody revealed a large amount of non-specific binding due to the primary but not 
secondary antibody, with no band corresponding to the predicted Rbbp9 molecular weight 
(Figure 4.3 B-C). This outcome necessitated detection of rbbp9 via mRNA levels for 
subsequent analyses.  
 
4.3.2. ML114 treatment affects zebrafish development.  
To test whether ML114 treatment affected zebrafish development, zebrafish embryos were 
treated with ML114, ML114 soluble fragment, or DMSO. Embryos were exposed to a range 
of ML114 and soluble fragment concentrations compared to DMSO using standard zebrafish 
embryo maintenance medium (E3). With no treatment at all (i.e., maintenance in E3 medium 
alone), approximately 65% of zebrafish embryos were alive at 24 hpf (Figure 4.4). Similarly, 
approximately 60-65% of zebrafish embryos treated with 0.25% DMSO, or DMSO plus 100 
μM soluble ML114 fragment also survived after 24 hpf (Figure 4.4). A small but statistically-
significant decrease in embryo viability was seen at 24 hpf, with control, 25 µM and 100 μM 
ML114.  
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Figure 4.3 Protein expression of RBBP9 in zebrafish. A) RBBP9 protein sequence 
comparison between human and zebrafish (Universal Protein Resource, UniProt). Where ‘*’ 
indicates positions which have a single, fully conserved residue between human and zebrafish 
(67%), ‘:’ indicates conservation between groups of strongly similar properties, ‘.’ indicates 
conservation between groups of weakly similar properties (7.6%), and the ‘blank space’ 
indicating non-conserved residues (12.6%). The red box corresponds to a region within the N-
terminal amino acids 2-51 where the antibody was raised to detect. Within this region 55% of 
the sequence is conserved between human and zebrafish Rbbp9 sequences B) Western blot of 
24 hpf untreated zebrafish lysate to detect RBBP9 protein using anti-RBBP9 antibody, and 
anti-rabbit secondary antibody, and C) Anti-rabbit secondary antibody only control.  
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Figure 4.4 Survival of treated zebrafish 24 hpf. Zebrafish treated with higher 
concentrations of ML114 have a significantly reduced rate of survival 24 hpf compared to 
control treated zebrafish. E3 control (n=12), DMSO control (n=33), 100 µM Fragment 
(n=29), 25 µM- (n=24), 50 µM- (n=24) and 100 µM-ML114 (n=33); * p < 0.05, ** p < 0.01. 
  
0
10
20
30
40
50
60
70
80
90
100
E3
control
DMSO
control
100 μM 
Fragment 
25 μM 
ML114 
50 μM 
ML114 
100 μM 
ML114 
%
 o
f 
su
rv
iv
in
g
 e
m
b
ry
o
s 
2
4
 h
p
f 
* 
** 
** 
** 
*  
** 
116 
 
However, as over half of the embryos treated with higher concentrations of ML114 (~50-
55%) were still viable at 24 hpf, the effects of ML114 treatment on zebrafish embryo 
development could be observed. 
 Phenotypic differences were visible at 24 hpf between zebrafish embryos treated with 
either DMSO or 100 μM ML114 soluble fragment, and those embryos treated with 100 μM 
ML114 (Figure 4.5). This included shorter overall body length, reduced area (and possibly 
pigmentation) of the eye, but no significant change in size of the pericardial cavity (Figure 
4.6). As at 24 hpf, embryos treated for 7 days with DMSO and 100 μM soluble ML114 
fragment developed normally (Figure 4.7 A-D). In contrast, zebrafish treated with ML114 for 
7 days showed gross anatomical changes (Figure 4.7 E-H). Body length and eye area was still 
significantly smaller in the ML114-treated embryos, though pigmentation levels seemed 
similar. The size of the pericardial cavity was significantly increased compared to DMSO- 
and soluble fragment-treated embryos (Figure 4.8). However, all the treated embryos had 
functioning hearts as seen by movement of blood cells. By 7 dpf control-treated zebrafish 
larvae had lost their yolk sac and developed in place a well-defined gastrointestinal tract 
(Figure 4.7 A-B). In contrast, zebrafish treated with ML114 had an enlarged gastrointestinal 
cavity with poorly-developed gastrointestinal tissue (Figures 4.7 C-D and 4.8 D). Changes 
due to ML114-treatment were observed at all concentrations, but were pronounced with 
higher concentrations.  
 Histological analyses of DMSO- and ML114-treated zebrafish larvae 7 dpf was 
performed to identify anatomical and cellular changes responsible for the morphological 
differences observed via live imaging. Representative brightfield images and H & E stained 
sections showed changes in cellular morphology between control- and ML114-treated 
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zebrafish that were consistent with the changes observed via whole animal imaging (Figure 
4.9). For example, ML114 treatment reduced eye size and altered eye anatomy (Figure 4.9 
and 4.10). All layers of the eye appeared to be present including; the outer plexiform layer, 
ganglion cell layer, inner plexiform layer, inner nuclear layer, outer nuclear layer, inner 
segment/outer segment of photoreceptor cells, and retinal epithelial cells. However, 
arrangement of cells within the layers of the eye appeared to be less organised and smaller in 
size after exposure to ML114-treatment compared with the even distribution of these layers 
seen in control-treated zebrafish (Figure 4.10 A-B).  
ML114 treatment also resulted in muscle fibres which appeared to have a more 
disorganised arrangement compared to the expected parallel alignment of muscle fibres seen 
with control-treated zebrafish (Figure 4.10 C-D). In addition, differences in development of 
the gastrointestinal tract were also seen with ML114-treated zebrafish. The area previously 
occupied by the yolk sac in control-treated embryos had been replaced by the gastrointestinal 
tract (Figure 4.10 E). In contrast, ML114-treated embryos displayed enlarged gastrointestinal 
spaces and abnormal looking gastrointestinal tissue (Figure 4.10 F). Interestingly, zebrafish 
brain development also appeared to be affected by ML114 treatment. Similarities in 
morphological landmarks such as white- (represented by pink stain) and grey-matter 
(represented by purple stain) were present between the two treatments. However, the grey 
matter arrangement appeared to be more disorganised in ML114-treated zebrafish compared 
to the neat and tightly packed arrangement of the grey matter seen in DMSO control-treated 
zebrafish (Figure 11 A-D). A significant difference was also seen in acellular space 
surrounding the brain between DMSO control- and ML114-treated zebrafish at 7 dpf (Figure 
4.11 E). 
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Figure 4.5 ML114 affects embryonic development 24 hpf. Representative images of treated 
zebrafish demonstrate phenotypic differences 24 hpf, where; A-B) DMSO control- and C-D) 
100 μM ML114 soluble fragment-treated zebrafish display no developmental abnormalities 
whilst, E-F) 50 μM and G-H) 100 μM ML114-treated zebrafish show visible developmental 
differences in; body length and shape (red arrows) and stage of eye development (black 
arrows and red boxes), with no differences observed in pericardial cavity space (yellow lines). 
Scale bar = 200 μM.  
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Figure 4.6 ML114 affects embryonic development of body and eye 24 hpf. Zebrafish 
treated with ML114 (50-100 μM) appeared to be behind in overall development at 24 hpf 
compared to control treated zebrafish (DMSO- and 100 μM ML114 soluble fragment. 
Differences were observed with treated zebrafish demonstrating; A) a shorter body length, 
and B) smaller eyes, C) with no differences in pericardial cavity. No differences were 
observed between DMSO-control and 100 μM ML114 soluble fragment treated zebrafish 24 
hpf. DMSO-control (n=7), 100 μM ML114 soluble fragment (n=5), 50 μM ML114 (n=3), and 
100 μM ML114 (n=7).   
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Figure 4.7 Anatomical changes resulting from ML114 treatment 7 dpf. Representative 
images of treated zebrafish demonstrate phenotypic differences 7 dpf, where; A) DMSO 
control- and B) 100 μM ML114 soluble fragment treated zebrafish display no developmental 
abnormalities whilst, C) 50 μM and D) 100 μM ML114-treated zebrafish exhibit 
developmental abnormalities with apparent differences in eye (red arrows), pericardial cavity 
space (yellow lines), yolk sac (orange lines) as well as body shape and size (white arrows and 
red lines). White scale bars = 600 μM and black scale bars = 300 μM.  
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Figure 4.8 ML114 affects embryonic development 7 dpf. Treated zebrafish (50 μM and 
100 μM ML114) were found to have severe developmental abnormalities. Treated zebrafish 
display; A) significantly shorter body length due to curvature, B) smaller eyes, C) increased 
pericardial cavity, and D) increased gastrointestinal space compared to DMSO-control and 
100 μM ML114 soluble fragment-treated zebrafish 7 dpf which had no significant differences. 
DMSO-control (n=5), 100 μM ML114 soluble fragment (n=4), 50 μM ML114 (n=3), and 100 
μM ML114 (n=5). 
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Figure 4.9 Histological representations of developmental changes in ML114-treated 
zebrafish 7 dpf. Histological analysis of treated zebrafish 7 dpf show morphological 
differences between A-B) DMSO control-, and C-D) 100 μM ML114-treatments. 
Representative images demonstrate changes in muscle fibre distribution, cellular distribution 
in zebrafish eye, and differences in size of pericardial space, and yolk sac. White scale bar = 
600 µm. 
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Figure 4.10 Morphological changes due to ML114 treatment at 7 dpf. Histological 
analysis of treated zebrafish 7 dpf show morphological differences between; A, C, E) DMSO 
control-, and B, D, F) 100 μM ML114-treatments. Representative images demonstrate 
changes in; A-B) cellular distribution in zebrafish eye, where all layers of the eye were 
present in both DMSO control- and ML114-treated zebrafish larvae: showing all layers 
including: i) lens, ii) ganglion cell layer, iii) inner plexiform layer, iv) inner nuclear layer, v) 
outer plexiform layer, vi) outer nuclear layer, vii) inner segment/outer segment of 
photoreceptor cells, and viii) retinal pigment epithelium. However, zebrafish treated with 
ML114 is missing the inner segment/outer segment of photoreceptor cells. Changes were also 
shown in: C-D) muscle fibre distribution where DMSO control- zebrafish show  parallel 
alignment of normal muscle fibres, whereas ML114-treated zebrafish muscle arrangement do 
not follow this pattern (black arrows), and E-F) differences in size of pericardial space, yolk 
sac size (green lines) and gastrointestinal tract (black arrows).  
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Figure 4.11 Increases in acellular space surrounding brain due to ML114 treatment at 7 
dpf. Histological analysis of treated zebrafish 7 dpf show lack of acellular space (red lines) 
surrounding the brains white- (pink stain) and grey-matter (purple stain) (red boxes) in A-B) 
DMSO control-, when compared to C-D) 100 μM ML114-treatments. E) Significant 
differences were seen in the acellular space surrounding the brain between DMSO control- 
and ML114 treatments. (n=3; ** p = 0.01).  
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4.3.3. Effect of rbbp9 and p53 morpholino’s in developing zebrafish.  
To investigate whether the observed anatomical and histological changes resulting from 
ML114 treatment might be due to p53-related stress responses, p53 transcript levels were 
assessed in control- and ML114-treated zebrafish embryos at 24 hpf and 7 dpf. These 
analyses showed no significant increase in p53 expression in zebrafish across all treatments 
(Figure 4.12). To identify the effects of Rbbp9 protein loss in zebrafish development, a 
translation-blocking morpholino (Summerton, 1999) was obtained based on the DNA 
sequence of the TAB strain zebrafish identified in this study (Figure 4.1). Morpholinos with a 
FITC tag were used to allow for visualisation of morpholino location in the developing 
zebrafish embryo after microinjection. Zebrafish embryos injected with phenol red but no 
morpholino showed no fluorescence at 24 hpf or 7 dpf, and did not present any phenotypic 
abnormalities (Figure 4.13 A-B and 4.14 A-B). In contrast, embryos injected with rbbp9 
morpholino’s showed fluorescence indicating the presence of morpholino’s within the 
developing embryos. Additionally, these embryos showed phenotypic abnormalities 
proportional to the amount of morpholino used (Figure 4.13 and 4.14). For instance embryos 
injected with 16 ng of rbbp9 morpholino showed changes most similar to those seen with 
ML114 treatment at 24 hpf, such as lack of eye pigmentation (Figure 4.13 E-F). At 7 dpf 
(Figure 4.14), zebrafish treated with both 8 ng and 16 ng of rbbp9 morpholino showed 
changes consistent with ML114 treatment. This included decreased body size, decreased eye 
size, and abnormal gastrointestinal tract anatomy (Figure 4.15 A-B). Some variation in the 
degree of these changes was observed, such that statistically-significant changes were only 
seen with 16 ng of rbbp9 morpholino. A slight but statistically insignificant difference was 
noted in the pericardial and gastrointestinal cavity (Figure 4.15 C-D) and a functioning heart 
was observed moving blood cells in the morpholino-treated zebrafish. 
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 Histological analyses of zebrafish embryos at 7 dpf revealed that embryos injected 
with the rbbp9 morpholino had some anatomical changes similar to those seen with ML114 
treatment (Figure 4.16). Unlike ML114-treatment, histological analyses showed normal 
organisation of the eye layers in both control- and rbbp9 morpholino treated zebrafish (Figure 
4.17 A,C,E). However, shortened body length due to rbbp9 morpholino treatment was 
accompanied by loosely assembled and disorganised muscle fibres similar to that seen with 
ML114 treatment (Figure 4.17 B, D, F). Differences in development of the gastrointestinal 
tract were also seen that were comparable to the changes seen with ML114-treated zebrafish. 
With the microinjection control, the gastrointestinal cavity was the expected size and 
contained properly-formed gastrointestinal tissue (Figure 4.18 A). However, rbbp9 
morpholino-treated zebrafish had an enlarged gastrointestinal cavity with large amounts of 
acellular space (Figure 4.18 C-B). Additionally, the cellular tissues within the gastrointestinal 
space of the rbbp9 morpholino-treated zebrafish looked abnormal in morphology compared to 
the control-treated zebrafish. Interestingly, comparison of brain development in the controls 
(DMSO and phenol red) showed brain development was affected by loss of Rbbp9 activity 
via 100 μM ML114, 8 ng- and 16 ng rbbp9-morpholino. The positioning of morphological 
landmarks of the brain appear to be similar such as white matter (represented by pink stain), 
however there appears to be more acellular space surrounding the grey matter (represented by 
purple stain) in zebrafish with loss of Rbbp9 (Figure 4.19 A-F). Investigation of the head 
showed acellular space surrounding the brain in rbbp9 morpholino treated zebrafish, an effect 
not seen in control–treated zebrafish. This difference in acellular space surrounding the brain 
was significant in both 8 ng- and 16 ng rbbp9 morpholino-treated zebrafish (Figure 4.19 G). 
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Figure 4.12 ML114-treatment does not up-regulate p53 mRNA expression. A) ML114-
treatment does not significantly up-regulate expression of p53 24 hpf across all treatments 
using actb1 as a housekeeping control. (n=3), B) ML114-treatment does not result in 
increased p53 mRNA expression using actb1 as a housekeeping control. (n=2).  
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Figure 4.13 rbbp9 morpholino affects embryonic development 24 hpf. Representative 
images of zebrafish 24 hpf which have been injected with; A-B) phenol red control, C-D) 8 
ng of rbbp9 morpholino, and E-F) 16 ng of rbbp9 morpholino. Differences in body shape 
were identified at higher concentrations of rbbp9 morpholino. Incorporation of morpholino 
was confirmed by positive FITC fluorescence (indicated by green dye). Scale bars = 600 µm. 
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Figure 4.14 rbbp9 morpholino affects embryonic development 7 dpf. Representative 
images of zebrafish larvae 7 dpf, which have been injected with; A-B) a phenol red control, 
C-D) 8 ng of rbbp9 morpholino, and E-F) 16 ng of rbbp9 morpholino. Higher concentrations 
of rbbp9 morpholino result in phenotypic changes in body size (black arrow), and eye 
development (red arrow). Incorporation of morpholino was confirmed by FITC fluorescence 
(indicated by green dye). Scale bars = 600 µm. 
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Figure 4.15 rbbp9 morpholino body, eye, heart and gastrointestinal development 7 dpf. 
rbbp9 morpholino (MO) resulted in; A) reduced body length, and B) smaller eyes, C) with no 
significant changes to  the yolk sac and D) pericardial cavity. (n=3; p < 0.05).  
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Figure 4.16 Histological representation of developmental changes in zebrafish treated 
with rbbp9 morpholino 7dpf. Representative histological images of zebrafish larvae 7 dpf, 
which have been injected with: A-B) a phenol red control, C-D) 8 ng of rbbp9 morpholino, 
and E-F) 16 ng of rbbp9 morpholino. Higher concentrations of rbbp9 morpholino result in 
phenotypic changes in body size, eye development, gastrointestinal cavity and tract. White 
scale bar = 600 µm. 
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Figure 4.17 Morphological differences of developmental changes to the eye and muscle 
in zebrafish treated with rbbp9 morpholino 7 dpf. Representative histological images of 
zebrafish larvae 7 dpf, which have been injected with; A-B) a phenol red control, C-D) 8 ng 
of rbbp9 morpholino, and E-F) 16 ng of rbbp9 morpholino. Higher concentrations of rbbp9 
morpholino result in; A, C, E) normal eye morphology showing all layers including: i) lens, 
ii) ganglion cell layer, iii) inner plexiform layer, iv) inner nuclear layer, v) outer plexiform 
layer, vi) outer nuclear layer, vii) inner segment/outer segment of photoreceptor cells, and 
viii) retinal pigment epithelium. Changes in morphology between treatments were seen in: B, 
D, F) muscle fibre distribution in zebrafish treated with rbbp9 morpholino’s (black arrows). 
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Figure 4.18 Morphological differences of developmental changes of the gastrointestinal 
tract in zebrafish treated with rbbp9 morpholino 7 dpf. Representative histological images 
of zebrafish larvae 7 dpf, show changes at the gastrointestinal tract (red arrows) and yolk sac 
(green lines) between A) Phenol red control, B) 8 ng of rbbp9 morpholino, and C) 16 ng of 
rbbp9 morpholino. 
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Figure 4.19 Increased acellular space surrounding the brain due to treatment with rbbp9 
morpholino at 7 dpf. Histological analysis of treated zebrafish 7 dpf show lack of acellular 
space (red lines) surrounding the brains white- (pink stain) and grey-matter (purple stain) (red 
boxes) in A-B) Phenol control-, when compared to C-D) 8 ng rbbp9 morpholino (MO) and E-
F) 16 ng rbbp9 morpholino. G) Significant changes were seen in the acellular space 
surrounding the brain between the Phenol red control- and 8 ng rbbp9- and 16 ng rbbp9-
morpholino treated zebrafish. (n=3; * p = 0.0358; ** p = 0.0007).   
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 A tp53 morpholino was used to assess whether changes seen with rbbp9 morpholino 
treatment might be due to activation of the tp53 pathway, a classical indicator of non-
specificity with morpholino treatments (Robu et al., 2007, Langheinrich et al., 2002). 
Fluorescence microscopy showed the tp53 morpholino was present throughout the zebrafish 
embryos up to 7 dpf. Consistent with published reports, use of this tp53 morpholino at 
concentrations up to 16 ng did not result in any phenotypic changes at either 24 hpf (Figure 
4.20) or 7 dpf (Figure 4.21). Notably, co-injection of 8 ng rbbp9 and 8 ng of tp53 
morpholino’s into zebrafish embryos resulted in the same range of phenotypic changes seen 
with both rbbp9 morpholino treatment and also ML114 treatment at 24 hpf and 7 dpf (Figure 
4.22 and 4.23). These data suggest that p53 activation may not be responsible for the 
phenotype that resulted from rbbp9 morpholino treatment. 
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Figure 4.20 tp53 morpholino does not affect embryonic development 24 hpf. 
Representative images of 24 hpf zebrafish which have been injected with; A-B) phenol red 
control, C-D) 8 ng of tp53 morpholino, and E-F) 16 ng tp53 morpholino. No changes in 
phenotype were seen in zebrafish injected with tp53 morpholino. Incorporation of morpholino 
was confirmed by FITC fluorescence (indicated by green dye). Scale bars = 600 µm. 
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Figure 4.21 tp53 morpholino does not affect embryonic development 7 dpf. 
Representative images of 7 dpf zebrafish which have been injected with; A-B) phenol red 
control, C-D) 8 ng of tp53 morpholino, and E-F) 16 ng tp53 morpholino. No changes in 
phenotype were seen in zebrafish injected with tp53 morpholino. Incorporation of morpholino 
was confirmed by positive FITC fluorescence (indicated by green dye). Scale bars = 600 µm. 
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Figure 4.22 Incorporation of rbbp9 and tp53 morpholino’s 24 hpf. Representative images 
of zebrafish at 24 hpf which have been injected with; A-B) a phenol red control, C-D) 16 ng 
of tp53 morpholino, E-F) 8 ng rbbp9 morpholino, and G-H) a co-injection of 8 ng rbbp9 and 
8 ng tp53 morpholino. Incorporation of morpholino was confirmed by FITC fluorescence 
(indicated by green dye). Scale bars = 600 µm. 
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Figure 4.23 Co-injection of rbbp9 and tp53 morpholino’s result in developmental 
changes 7 dpf. Representative images of zebrafish at 7 dpf which have been injected with; A-
B) a phenol red control, C-D) 16 ng of tp53 morpholino, E-F) 8 ng rbbp9 morpholino, and G-
H) a co-injection of 8 ng rbbp9 and 16 ng tp53 morpholino. Developmental changes seen 
with rbbp9 morpholino are phenocopied with the addition of tp53 morpholino. Incorporation 
of morpholino was confirmed by FITC fluorescence (indicated by green dye). Scale bars = 
600 µm. 
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4.4. DISCUSSION 
Rbbp9 is expressed in a variety of tissues throughout development (Bastian et al., 2008). 
However, whether it is critical for the development of any particular tissue is unknown. As a 
first step towards defining the role of Rbbp9 during embryonic development, this chapter 
investigated the effects of both ML114 and rbbp9 morpholino on zebrafish embryos. Specific 
anatomical and histological defects were consistently observed with both ML114 and rbbp9 
morpholino treatments including anatomical defects relating to body size/shape, eye size, 
pericardial cavity, muscle, brain and the gastrointestinal system. Interestingly, ML114 but not 
rbbp9 morpholino also affected organisation of the eye tissues. 
 
4.4.1. Comparison of consequences due to loss of Rbbp9 activities. 
Publically available online Affymetrix gene expression datasets show rbbp9 transcripts are 
expressed in many tissues during zebrafish development, particularly in the eye, heart, brain, 
liver, and digestive tract (Bastian et al., 2008). Interestingly the eye, heart, brain and 
gastrointestinal tract were greatly affected by ML114 treatment. This suggests the 
abnormalities observed with ML114 treatment could be due to loss of Rbbp9 SH activity in 
these tissues. This conclusion is supported by the finding that use of the rbbp9 morpholino 
resulted in a very similar set of anatomical and histological abnormalities that were not 
abolished by co-injection of the tp53 morpholino at high concentrations.  
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4.4.2. Effects of ML114 and rbbp9 morpholino treatments appear specific.  
The validated anti-human RBBP9 antibody (O'Connor et al., 2011, Shields et al., 2010, 
Nachmany et al., 2012) could not reliably detect changes in Rbbp9 protein expression, and 
currently no zebrafish-specific Rbbp9 antibody exists. Thus to determine whether the effects 
resulting from ML114 and rbbp9 morpholino treatment were specific, it is useful to compare 
against other zebrafish-based studies. 
Specific anatomical and cellular changes were observed here due to both ML114 and 
rbbp9 morpholino treatments. This included shortened body length, bent bodies (though not 
in all treated zebrafish), disorganised muscle fibres, differences in brain anatomy and 
malformation of the gastrointestinal tract are all tissues which has been shown to express 
Rbbp9 (Bastian et al., 2008). Published reports show that both morpholino- and chemical-
based investigations in zebrafish have, in some instances, been capable of initiating p53-
mediated toxicity responses (Robu et al., 2007, Langheinrich et al., 2002, Jeon and Lee, 2013, 
Ekker and Larson, 2001). Classic markers of p53-mediated toxicity include: spinal curvature 
(or U-shaped body), body shortening, smaller eyes and head, pericardial edema and enlarged 
yolk sac (Robu et al., 2007, Bilotta et al., 2004, Zhang et al., 2010, Shi et al., 2011, Jeon and 
Lee, 2013, Melo et al., 2015, Peng et al., 2015, Henry et al., 1997). Co-incident with these 
changes is the up-regulation of p53 mRNA transcripts, enabling p53 mRNA expression to be 
used as an indicator of toxic effects in zebrafish. In contrast, embryos with suppressed p53 
activity have been found to be morphologically indistinguishable from control embryos 
(Langheinrich et al., 2002). p53-mediated zebrafish toxicity due to the commonly used 
agricultural pesticide, cypermethrin, resulted in a clear upregulation of p53 transcripts in a 
concentration-dependent manner (fold increases from 1.62-3.47) (Shi et al., 2011). Toxicity 
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assays using silver, gold and platinum nanoparticles in zebrafish embryos also resulted in 
developmental defects (Asharani et al., 2011). High mortality rates were a result of toxicity 
due to nanoparticle treatments. Control-treated zebrafish had a mortality rate of less than 3%, 
whereas the mortality rate of zebrafish treated with nanoparticles showed a concentration-
dependent effect ranging from 10-43% (Asharani et al., 2011). Interestingly, there was a small 
difference in survival rate between no-treatment control zebrafish (68%) and DMSO control-
treated zebrafish (60%), soluble fragment (60%) as well as 50% of 100 M ML114-treated 
zebrafish surviving 24 hours post treatment. These data indicate that the differences in 
survival rates due to ML114 toxicity were much smaller (at ~10%) than published 
chemical/nanopartical toxicity effects. Phenotypic changes observed as a result of exposure to 
nanoparticles also included: pericardial effusion, abnormal cardiac morphology, 
micropthalmia and malpigmented eyes (Asharani et al., 2011, Kim et al., 2013). Importantly, 
these morphological changes associated with toxicity were also accompanied with high 
expression of p53 (with increases between 2-6 fold) suggesting these changes were due to 
activation of the p53 pathway (Kim et al., 2013, Shi et al., 2008). In comparison, no increase 
in p53 expression was seen in the studies shown here. 
Interestingly, ML114-treated zebrafish all had functioning hearts, as observed by 
circulating blood cells. Similar effects have been seen in published zebrafish toxicity studies, 
for example in a study that investigated the effects of acetylcholine esterase (AChE) inhibitors 
used to treat glaucoma and Alzheimer’s disease (Behra et al., 2004). In that study, the 
chemical AChE inhibitor GAL phenocopied the effects of ache gene mutation, namely 
reduced motility and myopathy/abnormal muscle distribution. However, two other AChE 
inhibitors did not induce the same myopathy; instead they induced non-specific/off-target 
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effects on neural development that were unrelated to AChE activity, although it is unknown 
whether this effect was mediated by activation of the p53 pathway. However, this toxicity was 
considered unlikely to be a generalized toxicity as all the embryos treated with AChE 
inhibitors had functioning hearts. This data suggests the phenotypes seen with ML114 
treatment could be specifically due to ML114-selective inhibition of Rbbp9 SH activity as 
phenotypic changes were accompanied with functional hearts and most phenotypes were 
phenocopied with loss of Rbbp9 via morpholino treatment. 
From the data shown here, zebrafish embryos treated with ML114 showed phenotypic 
changes similar to published effects attributed to p53-mediated toxicity. In addition to the fact 
that p53 mRNA levels weren’t increased by ML114 or rbbp9 morpholino treatment, p53 
morpholino was unable to rescue the effects of rbbp9 morpholino. However, it may still be 
possible the effects of ML114 and rbbp9 morpholino could have been non-specific, as the 
affected tissues are known to be affected by non-specific toxicity. For example, the observed 
phenotypes could be due to as yet undefined, p53-independent toxicity pathways. A curious 
difference between ML114 and rbbp9 morpholino was that ML114 affected eye anatomy in 
addition to eye size. If all the ML114 and rbbp9 morpholino effects were non-specific, it 
might be expected that the ML114 effect on eye anatomy would occur with both treatments. 
Alternately, if the effects are specific, it could be that eye development can accommodate loss 
of Rbbp9 protein by altering expression of other genes in the Rbbp9 pathway in a way that 
selective inhibition of Rbbp9 SH activity by ML114 cannot. 
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4.4.3. Off-target effects and Rbbp9 activities. 
Overexpression of the serine/threonine mitotic kinase Aurora-A has been implicated in many 
cancers such as breast, colon, and pancreatic cancers (Bischoff et al., 1998, Zhou et al., 1998). 
Interestingly, these are the same cancers in which RBBP9 has been found to be overexpressed 
in (Lee et al., 1988, Shields et al., 2010). Loss of Aurora-A in zebrafish embryogenesis has 
been shown to result in specific (i.e., not non-specific) phenotypic changes such as short bent 
bodies and growth retardation (Jeon and Lee, 2013), similar to the phenotypes observed here 
with ML114 and rbbp9 morpholino treatment. Co-injection of tp53 morpholino was found to 
partially rescue the phenotypic changes due to loss of Aurora-A (Jeon and Lee, 2013), 
whereas co-injection of tp53 morpholino did not rescue the changes brought upon by 
knockdown of Rbbp9.Although not explored in this study (due to time constraints), Western 
blot identification of p53 protein levels might provide further support for verifying p53 
knockdown in zebrafish. Another informative control for future studies to address whether the 
rbbp9 morpholino affects are off-target effects would be to introduce rbbp9 cDNA or mRNA 
which is not targeted by the current rbbp9 morpholino (Ekker and Larson, 2001). 
 
 Overall, the combined ML114 and rbbp9 morpholino data presented here suggest 
inhibition of Rbbp9 SH and Rb-binding activities could lead to abnormal development of 
tissues in which rbbp9 is expressed. This interpretation is consistent with the known 
requirement for other serine proteases during development (e.g., Furin). Further support for 
the specificity of these effects is still required, such as assessment of p53 protein levels via 
Western blotting or cDNA/mRNA rescue assays together with rbbp9 morpholino. Further 
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understanding of the role of Rbbp9 activities in vivo will be beneficial for understanding its 
role in normal and cancer development.  
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CHAPTER 5: General Discussion 
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5.1. RBBP9 and the embryonic state.  
RBBP9 is reported to be expressed in hPSCs, many cell types during early embryogenesis 
(including the eye, muscle, heart, brain and digestive tract), and in cancer cells (Shields et al., 
2010, Woitach et al., 1998, Bastian et al., 2008, O'Connor et al., 2011). Currently, RBBP9 has 
two proposed mechanisms of action; i) RB-binding activity, and ii) SH activity (Shields et al., 
2010, Woitach et al., 1998). RBBP9 is thought to have a role in cell cycle regulation due to its 
ability to bind to RB protein, which itself regulates the activity of E2F transcription factors 
required for cell cycle progression (Woitach et al., 1998). RBBP9 has also been shown to 
have SH activity (Shields et al., 2010), and loss of RBBP9 SH activity resulted in decreased 
proliferation of human pancreatic carcinoma cells and consequently reduced tumorigenesis in 
an in vivo assay. More recently, RBBP9 was identified as a candidate regulator of PSC 
maintenance. siRNA-mediated loss of RBBP9 protein resulted in down-regulation of 
pluripotency-associated markers, decreased expression of some cell cycle genes, and up-
regulation of genes associated with neural differentiation (O'Connor et al., 2011). However, of 
the two proposed RBBP9 activities it was unclear what contribution each made to the 
regulation of pluripotency in hPSCs. 
The discovery of ML114 as a highly potent and selective inhibitor of RBBP9 SH 
activity (Bachovchin et al., 2010b) enabled the studies presented here to begin defining the 
relative contribution of RBBP9 SH activity to hPSC maintenance and also embryonic 
development. Data presented within this thesis show the requirement for RBBP9 SH activity 
in hPSC maintenance, and possibly also embryogenesis. Chapter 2 shows RBBP9 SH activity 
appears to be required to promote hPSC transition from G0/G1 to S-phase, but has no 
noticeable effect on hPSC differentiation within the 7-day timeframe studied. This finding is 
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consistent with recent literature that shows decreased PSC proliferation does not necessarily 
induce differentiation. Chapter 3 suggests RBBP9 SH activity may regulate hPSC 
proliferation by acting directly on NFYA and indirectly on DEAF1. This finding is consistent 
with the emerging role for NFYA and DEAF1 in PSC maintenance. Chapter 4 begins to 
investigate the role of RBBP9 SH activity in early embryogenesis, with the data not 
discounting the possibility that it is required for normal eye, gut, brain and muscle 
development, at least in zebrafish embryos. This would be consistent with the known role for 
other SH proteins during embryonic development.. However, even though Rbbp9 is expressed 
in all these zebrafish tissues, the degree of overlap between ML114- and rbbp9 morpholino-
treated zebrafish with zebrafish toxicity phenotypes makes it difficult to conclusively interpret 
this data.  
Data presented here supporting the conclusion that the effects of ML114 were 
selective include the consistent dose-dependent effects caused by ML114 treatment in both 
hPSCs and zebrafish, and the lack of any effect resulting from treatment with the soluble 
ML114 cleavage product. From the ML114 identification study, incubation of cell-free 
RBBP9 protein with ML114 was found to increase the mass of the RBBP9 peptide fragment 
containing Ser75 by 110.09 Da (Bachovchin et al., 2010b). Therefore, more formal 
demonstration that the effects of ML114 on hPSCs are due to inhibition of RBBP9 SH 
activity could be performed in future by assessment of RBBP9 peptides from ML114-treated 
hPSCs; however, this was not possible for this thesis. 
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5.2. RBBP9 SH activity and its role in hPSC maintenance. 
5.2.1. ML114 selectively affects cell proliferation in hPSCs. 
Proper integration of a range of molecular networks is required to work together to govern the 
maintenance of key characteristics unique to hPSCs, i.e.: the ability to self-renew indefinitely 
and the potential to form any cell type of the body (Martin, 1981, Thomson et al., 1998). To 
elucidate the role of RBBP9 SH activity in hPSCs, the highly selective chemical inhibitor 
ML114 was used (Bachovchin et al., 2010b, O'Connor et al., 2011, Shields et al., 2010, 
Vorobiev et al., 2012, Woitach et al., 1998) and resulted in decreased hPSC proliferation 
without noticeably inducing differentiation during a 7 day assay period (see 2.4.1). 
Investigating the effect of ML114 at later time points could also be informative. Depletion of 
PRMT5 in hPSCs has similarly been shown to result in decreased proliferation of hPSCs 
whilst retaining markers of pluripotency (Gkountela et al., 2014). Additionally, loss of 
RBBP9 SH activity has been shown to reduce proliferation of human pancreatic carcinoma 
cells, similarly to the observed effects in hPSCs after ML114 treatment (Shields et al., 2010). 
Taken together, these data suggest that decreased proliferation observed with ML114 
treatment is also due to loss of SH activity. Comparison of the data presented here with 
published effects of siRNA-mediated loss of RBBP9 in hPSCs suggests RB-binding activity 
appears to be: i) required for inhibiting neural differentiation of hPSCs; ii) may also be 
involved in regulating hPSC proliferation (given the known role for RB/E2F interaction); and 
iii) may not be required for normal embryonic development if the effects seen in Chapter 4 
are specific (as ML114 treatment essentially phenocopied the effects of rbbp9 morpholino in 
zebrafish development).  
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5.2.2. Future opportunities for studying RBBP9 and its effectors in hPSCs. 
Gene expression profiling of ML114-treated hPSCs suggested that NFYA and DEAF1 may 
be direct and indirect (respectively) effectors of RBBP9 SH activity. Both NFYA and DEAF1 
are reported to have roles in embryonic development and self-renewal in various PSCs 
including hPSCs (Bolognese et al., 1999, Dolfini et al., 2012, Gu et al., 2010, Veraksa et al., 
2002, Bhattacharya et al., 2003, Farina et al., 1999, Grskovic et al., 2007, Mojsin et al., 2015, 
Oldfield et al., 2014). NFY binding motifs are located in the promoters of known hPSC 
regulatory genes such as OCT4, NANOG and SOX2 (Dolfini et al., 2012), and NFYA can act 
as both a transcriptional activator and repressor (Ceribelli et al., 2008, Peng and Jahroudi, 
2002, Deng et al., 2007, Peng and Jahroudi, 2003). Gene expression profiling of ML114-
treated hPSCs revealed a small but significant increase in NANOG transcripts, which has been 
shown to interact with NFYA in ESCs (Bhattacharya et al., 2003, Farina et al., 1999, 
Grskovic et al., 2007, Oldfield et al., 2014). Loss of NFYA has been shown in a few studies to 
also reduce expression of NANOG, as well as embryo death occurring with decreased levels 
of NFYA similar to the effects seen with depletion of Nanog in mESCs (Bhattacharya et al., 
2003, Farina et al., 1999, Oldfield et al., 2014, Mitsui et al., 2003). 
As previously mentioned, the gene expression fold changes associated with ML114 
treatment of hPSCs were quite small, although still statistically significant based both on raw 
p-values and p-values taking into account a false discovery rate cut off <0.05 (Kuehn et al., 
2008). Interestingly, a study in which NFYA was overexpressed in pluripotent human 
embryonal carcinoma cells showed high levels of NFYA decreased cell proliferation and 
expression of pluripotency markers (Mojsin et al., 2015, Grskovic et al., 2007). However, a 
separate study showed that shRNA-mediated loss of NFYA decreases mESC proliferation, 
151 
 
and NFYA expression has also been shown to decrease during hPSC differentiation (Grskovic 
et al., 2007). When viewed together with the data presented in Chapters 2 and 3, it is possible 
that NFYA protein levels need to be kept within strict limits (similar to OCT4, NANOG and 
SOX2) in order to maintain a pluripotent state. Alternately, there may be species-specific 
differences in the role of NFYA, and/or differences in its role in epiblast-like pluripotent cells 
(e.g., hPSCs) vs mESC-like pluripotent cells. 
 Although currently not completely understood, tight regulation of transcription factors 
is required to both maintain a state of pluripotency within an ESC, but also reprogram a 
somatic cell back into a pluripotent state (Hanna et al., 2002, Alon, 2007, Boyer et al., 2005, 
Gurdon, 1962, Takahashi and Yamanaka, 2006). From the data presented in this thesis, it 
appears that both proposed mechanisms of action of RBBP9 are beneficial to maintaining 
pluripotency. It would therefore be interesting to see whether inclusion of RBBP9 in the 
reprogramming cocktail would increase the efficiency of hiPSC production. Additionally, 
understanding mechanisms of RBBP9 in both naïve and primed stem cells would be useful. 
Both primed and naïve hPSCs retain the characteristics unique to stem cells with some key 
differences. Naïve hPSCs have better survival as single cells, shorter doubling time and can 
form germline chimeras in vivo while primed hPSCs do not have these characteristics (Tesar 
et al., 2007, Ware et al., 2014). Primed hPSCs were used in this study (Brons et al., 2007, 
Nichols and Smith, 2009, Tesar et al., 2007, Thomson et al., 1998). Further investigation of 
RBBP9 SH activity loss in naïve stem cells and its effect on the naïve hPSC cell cycle would 
be of interest. As naïve stem cells have a shorter doubling time than primed hPSCs, the effect 
of RBBP9 SH activity loss on naïve cell cycle could be compared to effects seen in primed 
hPSCs (Ware et al., 2014). Additional testing could also include more ESC lines such as the 
NTeraD2 and iPSC65 (O'Connor et al., 2011). This would allow for a more comprehensive 
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comparison with loss of RBBP9 activities in other ESCs enabling this work to be applicable 
to a broader audience in the hPSC field. 
Currently there are no reports of DEAF1 or NFYA in reprogramming, however stable 
expression of DEAF1 has been shown to be required to maintain a pluripotent state in both 
mESCs and hESCs (Gu et al., 2010). However, based on data presented in Chapters 2 and 3, 
overexpression of NFYA outside a useful range might decrease the efficiency of hiPSC 
production by decreasing cell proliferation. 
 
5.3. RBBP9 SH and its effectors in cancer progression. 
Self-renewal is a defining feature of both stem cells and cancer, where cancer is thought to be 
a disease of unregulated proliferation, including self-renewal of cancer stem cells (Bisson and 
Prowse, 2009, Reya et al., 2001, Reya et al., 2003, Bonnet and Dick, 1997, Wong et al., 
2008). RBBP9 expression has also been reported in human cancer cells, with one of the 
studies identifying its role as a SH in promoting proliferation of human pancreatic carcinoma 
cells (Shields et al., 2010, Woitach et al., 1998, O'Connor et al., 2011). Interestingly NFYA 
and DEAF1 have known roles in regulating cancer cells (Dai et al., 2015, Barker et al., 2008, 
Cubeddu et al., 2012, Benatti et al., 2016, Charafe-Jauffret et al., 2009). Loss of NFYA 
subunits has been found to result in differentiation of hESCs as well as reducing expression of 
CDCA8, a gene required in some human cancers such as lung cancer. Further investigations 
into RBBP9 SH and its effect on NFYA and DEAF1 could prove useful in understanding 
cancer cell proliferation and differentiation pathways, and potentially also for identification of 
new anti-cancer targets. 
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5.4. Rbbp9 SH and embryonic development.  
Chapter 4 showed that both ML114 and rbbp9 morpholino resulted in abnormal muscle, eye, 
heart, brain and gastrointestinal development. The RBBP9 expression pattern and results 
shown in Chapter 2 support a role for RBBP9 in embryonic development; however, specific 
technical issues limit the conclusions that can be drawn from the data in zebrafish. Recently, 
morpholino technology has been shown to have more off-target effects than previously 
reported (Kok et al., 2015). For example, poor correlation was identified between 
morpholino-induced and mutant phenotypes in zebrafish with the megamind morpholino. At 
present there is no available mutant Rbbp9 zebrafish to compare phenotypic changes arising 
from either rbbp9 morpholino or ML114 inhibition of Rbbp9 SH activity. The ML114 soluble 
fragment and p53 morpholino controls used here suggest the ML114 and rbbp9 morpholino 
treatment phenotypes could be specifically due to loss of RBBP9 activities (Langheinrich et 
al., 2002, Robu et al., 2007). This is supported by the lack of any increase in p53 transcript 
levels with the treatments, and the known role for SHs in embryonic development. However, 
as previously described, future studies could address the specificity/non-specific toxicity issue 
by assessing p53 protein levels, by cDNA/mRNA rescue experiments for the rbbp9 
morpholino work, or perhaps more effectively by using other gene knockdown technologies 
not available at the time of this thesis such as Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) technology (Gaj et al., 2013, Ablain et al., 2015, Hruscha et 
al., 2013, Hwang et al., 2013). Should the effects prove to be specific, then it would be 
interesting for future studies to explore whether NFYA or DEAF1 are involved in these 
developmental changes seen. 
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5.5. Summary. 
This thesis strongly suggests that RBBP9 SH activity is required for proliferation (but not 
differentiation) of hPSCs, and that it may also have a role in regulating normal development 
during early embryogenesis. The data presented also suggest that NFYA, and possibly also 
DEAF1, may be targets of RBBP9 SH activity. Overall, the results suggest that further 
investigation of RBBP9 activities could lead to a better understanding of the mechanisms 
behind normal and abnormal development and perhaps also improved methods of somatic cell 
reprogramming and cancer therapy. 
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Appendix 1: Transcripts up-regulated by ML114 treatment. 
Gene 
Symbol 
Score Feature P FDR (BH) 
Fold 
Change 
Gene 
Symbol 
Score Feature P FDR (BH) 
Fold 
Change 
REPS2 -1.2799934 0.001996 0.0213908 1.0049805 
RNU6ATA
C3P 
-1.724531 0.001996 0.0213908 1.0260427 
HHIPL2 -1.2835035 0.001996 0.0213908 1.0060279 RIIAD1 -1.7384378 0.001996 0.0213908 1.0107409 
SNX14 -1.3174063 0.001996 0.0213908 1.0045622 GGCX -1.7411335 0.001996 0.0213908 1.0051136 
FGF14 -1.3203425 0.001996 0.0213908 1.012611 LARP7 -1.7413593 0.001996 0.0213908 1.0136518 
C9orf152 -1.3608531 0.001996 0.0213908 1.0116378 C2orf73 -1.7455232 0.001996 0.0213908 1.0154788 
THEMIS -1.3704425 0.001996 0.0213908 1.008913 ST8SIA6 -1.7517903 0.001996 0.0213908 1.0231708 
GSK3B -1.3962801 0.001996 0.0213908 1.0016071 ZNF563 -1.7541013 0.001996 0.0213908 1.0183376 
LGALS17A -1.3976835 0.001996 0.0213908 1.0140159 PFKFB2 -1.7558437 0.001996 0.0213908 1.0071522 
ALKBH6 -1.4011802 0.001996 0.0213908 1.00215 NPR1 -1.7572846 0.001996 0.0213908 1.010633 
OR13A1 -1.4018358 0.001996 0.0213908 1.0082079 CBR1 -1.7624861 0.001996 0.0213908 1.0064749 
MAP4K4 -1.4349339 0.001996 0.0213908 1.0024057 ZRANB2 -1.7635249 0.001996 0.0213908 1.0027059 
TSC22D4 -1.4411056 0.001996 0.0213908 1.0037394 DLX5 -1.7707034 0.001996 0.0213908 1.0126272 
RNASEH2
B 
-1.477176 0.001996 0.0213908 1.0037863 PITRM1 -1.7724285 0.001996 0.0213908 1.0014494 
NWD1 -1.4854658 0.001996 0.0213908 1.0127319 F13A1 -1.7728683 0.001996 0.0213908 1.0137054 
NAPRT1 -1.4995182 0.001996 0.0213908 1.0035046 
ARHGAP2
8 
-1.7749045 0.001996 0.0213908 1.0082186 
APP -1.5000075 0.001996 0.0213908 1.0014371 SCML2 -1.7749857 0.001996 0.0213908 1.0029493 
PRAMEF6 -1.5007834 0.001996 0.0213908 1.0070778 HECTD2 -1.7789108 0.001996 0.0213908 1.0076337 
GPR19 -1.5145234 0.001996 0.0213908 1.0036769 KIAA0825 -1.7795945 0.001996 0.0213908 1.0247834 
SLC35F3 -1.5160319 0.001996 0.0213908 1.0021253 C8orf49 -1.7828204 0.001996 0.0213908 1.010407 
GRAMD1C -1.5166785 0.001996 0.0213908 1.0097952 CTPS2 -1.7848877 0.001996 0.0213908 1.0032021 
UCA1 -1.5240129 0.001996 0.0213908 1.0104064 KIAA1009 -1.7858151 0.001996 0.0213908 1.0244315 
ZNF304 -1.5457414 0.001996 0.0213908 1.0042737 NEMF -1.7915964 0.001996 0.0213908 1.0063361 
HMGB3P3
0 
-1.5479308 0.001996 0.0213908 1.0122679 ETV4 -1.7946588 0.001996 0.0213908 1.0114889 
HNRNPM -1.5552876 0.001996 0.0213908 1.0024612 MIR451B -1.7984893 0.001996 0.0213908 1.0196429 
SNRPD2P2 -1.556235 0.001996 0.0213908 1.0111087 PEX1 -1.8019079 0.001996 0.0213908 1.0051587 
ABT1 -1.563308 0.001996 0.0213908 1.0036556 PMS2 -1.8048815 0.001996 0.0213908 1.0068138 
RNY5P3 -1.6008215 0.001996 0.0213908 1.0122257 ACN9 -1.8073221 0.001996 0.0213908 1.0084744 
RNF215 -1.6042401 0.001996 0.0213908 1.0050034 AKR7A2 -1.8108251 0.001996 0.0213908 1.0030517 
GRIK2 -1.6193135 0.001996 0.0213908 1.0159427 ZNF844 -1.8143813 0.001996 0.0213908 1.0118251 
SEC23B -1.6211225 0.001996 0.0213908 1.0024199 MPV17 -1.8204109 0.001996 0.0213908 1.0019042 
ESRRB -1.6212719 0.001996 0.0213908 1.0124959 TSTA3 -1.820872 0.001996 0.0213908 1.0055397 
APH1B -1.6243191 0.001996 0.0213908 1.0078585 VPS8 -1.8248973 0.001996 0.0213908 1.0018282 
FIGNL1 -1.6309397 0.001996 0.0213908 1.0112131 RALGAPB -1.8287274 0.001996 0.0213908 1.0027687 
ABCG2 -1.6342263 0.001996 0.0213908 1.0139283 PTK7 -1.833024 0.001996 0.0213908 1.0057195 
ERCC6 -1.6396575 0.001996 0.0213908 1.0054655 PRKCQ -1.8359992 0.001996 0.0213908 1.0054168 
CCDC104 -1.6493947 0.001996 0.0213908 1.0077587 ERO1LB -1.8417381 0.001996 0.0213908 1.0061446 
C17orf78 -1.6621901 0.001996 0.0213908 1.0152651 HGF -1.8449903 0.001996 0.0213908 1.0109299 
NAT8L -1.6657251 0.001996 0.0213908 1.0035682 PILRB -1.8556796 0.001996 0.0213908 1.0058306 
RN5S466 -1.6660628 0.001996 0.0213908 1.0267446 LDHC -1.8558353 0.001996 0.0213908 1.0127872 
DNAJC18 -1.666802 0.001996 0.0213908 1.0038215 BGN -1.8637839 0.001996 0.0213908 1.0163933 
RAB13 -1.6697817 0.001996 0.0213908 1.005622 POGZ -1.8656599 0.001996 0.0213908 1.0021406 
FERMT1 -1.6709535 0.001996 0.0213908 1.0124099 MED30 -1.8692246 0.001996 0.0213908 1.0042039 
RAD9B -1.683909 0.001996 0.0213908 1.0075428 HSD3B7 -1.8694492 0.001996 0.0213908 1.0028069 
RIMBP3 -1.6915288 0.001996 0.0213908 1.0116905 SLC35G1 -1.8742526 0.001996 0.0213908 1.0118028 
FGF16 -1.696589 0.001996 0.0213908 1.0233463 RN5S458 -1.875796 0.001996 0.0213908 1.0179922 
ARHGAP3
0 
-1.7022305 0.001996 0.0213908 1.0058592 FYTTD1 -1.8812502 0.001996 0.0213908 1.0103096 
CAPS2 -1.7034143 0.001996 0.0213908 1.0179727 AK091192 -1.882605 0.001996 0.0213908 1.0170274 
MIR129-2 -1.7042131 0.001996 0.0213908 1.0163127 EIF4EBP2 -1.8835027 0.001996 0.0213908 1.0019466 
MDK -1.7147409 0.001996 0.0213908 1.0027891 ZNF548 -1.8842995 0.001996 0.0213908 1.0045969 
PHLDA1 -1.7169625 0.001996 0.0213908 1.004435 DKKL1 -1.8847324 0.001996 0.0213908 1.0164519 
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Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change Gene Symbol Score Feature P FDR (BH) 
Fold 
Change 
TBX3 -1.8927929 0.001996 0.0213908 1.0188518 TTC13 -1.9837686 0.001996 0.0213908 1.0030217 
PATL2 -1.894749 0.001996 0.0213908 1.0113072 CCDC93 -1.9840628 0.001996 0.0213908 1.0063568 
WASH3P -1.9037443 0.001996 0.0213908 1.0044533 STEAP4 -1.9846812 0.001996 0.0213908 1.0244252 
PHLDB2 -1.9051029 0.001996 0.0213908 1.0218127 DACT1 -1.9854626 0.001996 0.0213908 1.0172366 
ACPL2 -1.9052909 0.001996 0.0213908 1.0051831 ALX1 -1.9877526 0.001996 0.0213908 1.0133995 
HECW2 -1.9131447 0.001996 0.0213908 1.0061169 PFKFB4 -1.9882408 0.001996 0.0213908 1.0090425 
GLT25D1 -1.9178778 0.001996 0.0213908 1.0024711 CNTRL -1.9907414 0.001996 0.0213908 1.0149388 
C2orf80 -1.9194862 0.001996 0.0213908 1.0160613 KGFLP1 -1.9907962 0.001996 0.0213908 1.0060402 
KLF6 -1.9289713 0.001996 0.0213908 1.005873 CST4 -1.9917296 0.001996 0.0213908 1.0065932 
LAPTM4A -1.9292309 0.001996 0.0213908 1.0019748 TLE1 -1.9922362 0.001996 0.0213908 1.0061362 
CYP2B6 -1.9292499 0.001996 0.0213908 1.0283802 RPS15A -1.9936416 0.001996 0.0213908 1.0010796 
KLK13 -1.9331532 0.001996 0.0213908 1.0099579 RING1 -1.994076 0.001996 0.0213908 1.0022953 
CYTH1 -1.9337715 0.001996 0.0213908 1.0056183 ACOX1 -1.9953366 0.001996 0.0213908 1.0048574 
KDM4D -1.9352649 0.001996 0.0213908 1.0169751 C9orf9 -1.9970024 0.001996 0.0213908 1.0043258 
CXXC4 -1.9361418 0.001996 0.0213908 1.006845 C1orf101 -1.9972491 0.001996 0.0213908 1.0151335 
KRT86 -1.936355 0.001996 0.0213908 1.004514 RN5S401 -1.9980244 0.001996 0.0213908 1.0203739 
DAAM2 -1.9378208 0.001996 0.0213908 1.0076092 NFU1 -1.9988124 0.001996 0.0213908 1.0071422 
ZNF187 -1.9382203 0.001996 0.0213908 1.0094795 STK17B -1.9997521 0.001996 0.0213908 1.0044921 
GALNT1 -1.9410724 0.001996 0.0213908 1.0049106 LGI4 -2.0002979 0.001996 0.0213908 1.0042544 
LINC00575 -1.9420804 0.001996 0.0213908 1.0172468 CCDC141 -2.0030082 0.001996 0.0213908 1.0192075 
LYPLA2 -1.9430473 0.001996 0.0213908 1.0021635 GPR25 -2.0032111 0.001996 0.0213908 1.0061546 
SKIV2L -1.9441851 0.001996 0.0213908 1.0043741 SLC46A3 -2.0057046 0.001996 0.0213908 1.0185128 
TMEM210 -1.9449658 0.001996 0.0213908 1.0064999 PLDN -2.0057221 0.001996 0.0213908 1.0070059 
IKBKE -1.9475891 0.001996 0.0213908 1.0080946 WDR41 -2.0065056 0.001996 0.0213908 1.0027827 
ITIH4 -1.9500919 0.001996 0.0213908 1.0121804 CRYBB1 -2.0129294 0.001996 0.0213908 1.0046499 
KAT5 -1.9507203 0.001996 0.0213908 1.0044563 FNIP1 -2.0139917 0.001996 0.0213908 1.0071651 
ADAM21 -1.9507797 0.001996 0.0213908 1.025773 ELP3 -2.016264 0.001996 0.0213908 1.0049722 
TRPC7 -1.9538273 0.001996 0.0213908 1.0165523 SKIDA1 -2.0181877 0.001996 0.0213908 1.003 
IL2RB -1.9544275 0.001996 0.0213908 1.0076873 C10orf76 -2.0216457 0.001996 0.0213908 1.0041522 
THAP9 -1.9545734 0.001996 0.0213908 1.0066431 CST5 -2.0225996 0.001996 0.0213908 1.0132322 
ZIC4 -1.954857 0.001996 0.0213908 1.0125145 IL1RAP -2.0232337 0.001996 0.0213908 1.0127351 
C6orf170 -1.9577676 0.001996 0.0213908 1.0085179 ZNF37BP -2.0244333 0.001996 0.0213908 1.0030395 
DGKD -1.9580713 0.001996 0.0213908 1.0025134 HERC6 -2.0255001 0.001996 0.0213908 1.011871 
C17orf49 -1.9611016 0.001996 0.0213908 1.0022326 OLR1 -2.0261353 0.001996 0.0213908 1.0099345 
ST3GAL2 -1.9631641 0.001996 0.0213908 1.0040502 CDCA2 -2.0291809 0.001996 0.0213908 1.0033184 
CEP290 -1.9635031 0.001996 0.0213908 1.016618 LRRIQ4 -2.0295222 0.001996 0.0213908 1.0106741 
HEXB -1.9636455 0.001996 0.0213908 1.0036351 LGI1 -2.0296884 0.001996 0.0213908 1.0810722 
CACNB2 -1.9642332 0.001996 0.0213908 1.0079583 BCL2L14 -2.0303368 0.001996 0.0213908 1.0030714 
R3HCC1L -1.9643728 0.001996 0.0213908 1.0085145 C2orf77 -2.0329033 0.001996 0.0213908 1.0092366 
KAZN -1.9664383 0.001996 0.0213908 1.0139674 MPLKIP -2.0345015 0.001996 0.0213908 1.0038451 
RN5S252 -1.9676021 0.001996 0.0213908 1.0137326 RPS29 -2.0349801 0.001996 0.0213908 1.0028445 
NPAS2 -1.968039 0.001996 0.0213908 1.006897 RN5S147 -2.0427551 0.001996 0.0213908 1.0263534 
CLDN16 -1.9698736 0.001996 0.0213908 1.0136818 C14orf1 -2.0501118 0.001996 0.0213908 1.0012593 
PRLR -1.9701979 0.001996 0.0213908 1.0072737 DYNC2LI1 -2.0554236 0.001996 0.0213908 1.019091 
ARFGEF1 -1.9711575 0.001996 0.0213908 1.004876 ACAD9 -2.0583484 0.001996 0.0213908 1.0046863 
FAHD2A -1.973668 0.001996 0.0213908 1.0061959 POTEE -2.0600194 0.001996 0.0213908 1.0067738 
ZNF124 -1.9747501 0.001996 0.0213908 1.0100759 MALL -2.0625612 0.001996 0.0213908 1.0031395 
SNX7 -1.9748245 0.001996 0.0213908 1.0126125 VWDE -2.0641244 0.001996 0.0213908 1.0040763 
RBP5 -1.9768652 0.001996 0.0213908 1.0100435 KCNA3 -2.0646698 0.001996 0.0213908 1.0058022 
ACSM3 -1.9830687 0.001996 0.0213908 1.0117302 DALRD3 -2.0650276 0.001996 0.0213908 1.0019815 
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JAG2 -2.0699287 0.001996 0.0213908 1.0046483 ALOX12P2 -2.1540121 0.001996 0.0213908 1.0076398 
TACSTD2 -2.0736111 0.001996 0.0213908 1.0097622 PJA1 -2.1558155 0.001996 0.0213908 1.0071788 
PRELID2 -2.074852 0.001996 0.0213908 1.0059201 MDH1B -2.1560985 0.001996 0.0213908 1.0199387 
GBP4 -2.0768307 0.001996 0.0213908 1.0143858 TDRD9 -2.1577314 0.001996 0.0213908 1.0086261 
RPS7P10 -2.0793556 0.001996 0.0213908 1.0138692 POLR2J4 -2.1640253 0.001996 0.0213908 1.0033752 
TRIM4 -2.0824415 0.001996 0.0213908 1.0037465 TBC1D20 -2.1677669 0.001996 0.0213908 1.0019575 
TP53INP2 -2.0829377 0.001996 0.0213908 1.0101357 DDX11L2 -2.1681626 0.001996 0.0213908 1.0070005 
DIP2A -2.0847955 0.001996 0.0213908 1.0038225 RPL32P3 -2.169936 0.001996 0.0213908 1.0043728 
IDH1 -2.0880066 0.001996 0.0213908 1.0025683 BRWD3 -2.1719996 0.001996 0.0213908 1.0047059 
SPG20OS -2.0883352 0.001996 0.0213908 1.0332299 RALGDS -2.1741414 0.001996 0.0213908 1.0054976 
PCNP -2.0888 0.001996 0.0213908 1.0042352 RN5S169 -2.1763193 0.001996 0.0213908 1.0192246 
TNMD -2.0889825 0.001996 0.0213908 1.0067554 FAM21A -2.1777316 0.001996 0.0213908 1.0033646 
KIAA1257 -2.0930533 0.001996 0.0213908 1.01126 NTN1 -2.1801825 0.001996 0.0213908 1.0049303 
OR2A4 -2.0931675 0.001996 0.0213908 1.0211309 PDHA1 -2.181244 0.001996 0.0213908 1.0030058 
DARS2 -2.0959582 0.001996 0.0213908 1.0062112 SRGAP2 -2.1854109 0.001996 0.0213908 1.0032583 
FGF13 -2.0991968 0.001996 0.0213908 1.007385 KIAA1109 -2.1875205 0.001996 0.0213908 1.0043452 
CD44 -2.0995949 0.001996 0.0213908 1.0071113 ZNF300 -2.1901555 0.001996 0.0213908 1.0104705 
PPP2R5A -2.102642 0.001996 0.0213908 1.0060636 RASSF4 -2.191064 0.001996 0.0213908 1.0042317 
INVS -2.1036416 0.001996 0.0213908 1.0096472 ZAR1L -2.1913549 0.001996 0.0213908 1.0094806 
TACC2 -2.104876 0.001996 0.0213908 1.0073431 NTN4 -2.1932044 0.001996 0.0213908 1.012505 
HINT3 -2.1054207 0.001996 0.0213908 1.0157575 MTMR11 -2.1933873 0.001996 0.0213908 1.0079339 
OR52L1 -2.1071619 0.001996 0.0213908 1.0157486 MTERF -2.1938963 0.001996 0.0213908 1.0060936 
FNDC7 -2.1072835 0.001996 0.0213908 1.0249714 ZSWIM1 -2.1944651 0.001996 0.0213908 1.0043079 
PIGN -2.1074875 0.001996 0.0213908 1.0087646 FUT10 -2.1952191 0.001996 0.0213908 1.0021169 
DNAJA4 -2.1111346 0.001996 0.0213908 1.0091457 MRPS11 -2.1957038 0.001996 0.0213908 1.0027853 
MEIS3P2 -2.1132045 0.001996 0.0213908 1.0106444 FOXB1 -2.1971836 0.001996 0.0213908 1.0169448 
HAGH -2.1132232 0.001996 0.0213908 1.0050674 ECI2 -2.1987346 0.001996 0.0213908 1.0066732 
KIAA0913 -2.1134607 0.001996 0.0213908 1.0080219 PLXND1 -2.1993385 0.001996 0.0213908 1.0075863 
OR6Y1 -2.1191086 0.001996 0.0213908 1.0149698 RENBP -2.2017271 0.001996 0.0213908 1.0084113 
MEAF6 -2.1199019 0.001996 0.0213908 1.0059864 LRRIQ1 -2.2019911 0.001996 0.0213908 1.0243809 
DIRC1 -2.1212216 0.001996 0.0213908 1.0150113 BCKDHB -2.2023005 0.001996 0.0213908 1.0032739 
FAM108B1 -2.1215154 0.001996 0.0213908 1.0099885 SETD9 -2.2057233 0.001996 0.0213908 1.0076584 
XRCC5 -2.1225097 0.001996 0.0213908 1.0016368 SYPL2 -2.2061465 0.001996 0.0213908 1.0084411 
SPAG1 -2.1251891 0.001996 0.0213908 1.0132762 SFXN1 -2.2076774 0.001996 0.0213908 1.0045718 
CWC25 -2.1265825 0.001996 0.0213908 1.0047966 ABCB4 -2.2077353 0.001996 0.0213908 1.0164739 
KDM8 -2.1304069 0.001996 0.0213908 1.0055506 LRCH3 -2.2091355 0.001996 0.0213908 1.0029145 
CDK9 -2.1310958 0.001996 0.0213908 1.0029795 CLEC4D -2.2093228 0.001996 0.0213908 1.0222178 
SULT1A2 -2.1326131 0.001996 0.0213908 1.0045052 SOGA1 -2.2095608 0.001996 0.0213908 1.003413 
ENDOD1 -2.1327645 0.001996 0.0213908 1.0037097 TEKT3 -2.2102722 0.001996 0.0213908 1.0136562 
ZNF133 -2.1328718 0.001996 0.0213908 1.0046269 PROS1 -2.2106755 0.001996 0.0213908 1.0238451 
ZNF230 -2.1346284 0.001996 0.0213908 1.0149737 GLT25D2 -2.2112843 0.001996 0.0213908 1.0274081 
SPINK2 -2.1346884 0.001996 0.0213908 1.0241619 CABYR -2.2113578 0.001996 0.0213908 1.0030743 
KDELC1 -2.1423582 0.001996 0.0213908 1.0047919 DLK1 -2.2133829 0.001996 0.0213908 1.0303672 
GBA -2.1432765 0.001996 0.0213908 1.0091013 C6orf10 -2.2147427 0.001996 0.0213908 1.0219906 
FAM107B -2.1435695 0.001996 0.0213908 1.0057873 GAA -2.2154108 0.001996 0.0213908 1.0080524 
BHLHE22 -2.1465201 0.001996 0.0213908 1.007612 FAM211B -2.217049 0.001996 0.0213908 1.0053218 
DLG5 -2.1477206 0.001996 0.0213908 1.0023397 ANKK1 -2.2185168 0.001996 0.0213908 1.0048648 
ATF7IP2 -2.147842 0.001996 0.0213908 1.0141226 RWDD2A -2.2186788 0.001996 0.0213908 1.0109222 
TCEAL8 -2.1509434 0.001996 0.0213908 1.012523 PYGO1 -2.21981 0.001996 0.0213908 1.0161079 
MRPS14 -2.1517015 0.001996 0.0213908 1.002564 HNRNPA2B1 -2.2210485 0.001996 0.0213908 1.0028571 
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C9orf40 -2.2210552 0.001996 0.0213908 1.0039761 GSC -2.2799763 0.001996 0.02139076 1.0265194 
AP3B2 -2.2243813 0.001996 0.0213908 1.0164718 TMEM187 -2.2808468 0.001996 0.02139076 1.0150119 
PAK1 -2.2244025 0.001996 0.0213908 1.0042106 OXER1 -2.2812943 0.001996 0.02139076 1.007213 
CXorf58 -2.2244146 0.001996 0.0213908 1.0112538 WBSCR17 -2.2819431 0.001996 0.02139076 1.0076466 
CDC42SE1 -2.224568 0.001996 0.0213908 1.0040474 RABL2A -2.2844062 0.001996 0.02139076 1.0055271 
ETFA -2.2250061 0.001996 0.0213908 1.0040042 ITPRIPL2 -2.2854381 0.001996 0.02139076 1.0055761 
RORA -2.2256215 0.001996 0.0213908 1.0089713 DEFB109P1B -2.2882232 0.001996 0.02139076 1.0175794 
KLHL4 -2.2289661 0.001996 0.0213908 1.0223595 MCL1 -2.2896337 0.001996 0.02139076 1.0028051 
C5orf60 -2.2302147 0.001996 0.0213908 1.0110504 BSDC1 -2.2899424 0.001996 0.02139076 1.0028184 
AAAS -2.2302438 0.001996 0.0213908 1.0020823 IRAK3 -2.2905969 0.001996 0.02139076 1.0161446 
CD79B -2.2320422 0.001996 0.0213908 1.0079027 AK123300 -2.2924893 0.001996 0.02139076 1.0210274 
HPS6 -2.232197 0.001996 0.0213908 1.0040556 RAB7A -2.2935063 0.001996 0.02139076 1.0023525 
UNC45A -2.2342121 0.001996 0.0213908 1.001968 HDAC3 -2.29403 0.001996 0.02139076 1.0020831 
WNK1 -2.2363948 0.001996 0.0213908 1.0095624 CRIPAK -2.2959411 0.001996 0.02139076 1.0078865 
SF3B1 -2.2392839 0.001996 0.0213908 1.0019713 LOC349196 -2.2960041 0.001996 0.02139076 1.0210847 
ADH1A -2.2398547 0.001996 0.0213908 1.0074848 PXDC1 -2.29635 0.001996 0.02139076 1.0232355 
PHOX2A -2.2429524 0.001996 0.0213908 1.0058183 NKD1 -2.2965053 0.001996 0.02139076 1.0101542 
PTH1R -2.2453753 0.001996 0.0213908 1.0122004 ACVR1C -2.2974534 0.001996 0.02139076 1.0078979 
FAM222B -2.245568 0.001996 0.0213908 1.0035874 NIT2 -2.2999532 0.001996 0.02139076 1.003787 
TRIM66 -2.2489402 0.001996 0.0213908 1.0156932 MRP63 -2.3000595 0.001996 0.02139076 1.0012488 
TRAPPC6B -2.2501614 0.001996 0.0213908 1.0074496 NM_033490.1 -2.3009322 0.001996 0.02139076 1.004476 
CCNT2 -2.25027 0.001996 0.0213908 1.0036533 PHC2 -2.3016874 0.001996 0.02139076 1.0109197 
DDX50 -2.2506276 0.001996 0.0213908 1.00344 IPP -2.3024306 0.001996 0.02139076 1.0161808 
IARS2 -2.250767 0.001996 0.0213908 1.0036751 STX5 -2.3030033 0.001996 0.02139076 1.004657 
TSPEAR -2.2507692 0.001996 0.0213908 1.0150528 NPIP -2.3042784 0.001996 0.02139076 1.0011828 
INPP5K -2.2518873 0.001996 0.0213908 1.006631 ADRA2C -2.3049498 0.001996 0.02139076 1.0048342 
ARHGAP5-
AS1 -2.2519491 0.001996 0.0213908 1.012561 SEC16A -2.3058304 0.001996 0.02139076 1.001863 
ZBTB38 -2.2530067 0.001996 0.0213908 1.0109068 GTF2B -2.3065654 0.001996 0.02139076 1.0038333 
GRM6 -2.2547148 0.001996 0.0213908 1.0043836 IMPDH2 -2.3065812 0.001996 0.02139076 1.0013444 
KIAA1324L -2.2555783 0.001996 0.0213908 1.0050584 FBXL5 -2.3066514 0.001996 0.02139076 1.0041682 
TMEM135 -2.2557232 0.001996 0.0213908 1.003258 CTSK -2.3072115 0.001996 0.02139076 1.0120857 
LPHN1 -2.257415 0.001996 0.0213908 1.0015623 AS3MT -2.3104214 0.001996 0.02139076 1.0065473 
NECAB2 -2.2578534 0.001996 0.0213908 1.0076653 AKAP6 -2.3106135 0.001996 0.02139076 1.0196738 
AGR2 -2.2579141 0.001996 0.0213908 1.0165457 NUCB1 -2.3106754 0.001996 0.02139076 1.0038482 
PRUNE -2.2596546 0.001996 0.0213908 1.0037655 ATP5S -2.3118794 0.001996 0.02139076 1.0051228 
BCMO1 -2.2610851 0.001996 0.0213908 1.008286 ANP32A -2.3130231 0.001996 0.02139076 1.0026923 
TTLL7 -2.2612976 0.001996 0.0213908 1.0093028 FAM86B2 -2.315678 0.001996 0.02139076 1.0047083 
FAM86B1 -2.2629094 0.001996 0.0213908 1.0063884 PEX7 -2.3175685 0.001996 0.02139076 1.0058856 
MAP2 -2.2629546 0.001996 0.0213908 1.0301178 MC3R -2.3212314 0.001996 0.02139076 1.0078109 
GFM2 -2.2642055 0.001996 0.0213908 1.0049669 ELK3 -2.3216879 0.001996 0.02139076 1.012423 
NKAIN2 -2.2667648 0.001996 0.0213908 1.0279418 SLC35E3 -2.3232867 0.001996 0.02139076 1.0143825 
NANOG -2.2722202 0.001996 0.0213908 1.0074623 PBXIP1 -2.3240384 0.001996 0.02139076 1.0076985 
ZFAND3 -2.2731239 0.001996 0.0213908 1.0036872 CBR3 -2.3242885 0.001996 0.02139076 1.0062393 
NXF2B -2.2731584 0.001996 0.0213908 1.0125143 RASA4CP -2.325357 0.001996 0.02139076 1.0117645 
NAA30 -2.2738485 0.001996 0.0213908 1.0045424 ATP8A1 -2.3262725 0.001996 0.02139076 1.0038645 
KCTD15 -2.2740946 0.001996 0.0213908 1.005924 FASTK -2.3267687 0.001996 0.02139076 1.0026126 
FDXACB1 -2.2755055 0.001996 0.0213908 1.010671 PHF7 -2.3300934 0.001996 0.02139076 1.010596 
RRAGB -2.2767712 0.001996 0.0213908 1.0110133 BAP1 -2.3306709 0.001996 0.02139076 1.0026515 
TMBIM4 -2.2775936 0.001996 0.0213908 1.0080686 GDPD1 -2.3320256 0.001996 0.02139076 1.0136154 
NMI -2.2789717 0.001996 0.0213908 1.02123 FYCO1 -2.3327109 0.001996 0.02139076 1.0057486 
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GRK4 -2.3327715 0.001996 0.0213908 1.0130738 C21orf90 -2.3847203 0.001996 0.0213908 1.0198372 
RN5S496 -2.3335358 0.001996 0.0213908 1.0300294 HJURP -2.3851503 0.001996 0.0213908 1.0043893 
ANKRD36P1 -2.3338601 0.001996 0.0213908 1.0170667 SPG20 -2.3866169 0.001996 0.0213908 1.0091405 
PRDM5 -2.3339789 0.001996 0.0213908 1.0056678 HSD17B14 -2.3892067 0.001996 0.0213908 1.0108347 
WDR55 -2.3404909 0.001996 0.0213908 1.0051425 DNHD1 -2.3892378 0.001996 0.0213908 1.0172192 
SFXN2 -2.3409586 0.001996 0.0213908 1.0082796 RHBDF1 -2.389297 0.001996 0.0213908 1.0111794 
C18orf32 -2.3419861 0.001996 0.0213908 1.0077326 TCEA2 -2.3899112 0.001996 0.0213908 1.0102906 
CYLC1 -2.3423593 0.001996 0.0213908 1.0202801 RPS19 -2.3913066 0.001996 0.0213908 1.0016791 
ZNF706 -2.3443576 0.001996 0.0213908 1.0066051 KIF24 -2.3915567 0.001996 0.0213908 1.0092832 
TGFB2 -2.3468009 0.001996 0.0213908 1.025841 LYSMD1 -2.392519 0.001996 0.0213908 1.0049364 
C7orf55 -2.3468227 0.001996 0.0213908 1.0028876 ERMP1 -2.3925448 0.001996 0.0213908 1.0039636 
VMA21 -2.3481078 0.001996 0.0213908 1.0023859 TRPV1 -2.3928469 0.001996 0.0213908 1.0047232 
RNF139 -2.3487549 0.001996 0.0213908 1.003806 ACACB -2.3961854 0.001996 0.0213908 1.0036717 
PPIC -2.3496056 0.001996 0.0213908 1.0063746 GMPPA -2.3979221 0.001996 0.0213908 1.0063678 
LAMP1 -2.3519578 0.001996 0.0213908 1.0025274 HIBADH -2.3980151 0.001996 0.0213908 1.0073 
DYNC1I1 -2.3539169 0.001996 0.0213908 1.0070699 NIN -2.399713 0.001996 0.0213908 1.0090056 
USP30 -2.3539604 0.001996 0.0213908 1.0086677 RBM43 -2.3998581 0.001996 0.0213908 1.0121187 
OPN5 -2.3548689 0.001996 0.0213908 1.020126 ARAP1 -2.4005239 0.001996 0.0213908 1.0041229 
TRA2A -2.3549497 0.001996 0.0213908 1.0082881 NEU1 -2.4025721 0.001996 0.0213908 1.0041659 
SPRY1 -2.3570037 0.001996 0.0213908 1.0042264 TTC33 -2.4035983 0.001996 0.0213908 1.0097887 
UEVLD -2.3585836 0.001996 0.0213908 1.0115425 TIMELESS -2.4056442 0.001996 0.0213908 1.0055838 
HCG4 -2.3602228 0.001996 0.0213908 1.012532 TP53INP1 -2.4062547 0.001996 0.0213908 1.0110482 
SLC35D2 -2.3618173 0.001996 0.0213908 1.0135391 SPATA12 -2.406866 0.001996 0.0213908 1.0167304 
PBLD -2.3620587 0.001996 0.0213908 1.0168008 SMAD5 -2.4073775 0.001996 0.0213908 1.0022683 
SSTR1 -2.3649206 0.001996 0.0213908 1.0114066 CXXC5 -2.4078018 0.001996 0.0213908 1.0036897 
OR6C6 -2.36503 0.001996 0.0213908 1.018775 TAS2R20 -2.4104515 0.001996 0.0213908 1.02365 
FLJ35776 -2.3661543 0.001996 0.0213908 1.0168766 TUBE1 -2.4110589 0.001996 0.0213908 1.0093267 
GTF2A1 -2.366582 0.001996 0.0213908 1.003515 LRRC9 -2.4113358 0.001996 0.0213908 1.0396942 
ZBTB48 -2.3666492 0.001996 0.0213908 1.0025895 ANKRD20A3 -2.4118545 0.001996 0.0213908 1.010526 
RILPL2 -2.3671837 0.001996 0.0213908 1.0079884 ENTPD1 -2.413175 0.001996 0.0213908 1.0162499 
MANBA -2.3696204 0.001996 0.0213908 1.0053559 ILDR2 -2.414227 0.001996 0.0213908 1.0189193 
ZEB2 -2.370172 0.001996 0.0213908 1.0402385 LTB4R -2.4143386 0.001996 0.0213908 1.008113 
IFT140 -2.3707002 0.001996 0.0213908 1.002783 PCMTD1 -2.4152095 0.001996 0.0213908 1.0039651 
WDR96 -2.3726477 0.001996 0.0213908 1.0319513 LRP4 -2.4158842 0.001996 0.0213908 1.0080327 
C3orf67 -2.3734712 0.001996 0.0213908 1.0081389 LOC100129534 -2.4159697 0.001996 0.0213908 1.0126652 
ABCD1 -2.3739416 0.001996 0.0213908 1.0082842 PPFIBP1 -2.4172405 0.001996 0.0213908 1.0096642 
KAT7 -2.3760821 0.001996 0.0213908 1.0040655 NFATC4 -2.4177063 0.001996 0.0213908 1.0113541 
BEX5 -2.3764752 0.001996 0.0213908 1.0084192 C20orf132 -2.4177322 0.001996 0.0213908 1.0130384 
KLF7 -2.3772576 0.001996 0.0213908 1.0033724 HEBP2 -2.4184816 0.001996 0.0213908 1.0078271 
KRT8P11 -2.3773588 0.001996 0.0213908 1.0011793 FRYL -2.4206998 0.001996 0.0213908 1.0043793 
USP3 -2.3777031 0.001996 0.0213908 1.0143411 MST1 -2.4226339 0.001996 0.0213908 1.0116151 
CBFA2T2 -2.3779619 0.001996 0.0213908 1.0060233 DOCK4 -2.4243904 0.001996 0.0213908 1.0120587 
TMTC2 -2.3783865 0.001996 0.0213908 1.0263994 OR4D1 -2.4250242 0.001996 0.0213908 1.0168026 
PRRG2 -2.3784915 0.001996 0.0213908 1.0109105 SOX11 -2.4264617 0.001996 0.0213908 1.0048257 
TSPAN3 -2.3800234 0.001996 0.0213908 1.0029844 C11orf63 -2.4296445 0.001996 0.0213908 1.018876 
MAGEH1 -2.3809688 0.001996 0.0213908 1.0078878 FAM172A -2.4297378 0.001996 0.0213908 1.0085444 
SRP9 -2.3821653 0.001996 0.0213908 1.0009578 TMEM204 -2.4298258 0.001996 0.0213908 1.0042499 
TMEM63A -2.3823342 0.001996 0.0213908 1.0182832 FAM125B -2.4307193 0.001996 0.0213908 1.0031486 
C10orf107 -2.3842859 0.001996 0.0213908 1.024969 OR5H1 -2.4307227 0.001996 0.0213908 1.0857778 
F8 -2.3847142 0.001996 0.0213908 1.0123029 PPP3CC -2.4307249 0.001996 0.0213908 1.0075042 
 
197 
 
Gene Symbol Score Feature P FDR (BH) Fold Change Gene Symbol Score Feature P FDR (BH) 
Fold 
Change 
TM9SF1 -2.432294 0.001996 0.0213908 1.00700008 CNOT6L -2.4880493 0.001996 0.0213908 1.00388975 
SCAND3 -2.4326407 0.001996 0.0213908 1.008165029 CRYBG3 -2.4902677 0.001996 0.0213908 1.00991161 
RIT1 -2.4326521 0.001996 0.0213908 1.010143473 ESYT1 -2.49037 0.001996 0.0213908 1.00590625 
AMOTL1 -2.4329134 0.001996 0.0213908 1.010929875 ZNF793 -2.4905476 0.001996 0.0213908 1.00380815 
VKORC1 -2.4336966 0.001996 0.0213908 1.001817081 PON2 -2.4917048 0.001996 0.0213908 1.0016526 
C15orf44 -2.4349872 0.001996 0.0213908 1.004840995 ARL6IP5 -2.4923503 0.001996 0.0213908 1.00454273 
GPR50 -2.4366815 0.001996 0.0213908 1.013241732 DBP -2.4952871 0.001996 0.0213908 1.00585979 
KIAA1586 -2.4380922 0.001996 0.0213908 1.001726349 LOC93463 -2.4988241 0.001996 0.0213908 1.0095541 
KIAA0895L -2.4383058 0.001996 0.0213908 1.009817162 RSPH3 -2.5014912 0.001996 0.0213908 1.01064198 
MAPK10 -2.4391153 0.001996 0.0213908 1.021687287 ZC3H11A -2.5034792 0.001996 0.0213908 1.00494645 
BSCL2 -2.4427872 0.001996 0.0213908 1.003350015 C15orf29 -2.5054595 0.001996 0.0213908 1.00309491 
KRTAP27-1 -2.450433 0.001996 0.0213908 1.017529081 AP2B1 -2.5055991 0.001996 0.0213908 1.00130068 
RIPK4 -2.4531427 0.001996 0.0213908 1.009185237 PDE8A -2.506371 0.001996 0.0213908 1.01216466 
KLHL36 -2.454288 0.001996 0.0213908 1.001278032 HIP1R -2.5079905 0.001996 0.0213908 1.00844312 
FAM20C -2.4548965 0.001996 0.0213908 1.008011149 SENP8 -2.508438 0.001996 0.0213908 1.00529727 
OLIG3 -2.4549056 0.001996 0.0213908 1.021899222 SUGT1P3 -2.5101267 0.001996 0.0213908 1.01324046 
RHBDD1 -2.4553436 0.001996 0.0213908 1.009215075 TSHZ1 -2.5109085 0.001996 0.0213908 1.01232422 
PDXDC2P -2.4560243 0.001996 0.0213908 1.007036087 TRIM36 -2.5116104 0.001996 0.0213908 1.01731037 
RASA1 -2.4561751 0.001996 0.0213908 1.006946036 HDAC5 -2.51295 0.001996 0.0213908 1.00617208 
CAPZA3 -2.4565347 0.001996 0.0213908 1.046710823 GPR137C -2.5142599 0.001996 0.0213908 1.00562081 
RIMKLBP1 -2.4577065 0.001996 0.0213908 1.004029657 MLLT4-AS1 -2.517251 0.001996 0.0213908 1.00843189 
SRPX2 -2.4589453 0.001996 0.0213908 1.015328365 CD177 -2.5197366 0.001996 0.0213908 1.01109401 
RPS28 -2.4602337 0.001996 0.0213908 1.00172198 USP20 -2.5201991 0.001996 0.0213908 1.00437166 
AK021889 -2.4606101 0.001996 0.0213908 1.027998992 SLC12A7 -2.5207188 0.001996 0.0213908 1.00374131 
IL10RB -2.4617718 0.001996 0.0213908 1.009860047 FBXL4 -2.5223723 0.001996 0.0213908 1.00746524 
PFKL -2.4628987 0.001996 0.0213908 1.004677399 TFF3 -2.5276949 0.001996 0.0213908 1.01135453 
SDHAF2 -2.4632655 0.001996 0.0213908 1.002712592 WNT11 -2.5282852 0.001996 0.0213908 1.00695652 
ARF6 -2.4639365 0.001996 0.0213908 1.003302893 CCL2 -2.5289608 0.001996 0.0213908 1.00448384 
NONO -2.4639562 0.001996 0.0213908 1.00242173 C6orf165 -2.5293177 0.001996 0.0213908 1.0118106 
OGT -2.4647152 0.001996 0.0213908 1.004036113 NADKD1 -2.5312118 0.001996 0.0213908 1.00992297 
LYRM1 -2.4649736 0.001996 0.0213908 1.003899503 ZNF160 -2.5315384 0.001996 0.0213908 1.00693807 
TRIP11 -2.4677641 0.001996 0.0213908 1.011120299 FAM160B1 -2.5353564 0.001996 0.0213908 1.00612919 
MSX2 -2.4678131 0.001996 0.0213908 1.03840718 MAPRE3 -2.5367042 0.001996 0.0213908 1.00797748 
NDUFA2 -2.4680542 0.001996 0.0213908 1.003355805 DCAF5 -2.5397185 0.001996 0.0213908 1.00596003 
TMEM186 -2.4680743 0.001996 0.0213908 1.007826571 CENPA -2.5400845 0.001996 0.0213908 1.00464927 
CMPK2 -2.4694419 0.001996 0.0213908 1.005087749 NSMCE1 -2.5410872 0.001996 0.0213908 1.00844785 
TMEM59 -2.470586 0.001996 0.0213908 1.0018463 TACR1 -2.5411062 0.001996 0.0213908 1.03061224 
METTL4 -2.4712039 0.001996 0.0213908 1.006636435 UBA1 -2.5416162 0.001996 0.0213908 1.00263295 
TBL1XR1 -2.4730486 0.001996 0.0213908 1.004583921 WNT8A -2.5417745 0.001996 0.0213908 1.02667588 
PCDHB8 -2.4734645 0.001996 0.0213908 1.041739034 BLVRA -2.5423064 0.001996 0.0213908 1.004817 
CCHCR1 -2.4742135 0.001996 0.0213908 1.003423489 GNG2 -2.5427996 0.001996 0.0213908 1.01270972 
OR10T1P -2.4788582 0.001996 0.0213908 1.017198472 ZNF600 -2.5471296 0.001996 0.0213908 1.01330857 
ANKRD36C -2.4804077 0.001996 0.0213908 1.006858435 NODAL -2.5475595 0.001996 0.0213908 1.04161647 
GPSM3 -2.4804699 0.001996 0.0213908 1.011917527 ANKRD20A8P -2.5485548 0.001996 0.0213908 1.01499081 
LIPH -2.4819038 0.001996 0.0213908 1.034492071 NAA40 -2.5485956 0.001996 0.0213908 1.00467922 
NM_023011.2 -2.4833234 0.001996 0.0213908 1.002494608 C19orf70 -2.5492099 0.001996 0.0213908 1.0037304 
PKDCC -2.4844849 0.001996 0.0213908 1.029561846 PLSCR1 -2.5494657 0.001996 0.0213908 1.01783948 
FN3KRP -2.4846304 0.001996 0.0213908 1.00556311 DDHD1 -2.5502626 0.001996 0.0213908 1.004928 
NGEF -2.4852998 0.001996 0.0213908 1.006564882 ELMOD3 -2.552865 0.001996 0.0213908 1.00993112 
MIF4GD -2.4859416 0.001996 0.0213908 1.010201511 SNX30 -2.5548191 0.001996 0.0213908 1.00686611 
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RNF24 -2.5549472 0.001996 0.0213908 1.0047028 CSMD3 -2.6028321 0.001996 0.0213908 1.0072171 
ARID5A -2.5551175 0.001996 0.0213908 1.0133329 SEMA3D -2.6031283 0.001996 0.0213908 1.0151722 
STAG3L3 -2.5562453 0.001996 0.0213908 1.0069181 DNAH12 -2.603146 0.001996 0.0213908 1.0209615 
KLF5 -2.5562678 0.001996 0.0213908 1.0106869 HNF1B -2.6047558 0.001996 0.0213908 1.0232646 
GDPGP1 -2.5581433 0.001996 0.0213908 1.0077368 JAKMIP3 -2.6058272 0.001996 0.0213908 1.0080203 
CTBP1-AS1 -2.5582541 0.001996 0.0213908 1.0056498 TBC1D28 -2.6062318 0.001996 0.0213908 1.0119632 
MLH3 -2.5591133 0.001996 0.0213908 1.0110073 HNRNPA1 -2.6072685 0.001996 0.0213908 1.0013975 
VGLL4 -2.5602132 0.001996 0.0213908 1.0030359 AY358241 -2.6074937 0.001996 0.0213908 1.0369273 
TMEM198B -2.5607995 0.001996 0.0213908 1.0093052 SCARNA9L -2.6081294 0.001996 0.0213908 1.0176228 
MYEF2 -2.5608657 0.001996 0.0213908 1.0030971 AK098314 -2.609661 0.001996 0.0213908 1.0071255 
PRKAR1A -2.5608757 0.001996 0.0213908 1.0036244 SP5 -2.6099224 0.001996 0.0213908 1.0328157 
LINC00173 -2.5609812 0.001996 0.0213908 1.0114476 SLC40A1 -2.6103525 0.001996 0.0213908 1.0430797 
PIGB -2.5622685 0.001996 0.0213908 1.009066 LZIC -2.6108068 0.001996 0.0213908 1.0073221 
LINC00467 -2.5632256 0.001996 0.0213908 1.0283903 UGT3A1 -2.610956 0.001996 0.0213908 1.0157043 
EZH1 -2.5648081 0.001996 0.0213908 1.0091792 FAM83F -2.6140043 0.001996 0.0213908 1.0052526 
TIRAP -2.565106 0.001996 0.0213908 1.0147642 COPG1 -2.6141548 0.001996 0.0213908 1.0024959 
SPTBN1 -2.5659816 0.001996 0.0213908 1.0029979 PDE9A -2.6141837 0.001996 0.0213908 1.0031622 
ICAM3 -2.5660412 0.001996 0.0213908 1.0096561 TMEM194B -2.6149215 0.001996 0.0213908 1.0072006 
CAPN7 -2.5687421 0.001996 0.0213908 1.0058037 EHD3 -2.6187588 0.001996 0.0213908 1.0047239 
RYR2 -2.5689597 0.001996 0.0213908 1.0139063 UBL3 -2.6192716 0.001996 0.0213908 1.0033744 
FAM167A -2.5690995 0.001996 0.0213908 1.048299 EBAG9 -2.6200021 0.001996 0.0213908 1.0062548 
PHKA1 -2.5702083 0.001996 0.0213908 1.0084419 GFRA3 -2.6205884 0.001996 0.0213908 1.0080065 
LYPLAL1 -2.571339 0.001996 0.0213908 1.0198868 USP41 -2.6213366 0.001996 0.0213908 1.016804 
SPA17 -2.5729475 0.001996 0.0213908 1.0128341 PLXNA3 -2.6215163 0.001996 0.0213908 1.0082091 
DZIP3 -2.574858 0.001996 0.0213908 1.0077124 DCLK2 -2.6219428 0.001996 0.0213908 1.0270821 
CCDC92 -2.5755603 0.001996 0.0213908 1.0497748 LOC440173 -2.6219998 0.001996 0.0213908 1.0210912 
TMEM144 -2.5777999 0.001996 0.0213908 1.0228469 KBTBD2 -2.6223786 0.001996 0.0213908 1.0064897 
ST6GAL1 -2.5778454 0.001996 0.0213908 1.0026718 CD40 -2.6239402 0.001996 0.0213908 1.0133534 
RHPN1-AS1 -2.5794775 0.001996 0.0213908 1.0037498 ABL1 -2.6248008 0.001996 0.0213908 1.0019138 
FAM213A -2.5808093 0.001996 0.0213908 1.0070278 MYO3B -2.6282256 0.001996 0.0213908 1.0441029 
RNF5 -2.5808421 0.001996 0.0213908 1.003066 FAM125A -2.6283685 0.001996 0.0213908 1.0093727 
METTL20 -2.5815363 0.001996 0.0213908 1.019442 NIPAL3 -2.629674 0.001996 0.0213908 1.0069267 
IL1RAPL1 -2.5830552 0.001996 0.0213908 1.0429608 ARSD -2.6297321 0.001996 0.0213908 1.005765 
CCDC82 -2.5845311 0.001996 0.0213908 1.0051897 TNFAIP8L1 -2.6304088 0.001996 0.0213908 1.0105815 
VPS13C -2.584809 0.001996 0.0213908 1.011586 ARMCX4 -2.6308385 0.001996 0.0213908 1.0095408 
DCP1B -2.58512 0.001996 0.0213908 1.0051781 ARHGEF11 -2.6315128 0.001996 0.0213908 1.0026988 
OMA1 -2.5867204 0.001996 0.0213908 1.0153549 FMO4 -2.6316586 0.001996 0.0213908 1.0080619 
TIA1 -2.5874357 0.001996 0.0213908 1.005081 TMEM120A -2.6322788 0.001996 0.0213908 1.0043739 
ASB5 -2.5877983 0.001996 0.0213908 1.0607262 DENND1B -2.6331821 0.001996 0.0213908 1.0132699 
TMEM87B -2.5896898 0.001996 0.0213908 1.0122226 IER3 -2.6340002 0.001996 0.0213908 1.0101389 
CTSA -2.5910132 0.001996 0.0213908 1.0025431 RNU1-17P -2.6341368 0.001996 0.0213908 1.0050547 
MTMR10 -2.591687 0.001996 0.0213908 1.0112477 TAF6L -2.6342661 0.001996 0.0213908 1.006748 
CEP44 -2.5934557 0.001996 0.0213908 1.0086845 RIOK3 -2.6344542 0.001996 0.0213908 1.003893 
IL12RB2 -2.5936504 0.001996 0.0213908 1.0143816 
SNORD115-
35 -2.6356645 0.001996 0.0213908 1.0158439 
TPD52 -2.5938389 0.001996 0.0213908 1.0024854 LAS1L -2.638295 0.001996 0.0213908 1.0031024 
DUX4L7 -2.5942263 0.001996 0.0213908 1.0160225 RNF103 -2.6385226 0.001996 0.0213908 1.0123151 
NLRP12 -2.5964835 0.001996 0.0213908 1.0102364 EFHA2 -2.6426884 0.001996 0.0213908 1.0041393 
KIF27 -2.5965973 0.001996 0.0213908 1.0111717 PYROXD2 -2.6442531 0.001996 0.0213908 1.0156009 
SLC25A20 -2.5998713 0.001996 0.0213908 1.0119392 LCK -2.6442923 0.001996 0.0213908 1.0023846 
MARVELD2 -2.600306 0.001996 0.0213908 1.0093074 LANCL3 -2.6446746 0.001996 0.0213908 1.0351982 
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INPPL1 -2.6448093 0.001996 0.0213908 1.0058163 YAP1 -2.6930984 0.001996 0.0213908 1.0040751 
PPM1H -2.6451518 0.001996 0.0213908 1.0052473 RNF122 -2.6940034 0.001996 0.0213908 1.013324 
CLCN5 -2.645847 0.001996 0.0213908 1.008109 TMEM123 -2.695709 0.001996 0.0213908 1.0055757 
CARKD -2.6469192 0.001996 0.0213908 1.0052465 ZHX2 -2.6967569 0.001996 0.0213908 1.0050857 
GLI3 -2.6470121 0.001996 0.0213908 1.0085213 SP110 -2.6975587 0.001996 0.0213908 1.0152551 
DDB1 -2.6477036 0.001996 0.0213908 1.0020567 C1orf210 -2.6977332 0.001996 0.0213908 1.0031685 
POLR2J3 -2.648229 0.001996 0.0213908 1.0054889 LRRC3 -2.6978334 0.001996 0.0213908 1.0263937 
PTTG2 -2.6490159 0.001996 0.0213908 1.0244172 ZNF627 -2.699059 0.001996 0.0213908 1.0057793 
RBM4B -2.6493874 0.001996 0.0213908 1.00633 ZNF688 -2.7004914 0.001996 0.0213908 1.0103215 
DCBLD1 -2.6505891 0.001996 0.0213908 1.0117881 SFT2D2 -2.7007001 0.001996 0.0213908 1.0045406 
SPCS3 -2.6509556 0.001996 0.0213908 1.0043749 TIMM8B -2.7015659 0.001996 0.0213908 1.0042838 
UBXN4 -2.6521108 0.001996 0.0213908 1.0053404 C19orf54 -2.7020023 0.001996 0.0213908 1.0070612 
SUSD2 -2.6537375 0.001996 0.0213908 1.0103668 POLR2J2 -2.7036314 0.001996 0.0213908 1.0040749 
AADAT -2.6548402 0.001996 0.0213908 1.0115668 TARBP1 -2.7050889 0.001996 0.0213908 1.0133729 
PLA2G5 -2.6566135 0.001996 0.0213908 1.0202548 ZKSCAN1 -2.7071145 0.001996 0.0213908 1.0115951 
FBXO11 -2.6574804 0.001996 0.0213908 1.0035718 FAM159B -2.7071939 0.001996 0.0213908 1.035621 
ANKRD32 -2.657658 0.001996 0.0213908 1.0190915 PPP1R3B -2.7072477 0.001996 0.0213908 1.0175357 
REEP4 -2.6580669 0.001996 0.0213908 1.0061704 DNAJC4 -2.7086577 0.001996 0.0213908 1.0098773 
C6orf57 -2.6584747 0.001996 0.0213908 1.013086 HFM1 -2.7086708 0.001996 0.0213908 1.033095 
RAC2 -2.6598794 0.001996 0.0213908 1.0078102 ZNF285 -2.7090795 0.001996 0.0213908 1.0289051 
TEN1-
CDK3 -2.66049 0.001996 0.0213908 1.0071613 POLK -2.7112375 0.001996 0.0213908 1.0084708 
CHKB-
CPT1B -2.6617041 0.001996 0.0213908 1.011305 TRIM68 -2.7115853 0.001996 0.0213908 1.0155321 
LHX5 -2.6617545 0.001996 0.0213908 1.0535917 CLMN -2.7119131 0.001996 0.0213908 1.0118516 
STK38 -2.6658469 0.001996 0.0213908 1.0026591 EPHB2 -2.712277 0.001996 0.0213908 1.0049093 
MGC21881 -2.6688291 0.001996 0.0213908 1.0088579 SULT4A1 -2.7132519 0.001996 0.0213908 1.0092513 
SIPA1L2 -2.6732476 0.001996 0.0213908 1.0195142 PEX26 -2.7136021 0.001996 0.0213908 1.0059576 
GGT2 -2.6746738 0.001996 0.0213908 1.0077617 PCDHB7 -2.7137021 0.001996 0.0213908 1.0202507 
TBX6 -2.6755041 0.001996 0.0213908 1.0109733 TPST1 -2.7141699 0.001996 0.0213908 1.0035748 
UNK -2.6768322 0.001996 0.0213908 1.0077793 TYK2 -2.7147781 0.001996 0.0213908 1.006555 
TOB2 -2.6783767 0.001996 0.0213908 1.0100388 ENTPD4 -2.7150507 0.001996 0.0213908 1.0041463 
WASH4P -2.6785763 0.001996 0.0213908 1.0069506 GALE -2.7152076 0.001996 0.0213908 1.0111807 
ZNF135 -2.6799304 0.001996 0.0213908 1.0087484 FAM70A -2.7166352 0.001996 0.0213908 1.0210204 
CDAN1 -2.6799915 0.001996 0.0213908 1.0068565 SLC16A5 -2.7176281 0.001996 0.0213908 1.0093457 
DHRS13 -2.6803325 0.001996 0.0213908 1.0056276 MGARP -2.7182168 0.001996 0.0213908 1.0121596 
C11orf52 -2.6806229 0.001996 0.0213908 1.0100454 ZDHHC17 -2.718603 0.001996 0.0213908 1.0057697 
RP2 -2.6819539 0.001996 0.0213908 1.0105222 CNKSR3 -2.7199487 0.001996 0.0213908 1.0082597 
CFLAR -2.6822966 0.001996 0.0213908 1.0247582 GNGT1 -2.7202059 0.001996 0.0213908 1.0261263 
DOC2A -2.6826635 0.001996 0.0213908 1.007887 FAM184A -2.7206483 0.001996 0.0213908 1.0206624 
SEPP1 -2.68354 0.001996 0.0213908 1.0174517 COPA -2.7222051 0.001996 0.0213908 1.0026822 
HEY2 -2.6855718 0.001996 0.0213908 1.0209729 SNX33 -2.7250302 0.001996 0.0213908 1.0013401 
C9orf64 -2.686357 0.001996 0.0213908 1.0139226 ACBD4 -2.7251293 0.001996 0.0213908 1.0087409 
NUDT6 -2.6869908 0.001996 0.0213908 1.0079725 LOC440434 -2.7257073 0.001996 0.0213908 1.0037979 
CREBRF -2.6887124 0.001996 0.0213908 1.019673 DAK -2.7261771 0.001996 0.0213908 1.007363 
ATG7 -2.6896295 0.001996 0.0213908 1.0059085 HOXB9 -2.7268804 0.001996 0.0213908 1.0103033 
ATAT1 -2.6908549 0.001996 0.0213908 1.0093893 RN5S290 -2.728045 0.001996 0.0213908 1.0113838 
MTMR14 -2.6911253 0.001996 0.0213908 1.0039977 ZNF433 -2.7309792 0.001996 0.0213908 1.0133523 
ROGDI -2.691295 0.001996 0.0213908 1.0044563 KIF1B -2.7320095 0.001996 0.0213908 1.0042549 
HEATR7A -2.6918523 0.001996 0.0213908 1.0040286 GATA4 -2.732201 0.001996 0.0213908 1.0240351 
DCK -2.6925737 0.001996 0.0213908 1.0020613 PLGRKT -2.7339234 0.001996 0.0213908 1.0200531 
C6orf203 -2.6927586 0.001996 0.0213908 1.0140014 PIP4K2B -2.735092 0.001996 0.0213908 1.0030366 
 
200 
 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
WDR91 -2.7364379 0.001996 0.0213908 1.0036236 APOF -2.7805427 0.001996 0.0213908 1.0146593 
RTTN -2.7376664 0.001996 0.0213908 1.0067717 FMO5 -2.7817463 0.001996 0.0213908 1.0200564 
ST3GAL6 -2.7383972 0.001996 0.0213908 1.0136095 CCDC53 -2.7824047 0.001996 0.0213908 1.0181206 
ZBTB41 -2.7385102 0.001996 0.0213908 1.0087422 CALCR -2.7832145 0.001996 0.0213908 1.0561191 
GPX7 -2.7389362 0.001996 0.0213908 1.0096626 ANO1 -2.7834848 0.001996 0.0213908 1.0157689 
C1orf201 -2.739234 0.001996 0.0213908 1.0141375 UBE2H -2.7847267 0.001996 0.0213908 1.0034443 
NR1H3 -2.7402555 0.001996 0.0213908 1.0083355 ZNF658 -2.7852789 0.001996 0.0213908 1.0166759 
C1orf115 -2.7404561 0.001996 0.0213908 1.0075938 LIPT2 -2.7878058 0.001996 0.0213908 1.0063445 
VPS39 -2.7414879 0.001996 0.0213908 1.0046705 CD99L2 -2.7883938 0.001996 0.0213908 1.0123109 
ITLN2 -2.7459558 0.001996 0.0213908 1.0125294 CECR1 -2.7886562 0.001996 0.0213908 1.0057536 
GSTM1 -2.7463566 0.001996 0.0213908 1.0070916 FZD1 -2.7903684 0.001996 0.0213908 1.0099043 
SUMF2 -2.7465956 0.001996 0.0213908 1.008403 L3MBTL1 -2.7914209 0.001996 0.0213908 1.0141398 
C1orf74 -2.7469741 0.001996 0.0213908 1.0059368 WDR78 -2.7915238 0.001996 0.0213908 1.016088 
ZSCAN23 -2.7486771 0.001996 0.0213908 1.0175226 RAB5B -2.7926185 0.001996 0.0213908 1.0043175 
BVES -2.7542943 0.001996 0.0213908 1.011552 FBXO7 -2.7944442 0.001996 0.0213908 1.0039703 
BMP1 -2.7558519 0.001996 0.0213908 1.0080778 FTSJD2 -2.7950888 0.001996 0.0213908 1.0037807 
LHX1 -2.7559317 0.001996 0.0213908 1.0452115 MMS19 -2.7955176 0.001996 0.0213908 1.0036295 
MEIS2 -2.7566875 0.001996 0.0213908 1.038354 CYP39A1 -2.796556 0.001996 0.0213908 1.0153949 
NR2C1 -2.7572606 0.001996 0.0213908 1.0053668 LRRC3DN -2.7970082 0.001996 0.0213908 1.0295634 
CTAGE4 -2.7575353 0.001996 0.0213908 1.031192 SMAD3 -2.7973678 0.001996 0.0213908 1.0035796 
SPO11 -2.7601983 0.001996 0.0213908 1.0145872 DMTF1 -2.7976912 0.001996 0.0213908 1.0016645 
AKAP14 -2.7610928 0.001996 0.0213908 1.0125935 STAG3L1 -2.7989814 0.001996 0.0213908 1.007244 
COPZ1 -2.7617793 0.001996 0.0213908 1.0035035 KLF12 -2.8004885 0.001996 0.0213908 1.0098426 
PLA2G7 -2.7620385 0.001996 0.0213908 1.0184331 CDK5 -2.8013669 0.001996 0.0213908 1.0072982 
SLC38A3 -2.7628577 0.001996 0.0213908 1.008805 PMS2P1 -2.8016617 0.001996 0.0213908 1.0059359 
BRE -2.7633672 0.001996 0.0213908 1.0044053 PYDC1 -2.8027237 0.001996 0.0213908 1.0069039 
ZNF233 -2.7634397 0.001996 0.0213908 1.0091701 ZMAT2 -2.8033931 0.001996 0.0213908 1.0055151 
TBX19 -2.7635828 0.001996 0.0213908 1.0111541 FAM122A -2.804524 0.001996 0.0213908 1.0080114 
STIM1 -2.7638572 0.001996 0.0213908 1.0129129 KRT18 -2.8047655 0.001996 0.0213908 1.0072592 
HNRNPUL2 -2.7642578 0.001996 0.0213908 1.0055326 GUCY1A2 -2.8060361 0.001996 0.0213908 1.0106536 
PTPDC1 -2.7642983 0.001996 0.0213908 1.0081087 DDX60 -2.8087759 0.001996 0.0213908 1.0286048 
TOP2A -2.7649929 0.001996 0.0213908 1.0044281 TENC1 -2.8091848 0.001996 0.0213908 1.0182109 
FRMPD4 -2.7655968 0.001996 0.0213908 1.0270721 TSC2 -2.8092112 0.001996 0.0213908 1.0029877 
APLF -2.7661331 0.001996 0.0213908 1.0081897 MDP1 -2.8103337 0.001996 0.0213908 1.0081349 
RASGRP1 -2.7661401 0.001996 0.0213908 1.0148993 EPHX2 -2.8105353 0.001996 0.0213908 1.0145533 
GLS -2.767505 0.001996 0.0213908 1.0142614 RAB14 -2.8106708 0.001996 0.0213908 1.002921 
WDR81 -2.7678502 0.001996 0.0213908 1.0082758 WNT8B -2.8124654 0.001996 0.0213908 1.0258083 
SYPL1 -2.768931 0.001996 0.0213908 1.0035349 KRCC1 -2.8163698 0.001996 0.0213908 1.0166484 
SETD4 -2.7689743 0.001996 0.0213908 1.0141859 AHNAK -2.8181197 0.001996 0.0213908 1.0243512 
MCF2L2 -2.7694008 0.001996 0.0213908 1.0037509 OR5H14 -2.8186226 0.001996 0.0213908 1.1685847 
RNF31 -2.7695117 0.001996 0.0213908 1.0021348 FRRS1 -2.8188875 0.001996 0.0213908 1.0133706 
FAT4 -2.7707077 0.001996 0.0213908 1.0322178 PYGL -2.8189096 0.001996 0.0213908 1.0038651 
RNF152 -2.7733793 0.001996 0.0213908 1.0220043 GDPD3 -2.8200675 0.001996 0.0213908 1.0106394 
ARHGAP24 -2.7741889 0.001996 0.0213908 1.0369961 DTWD2 -2.8211728 0.001996 0.0213908 1.0326057 
SNX16 -2.7753298 0.001996 0.0213908 1.0125857 RHOBTB3 -2.8212489 0.001996 0.0213908 1.0168825 
RNY4P30 -2.777371 0.001996 0.0213908 1.0176737 EDIL3 -2.8213442 0.001996 0.0213908 1.0069528 
INMT -2.7782702 0.001996 0.0213908 1.0106154 SLC30A4 -2.8230965 0.001996 0.0213908 1.0298606 
CD48 -2.7784757 0.001996 0.0213908 1.0212601 NAT9 -2.8264013 0.001996 0.0213908 1.0128533 
ABHD13 -2.7787201 0.001996 0.0213908 1.0055982 BBS2 -2.8272836 0.001996 0.0213908 1.0142159 
CRYGA -2.7803199 0.001996 0.0213908 1.0217278 CKMT2 -2.8280552 0.001996 0.0213908 1.0173699 
 
201 
 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
CPT2 -2.8287072 0.001996 0.0213908 1.0061314 ATM -2.8944487 0.001996 0.0213908 1.004428 
CSRNP3 -2.828827 0.001996 0.0213908 1.0095512 TPTE2P6 -2.8945999 0.001996 0.0213908 1.0277127 
CHST9 -2.8293535 0.001996 0.0213908 1.0111598 SNX1 -2.8955948 0.001996 0.0213908 1.005052 
CACNB3 -2.8299959 0.001996 0.0213908 1.0118004 OR52A5 -2.897135 0.001996 0.0213908 1.054863 
FZD4 -2.8313063 0.001996 0.0213908 1.0089175 ZYG11A -2.8976858 0.001996 0.0213908 1.0153166 
CDC25C -2.8325804 0.001996 0.0213908 1.0086812 UHRF2 -2.8996646 0.001996 0.0213908 1.0054175 
GNB4 -2.8344565 0.001996 0.0213908 1.0103999 TUBB2A -2.9011045 0.001996 0.0213908 1.0091155 
RNF32 -2.8362624 0.001996 0.0213908 1.0049363 RAB38 -2.9011066 0.001996 0.0213908 1.0078001 
TRPV4 -2.8377799 0.001996 0.0213908 1.0126901 DCAF7 -2.904022 0.001996 0.0213908 1.0049878 
LIX1 -2.838939 0.001996 0.0213908 1.0679879 SEC24C -2.9046041 0.001996 0.0213908 1.0035148 
CHURC1-
FNTB -2.8406086 0.001996 0.0213908 1.0022673 RBM11 -2.9069914 0.001996 0.0213908 1.0095239 
KCNG1 -2.841635 0.001996 0.0213908 1.0112267 CXorf23 -2.9071726 0.001996 0.0213908 1.01093 
ODF2L -2.8417196 0.001996 0.0213908 1.0065522 SVOPL -2.9090971 0.001996 0.0213908 1.008431 
RPS20 -2.8420663 0.001996 0.0213908 1.0024903 C1orf145 -2.9093295 0.001996 0.0213908 1.0046377 
FLJ43879 -2.8425812 0.001996 0.0213908 1.0111566 TXNIP -2.9094082 0.001996 0.0213908 1.0213546 
ZNF512 -2.8426206 0.001996 0.0213908 1.0031921 BMPR1A -2.9101174 0.001996 0.0213908 1.0059206 
PURG -2.8428312 0.001996 0.0213908 1.005746 GLTP -2.9108919 0.001996 0.0213908 1.0082679 
C17orf65 -2.8443053 0.001996 0.0213908 1.0066045 ZNF578 -2.9120673 0.001996 0.0213908 1.0271875 
C4orf46 -2.8448648 0.001996 0.0213908 1.0041824 RPS2 -2.9125639 0.001996 0.0213908 1.0005038 
STK33 -2.8470006 0.001996 0.0213908 1.0094431 IL17RA -2.9127516 0.001996 0.0213908 1.0055695 
CLK2P -2.8471041 0.001996 0.0213908 1.0051862 MITD1 -2.9132125 0.001996 0.0213908 1.0125545 
NUDT16P1 -2.8475408 0.001996 0.0213908 1.0055412 NGLY1 -2.9166067 0.001996 0.0213908 1.0093824 
TGIF2 -2.8487108 0.001996 0.0213908 1.0051353 GLB1L -2.9182019 0.001996 0.0213908 1.01281 
NFASC -2.849162 0.001996 0.0213908 1.0153685 MPDU1 -2.9185707 0.001996 0.0213908 1.002452 
BCAR3 -2.8525564 0.001996 0.0213908 1.0142452 MR1 -2.9195786 0.001996 0.0213908 1.0231215 
ZNF396 -2.8532088 0.001996 0.0213908 1.0217288 ZNF385C -2.9223455 0.001996 0.0213908 1.0052891 
LANCL1 -2.8535146 0.001996 0.0213908 1.0062251 TPST2 -2.9237057 0.001996 0.0213908 1.0043109 
KRT78 -2.8538472 0.001996 0.0213908 1.004586 BAZ2A -2.9247398 0.001996 0.0213908 1.0023571 
ALG10 -2.8553 0.001996 0.0213908 1.006987 C10orf131 -2.9256899 0.001996 0.0213908 1.039316 
FAM193B -2.8600027 0.001996 0.0213908 1.0051477 ACTR2 -2.9258841 0.001996 0.0213908 1.0023076 
CDH9 -2.8626926 0.001996 0.0213908 1.0482886 MFAP3L -2.9267721 0.001996 0.0213908 1.0319356 
GSTO1 -2.8628633 0.001996 0.0213908 1.0164517 CABIN1 -2.9272306 0.001996 0.0213908 1.0026438 
SIPA1L1 -2.8637594 0.001996 0.0213908 1.0046187 MOCS1 -2.9311546 0.001996 0.0213908 1.0062888 
FLOT2 -2.8679866 0.001996 0.0213908 1.0045047 ING4 -2.9319054 0.001996 0.0213908 1.0068795 
ECM1 -2.8687358 0.001996 0.0213908 1.0155275 ITPR3 -2.9323614 0.001996 0.0213908 1.0044521 
TSPYL4 -2.8695636 0.001996 0.0213908 1.0035741 USP11 -2.9336864 0.001996 0.0213908 1.0037499 
THBS3 -2.8737768 0.001996 0.0213908 1.027034 LRRN2 -2.9339241 0.001996 0.0213908 1.0269785 
MYO6 -2.8756931 0.001996 0.0213908 1.0115793 CHST4 -2.9345399 0.001996 0.0213908 1.009198 
PPP1CA -2.8791323 0.001996 0.0213908 1.004462 ATG10 -2.9353012 0.001996 0.0213908 1.0143411 
PLCB2 -2.8796207 0.001996 0.0213908 1.0090012 MED23 -2.9355717 0.001996 0.0213908 1.0076282 
PGLS -2.8796535 0.001996 0.0213908 1.0104799 MDFIC -2.9365053 0.001996 0.0213908 1.0026 
CCNB2 -2.8801734 0.001996 0.0213908 1.0028086 LRRCC1 -2.9368965 0.001996 0.0213908 1.0077966 
TCTA -2.8818887 0.001996 0.0213908 1.0061805 TUBG2 -2.9378549 0.001996 0.0213908 1.0100611 
CCPG1 -2.8847779 0.001996 0.0213908 1.0209846 FLJ30403 -2.9406968 0.001996 0.0213908 1.0228534 
NMNAT1 -2.8854033 0.001996 0.0213908 1.0129707 ZC3HAV1L -2.9429644 0.001996 0.0213908 1.0083574 
LRIG3 -2.8875046 0.001996 0.0213908 1.0195268 ERLIN2 -2.9480365 0.001996 0.0213908 1.0058345 
POMT1 -2.8915738 0.001996 0.0213908 1.0065066 MYD88 -2.9490222 0.001996 0.0213908 1.0041355 
FST -2.8923689 0.001996 0.0213908 1.033116 C12orf57 -2.9492276 0.001996 0.0213908 1.0018601 
GOLGA2 -2.8934672 0.001996 0.0213908 1.0031289 MAN1A1 -2.9494963 0.001996 0.0213908 1.0152507 
GSTO2 -2.8942318 0.001996 0.0213908 1.0103263 ZNF839 -2.9501752 0.001996 0.0213908 1.0136366 
 
202 
 
Gene Symbol Score Feature P FDR (BH) 
Fold 
Change 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
ZNF765 -2.9521591 0.001996 0.0213908 1.0027661 PABPC1L -3.0044798 0.001996 0.0213908 1.0091152 
SGPP1 -2.9530702 0.001996 0.0213908 1.0038663 COG1 -3.0061015 0.001996 0.0213908 1.0048289 
TSPYL1 -2.9536475 0.001996 0.0213908 1.0019171 DDX25 -3.0066884 0.001996 0.0213908 1.0073857 
NRIP1 -2.9542162 0.001996 0.0213908 1.0118123 LRRC20 -3.006736 0.001996 0.0213908 1.0073977 
CSTB -2.9549433 0.001996 0.0213908 1.0017827 THAP6 -3.0099412 0.001996 0.0213908 1.0090609 
TMEM185B -2.9552388 0.001996 0.0213908 1.0058906 TRNAL41P -3.0102755 0.001996 0.0213908 1.0133628 
C4orf37 -2.9552823 0.001996 0.0213908 1.0143474 DDX11 -3.0104736 0.001996 0.0213908 1.0044576 
MAN1B1 -2.9560727 0.001996 0.0213908 1.001368 SCN5A -3.0123762 0.001996 0.0213908 1.0020891 
CAPN11 -2.9562417 0.001996 0.0213908 1.0202911 RNF141 -3.0129233 0.001996 0.0213908 1.0047569 
RFXANK -2.9564308 0.001996 0.0213908 1.0039486 IL13RA1 -3.0150038 0.001996 0.0213908 1.0101275 
SNX10 -2.9604664 0.001996 0.0213908 1.0080638 USP51 -3.0150775 0.001996 0.0213908 1.0059521 
ZMYM6 -2.9623321 0.001996 0.0213908 1.0083322 SEPSECS -3.0161184 0.001996 0.0213908 1.020082 
ITGA2B -2.9639059 0.001996 0.0213908 1.0052855 CHMP4C -3.0181644 0.001996 0.0213908 1.027344 
CDC7 -2.9647221 0.001996 0.0213908 1.0059498 SLC26A8 -3.0184641 0.001996 0.0213908 1.0149676 
KRT18P28 -2.9666076 0.001996 0.0213908 1.008598 GSN -3.0192308 0.001996 0.0213908 1.0032227 
NICN1 -2.9672722 0.001996 0.0213908 1.0080517 GPR126 -3.0195075 0.001996 0.0213908 1.018272 
LOC284788 -2.9675944 0.001996 0.0213908 1.0209701 MBTPS2 -3.0197275 0.001996 0.0213908 1.0055311 
CHFR -2.9682855 0.001996 0.0213908 1.0089779 RAD23A -3.0220992 0.001996 0.0213908 1.002498 
C19orf40 -2.9686228 0.001996 0.0213908 1.0056043 ATP2A1 -3.0221835 0.001996 0.0213908 1.0104831 
P2RX4 -2.9707286 0.001996 0.0213908 1.0153621 FBLN2 -3.0231294 0.001996 0.0213908 1.0108298 
PTBP3 -2.972676 0.001996 0.0213908 1.0034729 MCTP2 -3.0233415 0.001996 0.0213908 1.0134147 
WDR60 -2.9727863 0.001996 0.0213908 1.009275 ENGASE -3.0233727 0.001996 0.0213908 1.0080385 
STRADB -2.9743028 0.001996 0.0213908 1.0040575 ZNF137P -3.0241415 0.001996 0.0213908 1.0156706 
MTERFD3 -2.9781661 0.001996 0.0213908 1.0055351 STIL -3.0241722 0.001996 0.0213908 1.0062831 
OLFM3 -2.9782262 0.001996 0.0213908 1.0330947 SIX3 -3.0245612 0.001996 0.0213908 1.0120452 
SETD8 -2.9802718 0.001996 0.0213908 1.0041193 NPY1R -3.0246521 0.001996 0.0213908 1.0133587 
C7orf25 -2.9806818 0.001996 0.0213908 1.0220618 LRRIQ3 -3.0259285 0.001996 0.0213908 1.0339327 
CHRNB4 -2.9806929 0.001996 0.0213908 1.0159376 MAP2K3 -3.0282126 0.001996 0.0213908 1.0076589 
ATP5H -2.9817383 0.001996 0.0213908 1.0055624 RWDD2B -3.0294556 0.001996 0.0213908 1.0234685 
ITGA2 -2.986624 0.001996 0.0213908 1.0012569 TXLNG2P -3.0305861 0.001996 0.0213908 1.0059031 
PTGES3L-
AARSD1 -2.9896642 0.001996 0.0213908 1.0044692 CCDC125 -3.0312353 0.001996 0.0213908 1.017356 
FAM21C -2.9897245 0.001996 0.0213908 1.0045813 MSI1 -3.0336236 0.001996 0.0213908 1.0121332 
MINK1 -2.9898477 0.001996 0.0213908 1.0025639 WSB1 -3.0365371 0.001996 0.0213908 1.0072885 
CHRD -2.9909454 0.001996 0.0213908 1.0197771 MTA2 -3.0366387 0.001996 0.0213908 1.0035113 
PEX12 -2.9914286 0.001996 0.0213908 1.0135272 MSN -3.037024 0.001996 0.0213908 1.0028033 
SMARCAL1 -2.9916604 0.001996 0.0213908 1.0046313 ZFP2 -3.0377222 0.001996 0.0213908 1.0142558 
ATP5A1 -2.9931034 0.001996 0.0213908 1.001407 APOL2 -3.0387823 0.001996 0.0213908 1.0074528 
LRP10 -2.9940664 0.001996 0.0213908 1.0120088 AKAP7 -3.0389184 0.001996 0.0213908 1.0196578 
GABPB2 -2.9942596 0.001996 0.0213908 1.0149817 
KLRC4-
KLRK1 -3.0391849 0.001996 0.0213908 1.0140192 
DSCAM -2.9950003 0.001996 0.0213908 1.0074479 RNF181 -3.0401698 0.001996 0.0213908 1.0019089 
RCBTB1 -2.9958011 0.001996 0.0213908 1.0044403 WDR31 -3.0403489 0.001996 0.0213908 1.0167761 
PLA2G6 -2.9969234 0.001996 0.0213908 1.0248277 USF2 -3.0446261 0.001996 0.0213908 1.0034742 
RNFT1 -2.9971025 0.001996 0.0213908 1.0184363 ZNF436 -3.0452978 0.001996 0.0213908 1.010903 
EGFLAM -2.9974842 0.001996 0.0213908 1.0326713 RNY4P22 -3.0458643 0.001996 0.0213908 1.0117841 
CYP11A1 -2.9975845 0.001996 0.0213908 1.019591 FES -3.046452 0.001996 0.0213908 1.0121581 
CDH20 -2.9984768 0.001996 0.0213908 1.0121747 APLNR -3.047093 0.001996 0.0213908 1.066052 
TTC8 -2.9988312 0.001996 0.0213908 1.0084055 USP4 -3.0506356 0.001996 0.0213908 1.0035548 
SP1 -3.0012182 0.001996 0.0213908 1.0031993 NKX2-1 -3.0527072 0.001996 0.0213908 1.0116203 
UBE2Q2P2 -3.003238 0.001996 0.0213908 1.0074425 RN5S109 -3.0549076 0.001996 0.0213908 1.0288522 
PBX2 -3.0041125 0.001996 0.0213908 1.00383 PDK1 -3.0552711 0.001996 0.0213908 1.0168755 
 
203 
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Fold 
Change 
SHISA6 -3.0555033 0.001996 0.0213908 1.0095357 AK024925 -3.1176179 0.001996 0.0213908 1.0351756 
PIK3R3 -3.0565898 0.001996 0.0213908 1.0072183 UBR1 -3.119722 0.001996 0.0213908 1.0070521 
CEP112 -3.05905 0.001996 0.0213908 1.015582 PCBD1 -3.120011 0.001996 0.0213908 1.0050841 
TCL1B -3.0601417 0.001996 0.0213908 1.0143597 HERPUD2 -3.1209167 0.001996 0.0213908 1.0040449 
PITPNM2 -3.0609809 0.001996 0.0213908 1.011088 ZNF546 -3.1217648 0.001996 0.0213908 1.0232335 
ADAMTS16 -3.0620462 0.001996 0.0213908 1.0127794 MTRF1 -3.1220417 0.001996 0.0213908 1.004802 
KDM4C -3.0635391 0.001996 0.0213908 1.0097736 AP2A2 -3.1257053 0.001996 0.0213908 1.0015304 
DIAPH2 -3.0661688 0.001996 0.0213908 1.0105172 SST -3.1278234 0.001996 0.0213908 1.0090555 
PLCG1 -3.0696989 0.001996 0.0213908 1.0045909 ABLIM1 -3.1282816 0.001996 0.0213908 1.0051687 
TGFA -3.0718985 0.001996 0.0213908 1.0123743 ZSWIM4 -3.1283172 0.001996 0.0213908 1.005373 
IGSF9B -3.0725733 0.001996 0.0213908 1.017475 BOC -3.1284243 0.001996 0.0213908 1.016266 
CD1D -3.073723 0.001996 0.0213908 1.013935 SYNJ2 -3.1322744 0.001996 0.0213908 1.0065214 
IQCH -3.0762358 0.001996 0.0213908 1.0141442 GIT2 -3.1326648 0.001996 0.0213908 1.0057697 
TMPRSS11E -3.0769319 0.001996 0.0213908 1.0259925 NCOA4 -3.1328261 0.001996 0.0213908 1.0055042 
TMLHE -3.0771365 0.001996 0.0213908 1.0036979 ROR2 -3.1334369 0.001996 0.0213908 1.0353599 
FAM18B2 -3.0785837 0.001996 0.0213908 1.0103436 TMEM185A -3.1346568 0.001996 0.0213908 1.004569 
RNF180 -3.0792785 0.001996 0.0213908 1.0091393 TSHB -3.1356361 0.001996 0.0213908 1.0118427 
ALDH9A1 -3.0806933 0.001996 0.0213908 1.0032696 NCKAP1L -3.1356413 0.001996 0.0213908 1.0146991 
HTRA2 -3.0812652 0.001996 0.0213908 1.0049404 C4orf36 -3.1361726 0.001996 0.0213908 1.0331368 
FBXL20 -3.0819544 0.001996 0.0213908 1.0101215 GUSBP1 -3.1372872 0.001996 0.0213908 1.0052025 
SLC4A4 -3.0826862 0.001996 0.0213908 1.0117506 PNMA1 -3.1376218 0.001996 0.0213908 1.0062606 
ZIC2 -3.0828928 0.001996 0.0213908 1.0081305 FAM72D -3.1379234 0.001996 0.0213908 1.0051616 
C6orf223 -3.0839455 0.001996 0.0213908 1.0114365 PDK3 -3.1381425 0.001996 0.0213908 1.0053912 
ZNF503 -3.0853795 0.001996 0.0213908 1.0105508 VRK3 -3.1387945 0.001996 0.0213908 1.0057904 
PLEKHM1 -3.0870562 0.001996 0.0213908 1.0052701 VANGL1 -3.1403714 0.001996 0.0213908 1.0265676 
TRAPPC11 -3.0871295 0.001996 0.0213908 1.0089235 KIAA1456 -3.1413877 0.001996 0.0213908 1.0277534 
SLC25A16 -3.0878678 0.001996 0.0213908 1.0076057 FLJ46010 -3.1424961 0.001996 0.0213908 1.0241925 
PION -3.0896472 0.001996 0.0213908 1.0346055 ZNF671 -3.1432261 0.001996 0.0213908 1.008367 
HOMER3 -3.0909259 0.001996 0.0213908 1.0024579 MOSPD1 -3.143373 0.001996 0.0213908 1.0180044 
DMD -3.0920136 0.001996 0.0213908 1.0136019 HEATR4 -3.1434861 0.001996 0.0213908 1.021422 
ARHGAP11B -3.0947413 0.001996 0.0213908 1.0073051 RCAN2 -3.1465961 0.001996 0.0213908 1.0094633 
TMEM106B -3.0949487 0.001996 0.0213908 1.0073649 SIRT5 -3.1487103 0.001996 0.0213908 1.0073739 
SPRED2 -3.095924 0.001996 0.0213908 1.0066967 FAM219B -3.1488656 0.001996 0.0213908 1.0055733 
LCA5L -3.0959858 0.001996 0.0213908 1.008856 ERVH-6 -3.1489588 0.001996 0.0213908 1.023276 
ELMO1 -3.0960466 0.001996 0.0213908 1.0112031 TCTN1 -3.1496987 0.001996 0.0213908 1.0104451 
B4GALT1 -3.09879 0.001996 0.0213908 1.0067053 C18orf56 -3.1497502 0.001996 0.0213908 1.0068118 
STAT5B -3.0996771 0.001996 0.0213908 1.0037145 PAH -3.1506536 0.001996 0.0213908 1.0119685 
LRIG1 -3.1002411 0.001996 0.0213908 1.0061958 EPC1 -3.1522932 0.001996 0.0213908 1.004228 
CSTF2T -3.1007064 0.001996 0.0213908 1.0048882 NIPA1 -3.1533923 0.001996 0.0213908 1.0206771 
LPXN -3.1023567 0.001996 0.0213908 1.0272264 PLIN2 -3.1550249 0.001996 0.0213908 1.0076055 
NPM3 -3.1026734 0.001996 0.0213908 1.0123678 REST -3.1566872 0.001996 0.0213908 1.0061295 
SMA5 -3.1033453 0.001996 0.0213908 1.0054074 CEP41 -3.1569384 0.001996 0.0213908 1.0053255 
SLC5A9 -3.1055295 0.001996 0.0213908 1.0351958 GXYLT2 -3.1588468 0.001996 0.0213908 1.0122503 
CETN3 -3.1073088 0.001996 0.0213908 1.0165832 C8orf44 -3.15896 0.001996 0.0213908 1.0222096 
EPB42 -3.1081889 0.001996 0.0213908 1.0174556 SERPINE2 -3.1590743 0.001996 0.0213908 1.026012 
BAI1 -3.1084275 0.001996 0.0213908 1.005135 RAB43 -3.160237 0.001996 0.0213908 1.0065512 
APTX -3.1111776 0.001996 0.0213908 1.0012798 KLF11 -3.1617389 0.001996 0.0213908 1.0184969 
ANKRA2 -3.1125184 0.001996 0.0213908 1.0207129 ARL6IP1 -3.1637039 0.001996 0.0213908 1.0037589 
BIN2P1 -3.1153264 0.001996 0.0213908 1.019097 KIF20A -3.1664216 0.001996 0.0213908 1.0039574 
HIC2 -3.1168952 0.001996 0.0213908 1.0064114 CUL9 -3.1664819 0.001996 0.0213908 1.0093638 
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SPATA7 -3.1667102 0.001996 0.0213908 1.0129955 ARMC9 -3.2216305 0.001996 0.0213908 1.0065887 
PRDM1 -3.1702813 0.001996 0.0213908 1.0527297 RN5S504 -3.2291 0.001996 0.0213908 1.0344208 
XYLB -3.1704737 0.001996 0.0213908 1.0073867 CENPC1 -3.2298121 0.001996 0.0213908 1.0063006 
PRKCH -3.1711361 0.001996 0.0213908 1.0081907 ZNF75D -3.235701 0.001996 0.0213908 1.005434 
NUDT15 -3.1717951 0.001996 0.0213908 1.0149169 EGLN1 -3.2358968 0.001996 0.0213908 1.0078781 
RAB18 -3.1736116 0.001996 0.0213908 1.0115526 C1orf126 -3.2360597 0.001996 0.0213908 1.0334151 
OR8G3P -3.1749306 0.001996 0.0213908 1.0222257 ADHFE1 -3.236599 0.001996 0.0213908 1.0437104 
MAP3K1 -3.1764119 0.001996 0.0213908 1.0141771 EPB41L3 -3.2367952 0.001996 0.0213908 1.0183884 
NEK7 -3.1776408 0.001996 0.0213908 1.0092114 MS4A13 -3.2372413 0.001996 0.0213908 1.0153929 
SULT1C4 -3.1776409 0.001996 0.0213908 1.0210033 HECTD3 -3.2385693 0.001996 0.0213908 1.0069338 
ZNF692 -3.1815822 0.001996 0.0213908 1.0065517 HSD17B4 -3.2438064 0.001996 0.0213908 1.0075297 
ZFYVE27 -3.1829507 0.001996 0.0213908 1.0034773 CYB5R1 -3.2457291 0.001996 0.0213908 1.0051611 
FBXO4 -3.1831965 0.001996 0.0213908 1.0276872 C1orf192 -3.2494098 0.001996 0.0213908 1.0215175 
FITM2 -3.1836336 0.001996 0.0213908 1.0060158 SLA -3.2505097 0.001996 0.0213908 1.0084758 
LPCAT4 -3.1849435 0.001996 0.0213908 1.0064157 BMS1P5 -3.250716 0.001996 0.0213908 1.0076194 
S100A11 -3.18607 0.001996 0.0213908 1.0116296 VARS2 -3.2533419 0.001996 0.0213908 1.0051501 
XK -3.1861212 0.001996 0.0213908 1.0168246 UNC93A -3.2556246 0.001996 0.0213908 1.0200482 
YPEL1 -3.1863151 0.001996 0.0213908 1.0207503 SCP2 -3.2557124 0.001996 0.0213908 1.0138908 
TRAF3IP2 -3.1876395 0.001996 0.0213908 1.0093658 FOXK1 -3.2589555 0.001996 0.0213908 1.0078199 
GSTM4 -3.188083 0.001996 0.0213908 1.0109176 LRFN5 -3.2593678 0.001996 0.0213908 1.0231462 
MTHFR -3.1904683 0.001996 0.0213908 1.0127084 RWDD3 -3.2596603 0.001996 0.0213908 1.0142571 
ANKRD31 -3.1918657 0.001996 0.0213908 1.0233083 ELAC1 -3.2600889 0.001996 0.0213908 1.0193061 
LMNB1 -3.1920022 0.001996 0.0213908 1.007957 C8orf40 -3.2603623 0.001996 0.0213908 1.0098898 
PSKH2 -3.1928977 0.001996 0.0213908 1.0280119 HDHD2 -3.262779 0.001996 0.0213908 1.0060423 
APOBEC3C -3.1932738 0.001996 0.0213908 1.0088964 GUCA1A -3.2633312 0.001996 0.0213908 1.0025728 
EAPP -3.1946781 0.001996 0.0213908 1.0074694 C2orf68 -3.2643099 0.001996 0.0213908 1.0038507 
FAM173B -3.1954489 0.001996 0.0213908 1.0180108 PDCD4 -3.2673532 0.001996 0.0213908 1.0233876 
EIF2C4 -3.1970375 0.001996 0.0213908 1.0092374 GTF2H5 -3.2678754 0.001996 0.0213908 1.0070042 
COX6A1 -3.1971708 0.001996 0.0213908 1.0024321 NNT -3.2681803 0.001996 0.0213908 1.0069121 
CSMD1 -3.1984772 0.001996 0.0213908 1.0450455 FNDC3A -3.2688441 0.001996 0.0213908 1.0060032 
HTR1D -3.1985647 0.001996 0.0213908 1.0174246 AKAP13 -3.2699034 0.001996 0.0213908 1.0051399 
ZNF652 -3.2001143 0.001996 0.0213908 1.0029238 AF118077 -3.2718519 0.001996 0.0213908 1.0219611 
INTU -3.2003915 0.001996 0.0213908 1.0090294 AKAP10 -3.2756084 0.001996 0.0213908 1.0062669 
PCDHB13 -3.2038317 0.001996 0.0213908 1.0161432 FAM120B -3.2790042 0.001996 0.0213908 1.0080894 
LNX1 -3.2047995 0.001996 0.0213908 1.0100235 RN7SKP10 -3.2794121 0.001996 0.0213908 1.0094417 
MYO15B -3.2048028 0.001996 0.0213908 1.0142839 CD82 -3.2823474 0.001996 0.0213908 1.0106813 
RAB30 -3.2051267 0.001996 0.0213908 1.0105208 OAS2 -3.2823715 0.001996 0.0213908 1.0094045 
OR14A16 -3.2057081 0.001996 0.0213908 1.0446337 DDX59 -3.2842066 0.001996 0.0213908 1.0105633 
UBP1 -3.2058957 0.001996 0.0213908 1.003226 C4orf34 -3.2849274 0.001996 0.0213908 1.0141296 
FOXB2 -3.206654 0.001996 0.0213908 1.0090307 LLGL1 -3.2852503 0.001996 0.0213908 1.0039272 
TNFRSF1A -3.207058 0.001996 0.0213908 1.0052654 ARNT -3.2853249 0.001996 0.0213908 1.006728 
SLC16A3 -3.2079655 0.001996 0.0213908 1.0113457 RLIM -3.2857143 0.001996 0.0213908 1.0016339 
PER2 -3.2081743 0.001996 0.0213908 1.0056302 VEZT -3.2873657 0.001996 0.0213908 1.0067698 
SUPT4H1 -3.2086259 0.001996 0.0213908 1.002733 NUMA1 -3.2880635 0.001996 0.0213908 1.0046565 
KCTD2 -3.2097152 0.001996 0.0213908 1.0026745 SLC22A23 -3.289769 0.001996 0.0213908 1.0099793 
MANEAL -3.2100657 0.001996 0.0213908 1.0057915 DHRS7 -3.2905647 0.001996 0.0213908 1.0109341 
FAM19A2 -3.2164819 0.001996 0.0213908 1.028548 PHF8 -3.2931429 0.001996 0.0213908 1.0074616 
TRMT112 -3.2168174 0.001996 0.0213908 1.001705 TACC1 -3.2961746 0.001996 0.0213908 1.0059356 
SLC35E2 -3.2171002 0.001996 0.0213908 1.0030484 PXMP4 -3.2974328 0.001996 0.0213908 1.0128421 
SCUBE3 -3.2173332 0.001996 0.0213908 1.0220849 CNGA2 -3.2979179 0.001996 0.0213908 1.0142121 
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TMC6 -3.2983663 0.001996 0.0213908 1.006839 THTPA -3.3643112 0.001996 0.0213908 1.0087257 
RRNAD1 -3.2996708 0.001996 0.0213908 1.0091424 TSPAN12 -3.3643668 0.001996 0.0213908 1.016302 
SLC26A2 -3.3000509 0.001996 0.0213908 1.0123248 UBN2 -3.3674256 0.001996 0.0213908 1.0070703 
PRKAR2A -3.300548 0.001996 0.0213908 1.00192 ESPL1 -3.3675127 0.001996 0.0213908 1.0056956 
LMO7 -3.3009529 0.001996 0.0213908 1.0254785 SLC47A1 -3.3693059 0.001996 0.0213908 1.0443924 
STOX1 -3.3024618 0.001996 0.0213908 1.0168073 ERVH-4 -3.3699544 0.001996 0.0213908 1.0318449 
MMRN1 -3.3034627 0.001996 0.0213908 1.0309247 TMED10 -3.3706594 0.001996 0.0213908 1.0009602 
TMEM51 -3.303464 0.001996 0.0213908 1.0100269 KBTBD3 -3.3710139 0.001996 0.0213908 1.0292835 
ZFP64 -3.303978 0.001996 0.0213908 1.0059439 PPIL6 -3.3720528 0.001996 0.0213908 1.0307025 
ZNF679 -3.3047543 0.001996 0.0213908 1.0080174 MCOLN3 -3.3735346 0.001996 0.0213908 1.0322241 
S100Z -3.3051137 0.001996 0.0213908 1.0259826 ITGA5 -3.3738381 0.001996 0.0213908 1.0135648 
JAKMIP1 -3.306888 0.001996 0.0213908 1.0145722 PRSS1 -3.3739321 0.001996 0.0213908 1.0383418 
EFEMP1 -3.3083396 0.001996 0.0213908 1.0121802 C17orf57 -3.3770673 0.001996 0.0213908 1.0215438 
WNT3 -3.309911 0.001996 0.0213908 1.0437062 TTC12 -3.3812794 0.001996 0.0213908 1.0088533 
PRPF39 -3.3105434 0.001996 0.0213908 1.0087142 PTK2B -3.3815692 0.001996 0.0213908 1.0081248 
ZNF821 -3.3119951 0.001996 0.0213908 1.0130253 C2orf57 -3.384213 0.001996 0.0213908 1.0065825 
GNA14 -3.3137822 0.001996 0.0213908 1.0284905 GSTZ1 -3.384389 0.001996 0.0213908 1.0111799 
SAT1 -3.3138798 0.001996 0.0213908 1.0161245 RDM1 -3.3867416 0.001996 0.0213908 1.0145312 
FAM218A -3.3142603 0.001996 0.0213908 1.0060515 TRAPPC9 -3.3871999 0.001996 0.0213908 1.009603 
BDKRB1 -3.3176182 0.001996 0.0213908 1.0616044 NRM -3.3874448 0.001996 0.0213908 1.0056491 
ATP5J2P3 -3.3181664 0.001996 0.0213908 1.0229613 STARD13 -3.3883627 0.001996 0.0213908 1.0078829 
EWSR1 -3.319155 0.001996 0.0213908 1.00314 FAM126B -3.3887112 0.001996 0.0213908 1.0060978 
SLC12A6 -3.3197995 0.001996 0.0213908 1.009528 SZT2 -3.3906164 0.001996 0.0213908 1.0056282 
HGSNAT -3.3209753 0.001996 0.0213908 1.0214506 GPR37 -3.391974 0.001996 0.0213908 1.02855 
C12orf55 -3.3215725 0.001996 0.0213908 1.0223279 CYP26A1 -3.3929346 0.001996 0.0213908 1.099315 
RASGEF1B -3.3218969 0.001996 0.0213908 1.029881 NBPF15 -3.3933352 0.001996 0.0213908 1.0012679 
GIN1 -3.323031 0.001996 0.0213908 1.0155689 ADAMTS9 -3.3965119 0.001996 0.0213908 1.0309561 
GRAMD1A -3.3233068 0.001996 0.0213908 1.0044104 CTBS -3.3975853 0.001996 0.0213908 1.0285733 
SLCO2A1 -3.3236716 0.001996 0.0213908 1.0416111 C6orf89 -3.3975854 0.001996 0.0213908 1.0124358 
CHD9 -3.3240472 0.001996 0.0213908 1.0037784 SOAT1 -3.3977016 0.001996 0.0213908 1.0346861 
FAM54B -3.3277188 0.001996 0.0213908 1.004275 DRAM2 -3.3979569 0.001996 0.0213908 1.0081485 
C5orf24 -3.3313526 0.001996 0.0213908 1.0061665 HMGB2 -3.3989891 0.001996 0.0213908 1.006829 
LOC554206 -3.3314159 0.001996 0.0213908 1.0051331 MAN2B1 -3.4000077 0.001996 0.0213908 1.0074866 
DNAJB4 -3.3322387 0.001996 0.0213908 1.00694 RET -3.4000832 0.001996 0.0213908 1.0229474 
SP140L -3.3331086 0.001996 0.0213908 1.0078571 PRPF8 -3.4031105 0.001996 0.0213908 1.0019789 
EPSTI1 -3.3348298 0.001996 0.0213908 1.0354306 ANTXR2 -3.4081011 0.001996 0.0213908 1.0205912 
PJA2 -3.3351654 0.001996 0.0213908 1.0049693 CD9 -3.408212 0.001996 0.0213908 1.0067344 
C1orf168 -3.336721 0.001996 0.0213908 1.0392931 PCDHB9 -3.4109151 0.001996 0.0213908 1.0182276 
IVNS1ABP -3.3385626 0.001996 0.0213908 1.0099416 CCDC159 -3.4144684 0.001996 0.0213908 1.0229798 
CHEK2 -3.3400049 0.001996 0.0213908 1.0130756 EFNB1 -3.4165648 0.001996 0.0213908 1.0161486 
ARHGAP40 -3.3403562 0.001996 0.0213908 1.051158 MYF6 -3.4170618 0.001996 0.0213908 1.0192603 
LEF1 -3.3416048 0.001996 0.0213908 1.0527489 SLC30A1 -3.419178 0.001996 0.0213908 1.0080125 
GPX2 -3.3514018 0.001996 0.0213908 1.0278508 FAM208A -3.4204346 0.001996 0.0213908 1.0151934 
MAPK7 -3.3530387 0.001996 0.0213908 1.0050153 LIG4 -3.421977 0.001996 0.0213908 1.0060106 
SLC39A8 -3.3556927 0.001996 0.0213908 1.0180867 PTPRB -3.4223849 0.001996 0.0213908 1.0120689 
IGHMBP2 -3.3569291 0.001996 0.0213908 1.0051353 NCKAP1 -3.4247813 0.001996 0.0213908 1.0047325 
TOM1L2 -3.3580663 0.001996 0.0213908 1.0088514 EPHB3 -3.4259746 0.001996 0.0213908 1.0282459 
MYO7A -3.3583471 0.001996 0.0213908 1.0101284 ST14 -3.4272798 0.001996 0.0213908 1.0047619 
CUL7 -3.3593805 0.001996 0.0213908 1.0079362 CYP2R1 -3.427912 0.001996 0.0213908 1.0103852 
PRTG -3.3608143 0.001996 0.0213908 1.053438 NIPAL2 -3.42854 0.001996 0.0213908 1.0098553 
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STX17 -3.4320238 0.001996 0.0213908 1.0116728 DAB1 -3.5046938 0.001996 0.0213908 1.0122632 
FUT8 -3.4332393 0.001996 0.0213908 1.0189531 TTC39B -3.5080469 0.001996 0.0213908 1.0346441 
JHDM1D -3.433332 0.001996 0.0213908 1.0184459 RBM47 -3.5084746 0.001996 0.0213908 1.0059998 
LOC81691 -3.436161 0.001996 0.0213908 1.009877 WLS -3.5093585 0.001996 0.0213908 1.0439572 
SAYSD1 -3.4364252 0.001996 0.0213908 1.0061139 C6orf72 -3.5105504 0.001996 0.0213908 1.0027272 
TINF2 -3.4382591 0.001996 0.0213908 1.0101684 DSEL -3.5106913 0.001996 0.0213908 1.0254749 
VAMP5 -3.4388686 0.001996 0.0213908 1.0056878 ZBTB10 -3.5117 0.001996 0.0213908 1.0087346 
FAM47E-
STBD1 -3.4405535 0.001996 0.0213908 1.0276524 CYHR1 -3.5125762 0.001996 0.0213908 1.0062466 
INF2 -3.4413192 0.001996 0.0213908 1.0052006 CCKBR -3.5128711 0.001996 0.0213908 1.0228656 
HSD11B1L -3.4436989 0.001996 0.0213908 1.0073807 CDC14B -3.51384 0.001996 0.0213908 1.0094194 
NME5 -3.4452345 0.001996 0.0213908 1.0331207 H2AFY -3.5142356 0.001996 0.0213908 1.0080209 
MLL5 -3.4482785 0.001996 0.0213908 1.0065884 SNX17 -3.5149794 0.001996 0.0213908 1.0059082 
TMEM80 -3.4497376 0.001996 0.0213908 1.0086381 SPATA20 -3.5150637 0.001996 0.0213908 1.0131558 
RPS9 -3.4498131 0.001996 0.0213908 1.0035826 CLIP2 -3.516365 0.001996 0.0213908 1.0042276 
DENND4A -3.4502052 0.001996 0.0213908 1.0132327 GOLGA8A -3.5168567 0.001996 0.0213908 1.0126643 
RNF187 -3.4508186 0.001996 0.0213908 1.0062522 CAPN2 -3.5175619 0.001996 0.0213908 1.0124461 
HSBP1 -3.451573 0.001996 0.0213908 1.0060587 KIAA0146 -3.5192788 0.001996 0.0213908 1.0021841 
PPP4R1L -3.4521662 0.001996 0.0213908 1.0131382 CCNDBP1 -3.5242069 0.001996 0.0213908 1.0145965 
NDRG3 -3.4530424 0.001996 0.0213908 1.0078724 ARL6IP6 -3.5249227 0.001996 0.0213908 1.0013867 
ODZ4 -3.4537373 0.001996 0.0213908 1.0341937 FGF17 -3.5266407 0.001996 0.0213908 1.0334074 
MON2 -3.454692 0.001996 0.0213908 1.0041666 TPT1-AS1 -3.5297642 0.001996 0.0213908 1.0057221 
LAMB1 -3.4553389 0.001996 0.0213908 1.0101904 GSS -3.531607 0.001996 0.0213908 1.0073241 
EML3 -3.4567052 0.001996 0.0213908 1.0074938 AP4B1 -3.5326122 0.001996 0.0213908 1.004934 
CUX1 -3.459115 0.001996 0.0213908 1.007378 WNT5B -3.536455 0.001996 0.0213908 1.0069757 
SERPINA1 -3.4600795 0.001996 0.0213908 1.0166951 C1GALT1C1 -3.5371982 0.001996 0.0213908 1.0145394 
VPS29 -3.4618326 0.001996 0.0213908 1.0050493 LETMD1 -3.5400477 0.001996 0.0213908 1.006717 
PAN2 -3.4618712 0.001996 0.0213908 1.017042 FUZ -3.5405137 0.001996 0.0213908 1.0051694 
KIAA1549 -3.464444 0.001996 0.0213908 1.0054821 PCED1B -3.5405164 0.001996 0.0213908 1.0197074 
FAM169B -3.4645234 0.001996 0.0213908 1.0111499 C9orf135 -3.5425708 0.001996 0.0213908 1.0142174 
ZNF701 -3.4648227 0.001996 0.0213908 1.0195576 SCYL3 -3.5429902 0.001996 0.0213908 1.0157234 
WDR5B -3.4698535 0.001996 0.0213908 1.0186145 HMG20A -3.5430581 0.001996 0.0213908 1.0055641 
C5orf4 -3.470266 0.001996 0.0213908 1.0282686 ADH1C -3.543306 0.001996 0.0213908 1.0150683 
CBR4 -3.4721796 0.001996 0.0213908 1.0151569 WDR19 -3.54368 0.001996 0.0213908 1.0094517 
ADAMTS19 -3.4748244 0.001996 0.0213908 1.0066361 TMEM14A -3.5446665 0.001996 0.0213908 1.0049307 
GAPDHP22 -3.4776355 0.001996 0.0213908 1.0165414 PLXNA2 -3.5460586 0.001996 0.0213908 1.0415034 
PPIL3 -3.4779393 0.001996 0.0213908 1.0032736 CACNA1F -3.5463312 0.001996 0.0213908 1.0074191 
FAM227A -3.4789296 0.001996 0.0213908 1.00947 HMGCL -3.5480544 0.001996 0.0213908 1.015728 
TCEANC -3.4855335 0.001996 0.0213908 1.0183503 EPM2AIP1 -3.5489216 0.001996 0.0213908 1.0066097 
PRMT8 -3.4881539 0.001996 0.0213908 1.008405 MSI2 -3.5502307 0.001996 0.0213908 1.0078125 
WDR25 -3.488313 0.001996 0.0213908 1.0026035 TMCO6 -3.5502724 0.001996 0.0213908 1.0076147 
FAM63A -3.4892859 0.001996 0.0213908 1.0105742 CARD8 -3.5515616 0.001996 0.0213908 1.0048367 
CD164 -3.4894912 0.001996 0.0213908 1.0040351 CASP8 -3.5515931 0.001996 0.0213908 1.0170939 
HMGN4 -3.4915436 0.001996 0.0213908 1.0041574 GLT1D1 -3.5522131 0.001996 0.0213908 1.0130655 
PIGV -3.4939493 0.001996 0.0213908 1.0155769 COX20 -3.5525189 0.001996 0.0213908 1.0059219 
CLUAP1 -3.4958293 0.001996 0.0213908 1.0193328 BMF -3.5541386 0.001996 0.0213908 1.0054398 
ZNF526 -3.4960085 0.001996 0.0213908 1.00343 OBFC1 -3.556273 0.001996 0.0213908 1.0089021 
SMYD2 -3.4968435 0.001996 0.0213908 1.0196931 BTBD3 -3.5564703 0.001996 0.0213908 1.0039299 
CER1 -3.4977608 0.001996 0.0213908 1.0671656 EFNB2 -3.5579419 0.001996 0.0213908 1.0257286 
GREB1L -3.4980406 0.001996 0.0213908 1.0830315 FLJ31958 -3.5600073 0.001996 0.0213908 1.0172117 
NAPB -3.5000963 0.001996 0.0213908 1.0068422 PBX3 -3.561133 0.001996 0.0213908 1.0041117 
 
207 
 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
FAM174B -3.5630108 0.001996 0.0213908 1.0077694 ZNF266 -3.6514642 0.001996 0.0213908 1.0081925 
BBS5 -3.5665669 0.001996 0.0213908 1.028075 GNS -3.6516967 0.001996 0.0213908 1.0054545 
CORO2A -3.5685825 0.001996 0.0213908 1.0126804 ZNF83 -3.6534669 0.001996 0.0213908 1.0134731 
FAM40B -3.5725459 0.001996 0.0213908 1.010779 RXFP2 -3.6536238 0.001996 0.0213908 1.0131402 
H2AFY2 -3.5763688 0.001996 0.0213908 1.0161316 NTPCR -3.6564916 0.001996 0.0213908 1.0046338 
TMEM27 -3.5808719 0.001996 0.0213908 1.0389853 AP2M1 -3.6573847 0.001996 0.0213908 1.0030771 
FSHR -3.5831269 0.001996 0.0213908 1.0312597 KCNH8 -3.6580781 0.001996 0.0213908 1.0168729 
TOR3A -3.5834402 0.001996 0.0213908 1.0091833 MPP2 -3.6590372 0.001996 0.0213908 1.0109143 
RNF170 -3.5860529 0.001996 0.0213908 1.016164 SULF1 -3.6613678 0.001996 0.0213908 1.0204168 
DDAH2 -3.5889463 0.001996 0.0213908 1.0053749 JRKL -3.6628382 0.001996 0.0213908 1.0234779 
KIF13B -3.5929555 0.001996 0.0213908 1.0099804 MCF2L -3.6637114 0.001996 0.0213908 1.0045812 
FLJ20464 -3.5932889 0.001996 0.0213908 1.0177033 GPR108 -3.6640178 0.001996 0.0213908 1.0069846 
CMC1 -3.5953044 0.001996 0.0213908 1.014432 CPA2 -3.6644885 0.001996 0.0213908 1.0127785 
TAS2R4 -3.5992193 0.001996 0.0213908 1.0053828 IRAK4 -3.6702107 0.001996 0.0213908 1.0107287 
RPS6KA4 -3.6019081 0.001996 0.0213908 1.0033826 NUF2 -3.6711908 0.001996 0.0213908 1.0149679 
EPB49 -3.6021114 0.001996 0.0213908 1.0121031 FAM149B1 -3.6722917 0.001996 0.0213908 1.0083628 
TXNRD3 -3.6034669 0.001996 0.0213908 1.013879 CCDC97 -3.6813205 0.001996 0.0213908 1.0048807 
CD3D -3.6043862 0.001996 0.0213908 1.011259 SMAD1 -3.6817633 0.001996 0.0213908 1.0033864 
ARRDC4 -3.6051417 0.001996 0.0213908 1.0325387 ZNF781 -3.682609 0.001996 0.0213908 1.0491767 
COQ6 -3.6074984 0.001996 0.0213908 1.0058211 TBC1D8 -3.6841902 0.001996 0.0213908 1.0082548 
ZNF302 -3.6085054 0.001996 0.0213908 1.0114556 KLHL14 -3.6848773 0.001996 0.0213908 1.0223273 
PARP11 -3.6092454 0.001996 0.0213908 1.0131456 TSPAN18 -3.6865137 0.001996 0.0213908 1.0069857 
GLYATL1 -3.6093386 0.001996 0.0213908 1.0200416 ACOT11 -3.6912764 0.001996 0.0213908 1.0058386 
COG7 -3.6123279 0.001996 0.0213908 1.0035146 NPRL2 -3.6931924 0.001996 0.0213908 1.0039038 
DKK1 -3.6144198 0.001996 0.0213908 1.117376 TBX22 -3.6954663 0.001996 0.0213908 1.0603389 
CDK5RAP3 -3.6191008 0.001996 0.0213908 1.0131049 GEMIN8 -3.6967136 0.001996 0.0213908 1.0182168 
C9orf100 -3.6198041 0.001996 0.0213908 1.009707 RNF146 -3.6981389 0.001996 0.0213908 1.0081627 
MARCH8 -3.6202414 0.001996 0.0213908 1.0098048 CHMP1B -3.6984895 0.001996 0.0213908 1.0066936 
LAMTOR2 -3.6216267 0.001996 0.0213908 1.0084197 AKR1E2 -3.7005817 0.001996 0.0213908 1.0186384 
TMEM154 -3.6223914 0.001996 0.0213908 1.0295177 AASDH -3.701064 0.001996 0.0213908 1.0123603 
TAF15 -3.6241078 0.001996 0.0213908 1.0027766 TDP1 -3.7013037 0.001996 0.0213908 1.0040399 
PPM1K -3.62448 0.001996 0.0213908 1.0108786 BABAM1 -3.7087144 0.001996 0.0213908 1.0025385 
CDH26 -3.626739 0.001996 0.0213908 1.0142837 C12orf76 -3.7155201 0.001996 0.0213908 1.007975 
RN5S198 -3.6271448 0.001996 0.0213908 1.0753471 CTSO -3.7163529 0.001996 0.0213908 1.0396996 
PLEKHH2 -3.6330678 0.001996 0.0213908 1.0154253 SNAP91 -3.7203997 0.001996 0.0213908 1.0166659 
YAF2 -3.6343532 0.001996 0.0213908 1.0293302 ZNF362 -3.7216426 0.001996 0.0213908 1.0050662 
GPR128 -3.6353931 0.001996 0.0213908 1.0315477 IFITM1 -3.7221018 0.001996 0.0213908 1.0083864 
ST8SIA4 -3.6362368 0.001996 0.0213908 1.0807968 GABARAP -3.7222254 0.001996 0.0213908 1.0030474 
SLC31A1 -3.6391267 0.001996 0.0213908 1.0013187 ZNF397 -3.722303 0.001996 0.0213908 1.0108809 
P2RY1 -3.6396251 0.001996 0.0213908 1.0287583 TGFB1 -3.7246451 0.001996 0.0213908 1.0325713 
EIF2D -3.641228 0.001996 0.0213908 1.0063056 C6orf70 -3.7274885 0.001996 0.0213908 1.0300914 
DKK4 -3.6424639 0.001996 0.0213908 1.1402494 MFAP4 -3.727642 0.001996 0.0213908 1.0675755 
LAPTM4B -3.6436728 0.001996 0.0213908 1.0030074 GYS1 -3.7283372 0.001996 0.0213908 1.0066134 
SLC35G3 -3.6450082 0.001996 0.0213908 1.0250785 POLD4 -3.7288354 0.001996 0.0213908 1.0092837 
C6orf130 -3.6453225 0.001996 0.0213908 1.0099752 PDE5A -3.7296228 0.001996 0.0213908 1.017088 
OSGEPL1 -3.6453519 0.001996 0.0213908 1.0140529 ZBTB25 -3.7383274 0.001996 0.0213908 1.0080071 
PPFIBP2 -3.6471754 0.001996 0.0213908 1.0197017 AMELY -3.7393839 0.001996 0.0213908 1.0162733 
IFT122 -3.647177 0.001996 0.0213908 1.0051325 IPCEF1 -3.7396787 0.001996 0.0213908 1.0209014 
KIFAP3 -3.6503234 0.001996 0.0213908 1.0178647 SYNRG -3.7413363 0.001996 0.0213908 1.0042159 
SH3BP1 -3.6505449 0.001996 0.0213908 1.003076 KIAA1244 -3.744904 0.001996 0.0213908 1.0052774 
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TCHP -3.7467614 0.001996 0.0213908 1.012025 VANGL2 -3.828137 0.001996 0.0213908 1.0026303 
PLCL1 -3.7469805 0.001996 0.0213908 1.0110224 TCEAL4 -3.8354354 0.001996 0.0213908 1.013034 
DUSP18 -3.7483447 0.001996 0.0213908 1.0149989 ADCK4 -3.8419324 0.001996 0.0213908 1.0058342 
DMXL2 -3.7504189 0.001996 0.0213908 1.0158793 RNF213 -3.8477847 0.001996 0.0213908 1.006892 
CD200 -3.7539584 0.001996 0.0213908 1.0060795 FIBP -3.8478829 0.001996 0.0213908 1.0033703 
LRTM2 -3.7554167 0.001996 0.0213908 1.0040184 SAMD3 -3.8482021 0.001996 0.0213908 1.0848147 
ANKRD6 -3.7568204 0.001996 0.0213908 1.0118838 RGL3 -3.8490334 0.001996 0.0213908 1.0114881 
HDDC3 -3.7572219 0.001996 0.0213908 1.0081655 DHRS1 -3.8492023 0.001996 0.0213908 1.0108351 
SHISA2 -3.7602361 0.001996 0.0213908 1.0382879 RGP1 -3.8510349 0.001996 0.0213908 1.00421 
NFYA -3.7607691 0.001996 0.0213908 1.0052176 AMPD3 -3.852034 0.001996 0.0213908 1.0064018 
MAN2A2 -3.7620979 0.001996 0.0213908 1.0170061 CHIC2 -3.8543769 0.001996 0.0213908 1.0081031 
UACA -3.7649786 0.001996 0.0213908 1.0126765 VWF -3.8583429 0.001996 0.0213908 1.0380063 
GATA6 -3.7655198 0.001996 0.0213908 1.0357236 SLC35F1 -3.8591883 0.001996 0.0213908 1.0105496 
ZIC1 -3.7675192 0.001996 0.0213908 1.0359554 PLEKHG3 -3.8609771 0.001996 0.0213908 1.0061981 
RAPGEF3 -3.7684929 0.001996 0.0213908 1.0173433 ZNF280D -3.8630386 0.001996 0.0213908 1.0116424 
RYR1 -3.7689069 0.001996 0.0213908 1.006022 BIVM -3.8658953 0.001996 0.0213908 1.0153586 
SOX17 -3.7730084 0.001996 0.0213908 1.0248636 GTSE1 -3.8678315 0.001996 0.0213908 1.0069342 
PSD4 -3.7751967 0.001996 0.0213908 1.0241871 ARAP3 -3.8704644 0.001996 0.0213908 1.0039851 
NCAM1 -3.7764613 0.001996 0.0213908 1.0131579 CDH12 -3.8739153 0.001996 0.0213908 1.0381318 
HEATR5B -3.7778315 0.001996 0.0213908 1.0071029 ZFYVE1 -3.8761386 0.001996 0.0213908 1.0059303 
BBS12 -3.7795579 0.001996 0.0213908 1.0116658 PTP4A3 -3.8766743 0.001996 0.0213908 1.0108482 
TTC30B -3.7819172 0.001996 0.0213908 1.0347673 FLOT1 -3.8830945 0.001996 0.0213908 1.0076006 
DSP -3.7845502 0.001996 0.0213908 1.0132054 CAMK2D -3.8844203 0.001996 0.0213908 1.0157038 
GOLGA1 -3.7848833 0.001996 0.0213908 1.0104361 ABHD12B -3.8886528 0.001996 0.0213908 1.0579268 
OAT -3.7862969 0.001996 0.0213908 1.0052739 RPP25 -3.8904769 0.001996 0.0213908 1.0048909 
FLRT3 -3.7878811 0.001996 0.0213908 1.0638391 LIN28B -3.8926448 0.001996 0.0213908 1.0029361 
STAT6 -3.7910116 0.001996 0.0213908 1.0126162 FOXRED1 -3.899359 0.001996 0.0213908 1.003062 
FANCF -3.7983556 0.001996 0.0213908 1.0127243 ALDH3A2 -3.8999487 0.001996 0.0213908 1.0130852 
C3orf75 -3.7991276 0.001996 0.0213908 1.0112326 GSTT2 -3.9001452 0.001996 0.0213908 1.0210277 
GRK5 -3.7995309 0.001996 0.0213908 1.0144377 BTN2A3P -3.9004349 0.001996 0.0213908 1.0108685 
FER1L5 -3.8008021 0.001996 0.0213908 1.0080788 AF090940 -3.9011068 0.001996 0.0213908 1.0173539 
MYL6B -3.8008924 0.001996 0.0213908 1.0032176 DDTL -3.901626 0.001996 0.0213908 1.0045583 
CRAT -3.8030638 0.001996 0.0213908 1.0107487 CHRNA3 -3.9032305 0.001996 0.0213908 1.0092981 
TCF12 -3.8058689 0.001996 0.0213908 1.0018644 THNSL2 -3.9045931 0.001996 0.0213908 1.0209475 
NMRK1 -3.805998 0.001996 0.0213908 1.0335893 ZNF518B -3.9048326 0.001996 0.0213908 1.0137359 
VENTX -3.8061339 0.001996 0.0213908 1.0124803 HAO2 -3.9084893 0.001996 0.0213908 1.0167264 
SLC27A3 -3.8067929 0.001996 0.0213908 1.0110517 OR5T1 -3.9088454 0.001996 0.0213908 1.0167345 
RBM5 -3.80733 0.001996 0.0213908 1.0135066 RHOH -3.9105472 0.001996 0.0213908 1.0417874 
SCNN1A -3.8075711 0.001996 0.0213908 1.0046135 FSCB -3.9116076 0.001996 0.0213908 1.020745 
FAM214A -3.8081791 0.001996 0.0213908 1.0223398 PBX1 -3.9139873 0.001996 0.0213908 1.0049962 
FAM160B2 -3.8089611 0.001996 0.0213908 1.0161519 SEPT7L -3.9140327 0.001996 0.0213908 1.0044566 
MAPK3 -3.8095882 0.001996 0.0213908 1.0029953 ACBD5 -3.9173562 0.001996 0.0213908 1.0099406 
TRAF5 -3.8105225 0.001996 0.0213908 1.0091211 ACTR3BP2 -3.9260773 0.001996 0.0213908 1.0135808 
SERINC3 -3.8147077 0.001996 0.0213908 1.0048102 PIK3CA -3.9300319 0.001996 0.0213908 1.007026 
ELF2 -3.8173073 0.001996 0.0213908 1.0092537 HPS1 -3.9338611 0.001996 0.0213908 1.0064045 
RPUSD3 -3.8173445 0.001996 0.0213908 1.0070738 LOH12CR1 -3.9341358 0.001996 0.0213908 1.010129 
MMP2 -3.81809 0.001996 0.0213908 1.0042262 H6PD -3.9355379 0.001996 0.0213908 1.0147523 
MTHFSD -3.8229865 0.001996 0.0213908 1.0138261 ARRB1 -3.9388304 0.001996 0.0213908 1.0351579 
GSTK1 -3.8245487 0.001996 0.0213908 1.0109533 TPCN1 -3.9392111 0.001996 0.0213908 1.0098157 
RN5S229 -3.8253458 0.001996 0.0213908 1.0379438 GLT8D1 -3.9413442 0.001996 0.0213908 1.0020783 
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ZNF76 -4.1275106 0.001996 0.0213908 1.0097682 RAD50 -4.2580521 0.001996 0.0213908 1.0096929 
PLA2G2A -4.1301084 0.001996 0.0213908 1.0319497 CSAD -4.2598227 0.001996 0.0213908 1.0143814 
NECAP1 -4.1345941 0.001996 0.0213908 1.0041567 HSD17B11 -4.2650749 0.001996 0.0213908 1.0057955 
RNF19A -4.1365048 0.001996 0.0213908 1.0261206 F2RL1 -4.2661322 0.001996 0.0213908 1.0116072 
PLEKHA1 -4.1386905 0.001996 0.0213908 1.0067486 PEX11B -4.2667174 0.001996 0.0213908 1.0099989 
YIPF1 -4.1414098 0.001996 0.0213908 1.0058386 PIK3C2B -4.2689912 0.001996 0.0213908 1.0109747 
ARHGEF25 -4.1422086 0.001996 0.0213908 1.0057391 RNASEL -4.2717031 0.001996 0.0213908 1.0258341 
LRFN3 -4.1422661 0.001996 0.0213908 1.0078822 CCDC167 -4.2744557 0.001996 0.0213908 1.0176511 
IL17RD -4.1481659 0.001996 0.0213908 1.0227204 EHHADH -4.2755141 0.001996 0.0213908 1.0271793 
EXOC1 -4.1578603 0.001996 0.0213908 1.0074659 PARP6 -4.2765435 0.001996 0.0213908 1.0112319 
MAST4 -4.1592251 0.001996 0.0213908 1.0054622 MLLT6 -4.2861125 0.001996 0.0213908 1.0171972 
ANKRD36 -4.1614859 0.001996 0.0213908 1.0090916 C4orf3 -4.2903158 0.001996 0.0213908 1.0097699 
FOXA2 -4.1622128 0.001996 0.0213908 1.0648303 CHN2 -4.2922966 0.001996 0.0213908 1.005724 
ADRBK1 -4.1657873 0.001996 0.0213908 1.0082816 PIK3R1 -4.2925496 0.001996 0.0213908 1.0272621 
CTNND1 -4.1696106 0.001996 0.0213908 1.004739 ZCCHC11 -4.2930727 0.001996 0.0213908 1.0066067 
POLR3GL -4.1720143 0.001996 0.0213908 1.0156923 MAGEF1 -4.2964968 0.001996 0.0213908 1.0066206 
TLE3 -4.1720804 0.001996 0.0213908 1.0118599 DERA -4.2995154 0.001996 0.0213908 1.0177412 
GLIPR1L2 -4.1730271 0.001996 0.0213908 1.029033 FBXL14 -4.3039021 0.001996 0.0213908 1.0081089 
ZBTB34 -4.1750669 0.001996 0.0213908 1.0024087 MYO3A -4.3076049 0.001996 0.0213908 1.0139544 
CPEB2 -4.1751991 0.001996 0.0213908 1.0093165 FGF8 -4.3078954 0.001996 0.0213908 1.040251 
C12orf66 -4.1802243 0.001996 0.0213908 1.0172114 RIN2 -4.3142768 0.001996 0.0213908 1.0140724 
KIAA1407 -4.1940433 0.001996 0.0213908 1.0292592 RIMKLB -4.314412 0.001996 0.0213908 1.0063584 
SLC24A6 -4.199591 0.001996 0.0213908 1.0081056 DOPEY1 -4.3148712 0.001996 0.0213908 1.0122388 
DET1 -4.2020361 0.001996 0.0213908 1.016903 ZMIZ1 -4.3159165 0.001996 0.0213908 1.0034606 
DHFRL1 -4.2052614 0.001996 0.0213908 1.010564 MFF -4.319461 0.001996 0.0213908 1.005103 
SLC35A5 -4.2055955 0.001996 0.0213908 1.0095388 ACOT4 -4.3202738 0.001996 0.0213908 1.0150331 
SEPT14 -4.2085983 0.001996 0.0213908 1.0057511 HDAC11 -4.3221026 0.001996 0.0213908 1.0159161 
MKRN1 -4.2110374 0.001996 0.0213908 1.0021029 CYP27A1 -4.3239144 0.001996 0.0213908 1.0197955 
PRPF40B -4.2146668 0.001996 0.0213908 1.0113982 PGK1 -4.3355583 0.001996 0.0213908 1.0011262 
RBKS -4.215676 0.001996 0.0213908 1.0073784 TMEM241 -4.3401554 0.001996 0.0213908 1.0052816 
MMAA -4.2164076 0.001996 0.0213908 1.0277209 NRSN2 -4.3466754 0.001996 0.0213908 1.0076329 
PGPEP1 -4.2190337 0.001996 0.0213908 1.0082453 PAG1 -4.3472298 0.001996 0.0213908 1.027159 
CHD2 -4.2216386 0.001996 0.0213908 1.0029037 XPC -4.3480475 0.001996 0.0213908 1.01028 
ANKRD26 -4.2258761 0.001996 0.0213908 1.0132955 PIGQ -4.3483092 0.001996 0.0213908 1.0098073 
PEX5 -4.2263666 0.001996 0.0213908 1.0044504 NBPF11 -4.3543062 0.001996 0.0213908 1.0033114 
PCDH10 -4.2274743 0.001996 0.0213908 1.0813966 DDX60L -4.3610767 0.001996 0.0213908 1.0312765 
PLEKHG6 -4.2288606 0.001996 0.0213908 1.0077318 MGEA5 -4.3734688 0.001996 0.0213908 1.0042523 
AGAP9 -4.2329822 0.001996 0.0213908 1.0073348 KEL -4.3740865 0.001996 0.0213908 1.0229765 
UFC1 -4.2344182 0.001996 0.0213908 1.0055724 ENPP2 -4.3753976 0.001996 0.0213908 1.0073459 
STK19 -4.236345 0.001996 0.0213908 1.0051712 CYFIP1 -4.3805123 0.001996 0.0213908 1.0042517 
FANCC -4.2419509 0.001996 0.0213908 1.0144036 RNF43 -4.3819038 0.001996 0.0213908 1.0341472 
HP1BP3 -4.242069 0.001996 0.0213908 1.0063379 TTC9 -4.383179 0.001996 0.0213908 1.0029936 
AK3 -4.2425463 0.001996 0.0213908 1.002064 EPHA4 -4.3839431 0.001996 0.0213908 1.0412992 
WASH1 -4.2436681 0.001996 0.0213908 1.0054604 ACOX3 -4.3858699 0.001996 0.0213908 1.010467 
CSTL1 -4.243723 0.001996 0.0213908 1.0417671 SLC43A2 -4.3970521 0.001996 0.0213908 1.0168033 
SVIL -4.2454042 0.001996 0.0213908 1.0174664 COQ2 -4.3977681 0.001996 0.0213908 1.0024483 
TMTC1 -4.2457102 0.001996 0.0213908 1.0133636 ZFPL1 -4.3980012 0.001996 0.0213908 1.0082802 
C14orf101 -4.2469018 0.001996 0.0213908 1.0090815 SLC25A27 -4.4008207 0.001996 0.0213908 1.0231117 
STAT5A -4.2558478 0.001996 0.0213908 1.0185109 RPRM -4.4008393 0.001996 0.0213908 1.0169744 
MXRA5 -4.2558665 0.001996 0.0213908 1.0149159 ZADH2 -4.410524 0.001996 0.0213908 1.0197783 
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CCDC15 -4.410826 0.001996 0.0213908 1.0159557 ZNF611 -4.5420855 0.001996 0.0213908 1.0135181 
PPP1CB -4.4115159 0.001996 0.0213908 1.0031775 TOM1 -4.5472979 0.001996 0.0213908 1.0055809 
HCP5 -4.4127236 0.001996 0.0213908 1.0101988 ADAM8 -4.548146 0.001996 0.0213908 1.0093296 
BTN3A2 -4.4152334 0.001996 0.0213908 1.0380931 TLK2 -4.5491405 0.001996 0.0213908 1.0048973 
ATP12A -4.4236603 0.001996 0.0213908 1.0244473 BANF2 -4.5524944 0.001996 0.0213908 1.0119579 
PDE1B -4.4289423 0.001996 0.0213908 1.0318169 EXOC7 -4.5535491 0.001996 0.0213908 1.0073786 
TPP1 -4.4349352 0.001996 0.0213908 1.0113121 COG4 -4.5556137 0.001996 0.0213908 1.0089371 
PERP -4.4351893 0.001996 0.0213908 1.0114704 APCDD1 -4.5568911 0.001996 0.0213908 1.0528608 
SLC29A4 -4.4353636 0.001996 0.0213908 1.0093976 COQ9 -4.5672914 0.001996 0.0213908 1.0020409 
CDYL2 -4.4364522 0.001996 0.0213908 1.0114691 RAD52 -4.5703486 0.001996 0.0213908 1.011019 
DHPS -4.4395815 0.001996 0.0213908 1.0071615 AB266802 -4.572911 0.001996 0.0213908 1.1868903 
SLC9A8 -4.4431207 0.001996 0.0213908 1.0111979 TAS2R31 -4.5729532 0.001996 0.0213908 1.0200014 
NAV2 -4.4451576 0.001996 0.0213908 1.0052175 MCC -4.5755962 0.001996 0.0213908 1.0260686 
KCNH5 -4.4470893 0.001996 0.0213908 1.0342819 GAL -4.578279 0.001996 0.0213908 1.0331207 
MYSM1 -4.4471005 0.001996 0.0213908 1.0072839 SPG11 -4.5829609 0.001996 0.0213908 1.0124861 
ZNF167 -4.4497159 0.001996 0.0213908 1.0174622 NUDT12 -4.5837822 0.001996 0.0213908 1.015282 
MUM1 -4.4525264 0.001996 0.0213908 1.0122598 ETFB -4.5840825 0.001996 0.0213908 1.0064974 
ARSG -4.454671 0.001996 0.0213908 1.0153621 IFT172 -4.5842867 0.001996 0.0213908 1.0096257 
SLC24A1 -4.4577081 0.001996 0.0213908 1.0150563 ZNF238 -4.5846562 0.001996 0.0213908 1.0082798 
KIAA1161 -4.4602441 0.001996 0.0213908 1.0350728 CTH -4.5866803 0.001996 0.0213908 1.0123518 
AKR1A1 -4.4619172 0.001996 0.0213908 1.0041657 ZSCAN16 -4.5881065 0.001996 0.0213908 1.0062076 
WDR27 -4.4634521 0.001996 0.0213908 1.0165749 MUTYH -4.5900023 0.001996 0.0213908 1.0080144 
CDS2 -4.4641023 0.001996 0.0213908 1.0021218 RHOU -4.5925558 0.001996 0.0213908 1.0382546 
CGGBP1 -4.4646965 0.001996 0.0213908 1.0068901 SAMD15 -4.5937644 0.001996 0.0213908 1.0208425 
TAS2R1 -4.464879 0.001996 0.0213908 1.0167421 CTNNBIP1 -4.5978583 0.001996 0.0213908 1.0023033 
ZNF334 -4.4654058 0.001996 0.0213908 1.0071571 CDH10 -4.5983671 0.001996 0.0213908 1.061313 
WDTC1 -4.4656256 0.001996 0.0213908 1.0155273 TCEANC2 -4.6017699 0.001996 0.0213908 1.0112956 
KDM6B -4.4684643 0.001996 0.0213908 1.0169648 FFAR2 -4.6052002 0.001996 0.0213908 1.0106984 
C3orf58 -4.4806813 0.001996 0.0213908 1.0318436 PCGF5 -4.6068659 0.001996 0.0213908 1.0183912 
GPR39 -4.4807592 0.001996 0.0213908 1.0505816 SLC22A3 -4.6100122 0.001996 0.0213908 1.0491974 
MED7 -4.4809873 0.001996 0.0213908 1.0113547 FN1 -4.613827 0.001996 0.0213908 1.0250147 
ZNF123P -4.4846274 0.001996 0.0213908 1.0095042 ZNF90 -4.6146033 0.001996 0.0213908 1.004447 
VPS28 -4.485019 0.001996 0.0213908 1.0124571 BHLHB9 -4.6170955 0.001996 0.0213908 1.0115701 
PCDHB14 -4.4853072 0.001996 0.0213908 1.018398 ZNF763 -4.619002 0.001996 0.0213908 1.0193611 
SMG6 -4.4855426 0.001996 0.0213908 1.0053881 TCF7 -4.6209417 0.001996 0.0213908 1.0039862 
MOBP -4.4903434 0.001996 0.0213908 1.0463712 ZDHHC21 -4.6234451 0.001996 0.0213908 1.0101055 
GBAP1 -4.4905845 0.001996 0.0213908 1.0326524 TRAPPC3 -4.6255686 0.001996 0.0213908 1.0079916 
KCNE3 -4.4945046 0.001996 0.0213908 1.0220819 MAML3 -4.6263754 0.001996 0.0213908 1.0330292 
AK7 -4.4966565 0.001996 0.0213908 1.0203518 PREX2 -4.6290284 0.001996 0.0213908 1.0112581 
NDUFB5 -4.4990869 0.001996 0.0213908 1.0042705 EPB41L4A -4.6367608 0.001996 0.0213908 1.027459 
COL4A5 -4.50334 0.001996 0.0213908 1.0155673 SEC22C -4.6416223 0.001996 0.0213908 1.0072459 
ZNF236 -4.5042274 0.001996 0.0213908 1.0086376 RIC3 -4.6437483 0.001996 0.0213908 1.0092245 
RNASE6 -4.5102186 0.001996 0.0213908 1.0297413 EML2 -4.6546666 0.001996 0.0213908 1.0134141 
AKAP3 -4.5111888 0.001996 0.0213908 1.0226585 CST2 -4.6626813 0.001996 0.0213908 1.0574353 
C7orf26 -4.5192795 0.001996 0.0213908 1.0035594 AGBL2 -4.6642187 0.001996 0.0213908 1.0135485 
FRZB -4.5236453 0.001996 0.0213908 1.0587343 ADAMTS3 -4.6672425 0.001996 0.0213908 1.0096122 
PPAPDC2 -4.5249515 0.001996 0.0213908 1.0147918 LZTR1 -4.6679547 0.001996 0.0213908 1.0100443 
STK36 -4.5253276 0.001996 0.0213908 1.0104678 TADA2A -4.6692588 0.001996 0.0213908 1.0131856 
PPP1R21 -4.5280386 0.001996 0.0213908 1.0117202 ARSE -4.6694221 0.001996 0.0213908 1.0341354 
PLCD1 -4.5363611 0.001996 0.0213908 1.009698 RFFL -4.6722472 0.001996 0.0213908 1.0057515 
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SPG21 -4.6772564 0.001996 0.0213908 1.0022904 HOOK2 -4.8542256 0.001996 0.0213908 1.0038012 
RMND5B -4.682072 0.001996 0.0213908 1.0105635 HAS2 -4.8562143 0.001996 0.0213908 1.1180481 
QARS -4.6958081 0.001996 0.0213908 1.0035506 PROCA1 -4.86176 0.001996 0.0213908 1.005907 
FLJ39653 -4.6978549 0.001996 0.0213908 1.0095763 EOMES -4.8646707 0.001996 0.0213908 1.1073978 
ZFP30 -4.6988054 0.001996 0.0213908 1.0129918 ADAD1 -4.8697401 0.001996 0.0213908 1.0290666 
CXCR4 -4.7099569 0.001996 0.0213908 1.0517751 LYRM5 -4.8706263 0.001996 0.0213908 1.0172812 
ARL2BP -4.7107309 0.001996 0.0213908 1.0052526 AK097033 -4.8761179 0.001996 0.0213908 1.0207193 
C11orf70 -4.7113681 0.001996 0.0213908 1.0182335 USP40 -4.8761749 0.001996 0.0213908 1.0153922 
SYNJ1 -4.719678 0.001996 0.0213908 1.0206852 PPP1R3E -4.8923137 0.001996 0.0213908 1.012851 
METTL23 -4.7238109 0.001996 0.0213908 1.0099518 LGR5 -4.8969784 0.001996 0.0213908 1.0873193 
FAN1 -4.7243002 0.001996 0.0213908 1.0042726 DUSP19 -4.9053515 0.001996 0.0213908 1.0440184 
COQ5 -4.732583 0.001996 0.0213908 1.0063067 USP53 -4.9073962 0.001996 0.0213908 1.0108065 
MYCBPAP -4.7327471 0.001996 0.0213908 1.0214738 ALDH16A1 -4.9077391 0.001996 0.0213908 1.0042218 
CARD6 -4.7395245 0.001996 0.0213908 1.0340172 ZNF329 -4.9113262 0.001996 0.0213908 1.0084776 
DENND5A -4.7403277 0.001996 0.0213908 1.0062076 KDM1B -4.9139594 0.001996 0.0213908 1.0073021 
SRR -4.7434937 0.001996 0.0213908 1.0105849 TMEM116 -4.9150359 0.001996 0.0213908 1.0142249 
CPNE4 -4.743621 0.001996 0.0213908 1.0106351 FGF20 -4.9201953 0.001996 0.0213908 1.0069283 
B9D1 -4.7485476 0.001996 0.0213908 1.0108993 ZNF514 -4.9283002 0.001996 0.0213908 1.0188606 
THBS2 -4.7605123 0.001996 0.0213908 1.0223397 TSPAN14 -4.9285999 0.001996 0.0213908 1.0086533 
OAS3 -4.7618795 0.001996 0.0213908 1.0096341 IGF2R -4.932157 0.001996 0.0213908 1.0040169 
NIT1 -4.7652354 0.001996 0.0213908 1.0102736 CEACAM1 -4.9493116 0.001996 0.0213908 1.0096549 
NUDT13 -4.7729971 0.001996 0.0213908 1.0286674 C1QTNF6 -4.9643211 0.001996 0.0213908 1.0185442 
AKIP1 -4.7748749 0.001996 0.0213908 1.0093839 ENPP6 -4.9694112 0.001996 0.0213908 1.0182297 
PI4KA -4.7787739 0.001996 0.0213908 1.007004 PIGP -4.9702118 0.001996 0.0213908 1.0210599 
MDM1 -4.7819751 0.001996 0.0213908 1.0185371 HNRPLL -4.9713921 0.001996 0.0213908 1.0060383 
C14orf133 -4.7836994 0.001996 0.0213908 1.0096325 NDST2 -4.9741271 0.001996 0.0213908 1.0057143 
STAP2 -4.7881175 0.001996 0.0213908 1.017974 PCDHB10 -4.9756101 0.001996 0.0213908 1.0254032 
KIAA1383 -4.7889435 0.001996 0.0213908 1.0154163 NPRL3 -4.984006 0.001996 0.0213908 1.0066185 
KIF5B -4.7901227 0.001996 0.0213908 1.0026333 PPL -4.9863059 0.001996 0.0213908 1.0037997 
ARFGAP2 -4.7915214 0.001996 0.0213908 1.0112265 ZNF154 -4.9889304 0.001996 0.0213908 1.015638 
C2orf42 -4.7954687 0.001996 0.0213908 1.0104258 KAL1 -5.0049557 0.001996 0.0213908 1.0107243 
TRIM38 -4.7985559 0.001996 0.0213908 1.0675249 PNLIPRP3 -5.0083317 0.001996 0.0213908 1.0105715 
SERPINB1 -4.8079699 0.001996 0.0213908 1.0183986 ZNF18 -5.0101324 0.001996 0.0213908 1.0119015 
SMPD1 -4.8080799 0.001996 0.0213908 1.0239752 UFL1 -5.0219823 0.001996 0.0213908 1.0174858 
KRT8 -4.812484 0.001996 0.0213908 1.0060244 AGAP8 -5.0341035 0.001996 0.0213908 1.007287 
NEK9 -4.8145222 0.001996 0.0213908 1.0120651 HHLA1 -5.0358568 0.001996 0.0213908 1.0536203 
RANBP10 -4.8170304 0.001996 0.0213908 1.004851 ZFYVE19 -5.0439232 0.001996 0.0213908 1.0093951 
CREBL2 -4.8190746 0.001996 0.0213908 1.0086933 LOC729737 -5.0444232 0.001996 0.0213908 1.0091 
GMPR -4.8237568 0.001996 0.0213908 1.0911464 CDA -5.0461915 0.001996 0.0213908 1.0631876 
ZNF319 -4.8255686 0.001996 0.0213908 1.0111082 SAMD13 -5.0574514 0.001996 0.0213908 1.0295758 
ARHGAP19 -4.8273328 0.001996 0.0213908 1.0062989 RIMBP2 -5.0624247 0.001996 0.0213908 1.0322536 
TMEM62 -4.8277828 0.001996 0.0213908 1.0303286 PPP2R1A -5.0629489 0.001996 0.0213908 1.0027174 
COPS7A -4.8292638 0.001996 0.0213908 1.0088004 TCFL5 -5.0659282 0.001996 0.0213908 1.0035371 
CEP95 -4.8293639 0.001996 0.0213908 1.0073662 SDCCAG8 -5.0660175 0.001996 0.0213908 1.0133023 
C12orf32 -4.8314607 0.001996 0.0213908 1.004152 RFESD -5.0690527 0.001996 0.0213908 1.0425203 
PCDHB15 -4.8330505 0.001996 0.0213908 1.0176964 YTHDC1 -5.0694397 0.001996 0.0213908 1.0084776 
ZC3H6 -4.8370978 0.001996 0.0213908 1.0343041 GPRASP2 -5.0740356 0.001996 0.0213908 1.0133355 
MSTO1 -4.8373797 0.001996 0.0213908 1.0046893 GPCPD1 -5.074161 0.001996 0.0213908 1.0306706 
RBP1 -4.8423284 0.001996 0.0213908 1.0191574 SYT4 -5.0787285 0.001996 0.0213908 1.0143987 
GEMIN8P4 -4.8512124 0.001996 0.0213908 1.0178483 CYP1B1 -5.0860927 0.001996 0.0213908 1.043076 
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TMEM136 -5.0921366 0.001996 0.0213908 1.0110164 ZFHX4 -5.3788923 0.001996 0.0213908 1.0345725 
FPGT -5.0984717 0.001996 0.0213908 1.028887 KLHDC1 -5.3844307 0.001996 0.0213908 1.0380547 
ABHD11 -5.09922 0.001996 0.0213908 1.0118984 FAM160A2 -5.3981968 0.001996 0.0213908 1.0080945 
DRG2 -5.1000453 0.001996 0.0213908 1.0035537 APOBEC3B -5.4042199 0.001996 0.0213908 1.0223258 
GPSM2 -5.1078541 0.001996 0.0213908 1.0146413 REC8 -5.4107682 0.001996 0.0213908 1.0082783 
PEX6 -5.1090655 0.001996 0.0213908 1.0093685 PNPLA4 -5.4171241 0.001996 0.0213908 1.0139772 
MCMDC2 -5.1092302 0.001996 0.0213908 1.0317315 HSD17B8 -5.4174196 0.001996 0.0213908 1.0161502 
FAHD2B -5.1099485 0.001996 0.0213908 1.0056999 ADCY5 -5.4180792 0.001996 0.0213908 1.0121851 
GUSB -5.1180958 0.001996 0.0213908 1.0121485 MID2 -5.4310826 0.001996 0.0213908 1.0217825 
TAF7 -5.1269016 0.001996 0.0213908 1.00697 AHSA2 -5.4399824 0.001996 0.0213908 1.0151004 
TMEM218 -5.1413151 0.001996 0.0213908 1.0196274 NBR1 -5.4407052 0.001996 0.0213908 1.0121747 
TBC1D2 -5.1532316 0.001996 0.0213908 1.0117418 HNRNPH2 -5.444488 0.001996 0.0213908 1.0046656 
CLSTN3 -5.1645324 0.001996 0.0213908 1.0117293 ELMO2 -5.4565653 0.001996 0.0213908 1.0081857 
PTPN6 -5.1679292 0.001996 0.0213908 1.0109596 HS1BP3 -5.4882551 0.001996 0.0213908 1.0042022 
VPS33B -5.1684103 0.001996 0.0213908 1.0104607 SPATA6 -5.4911694 0.001996 0.0213908 1.0125199 
PROX1 -5.1725436 0.001996 0.0213908 1.0395958 H1F0 -5.4952313 0.001996 0.0213908 1.0122601 
EFHC1 -5.174051 0.001996 0.0213908 1.0105422 OPRK1 -5.4999066 0.001996 0.0213908 1.019502 
PARP14 -5.17558 0.001996 0.0213908 1.0105194 SATB2 -5.5016916 0.001996 0.0213908 1.0286901 
MAGI2 -5.1762763 0.001996 0.0213908 1.010886 CAPN1 -5.5102841 0.001996 0.0213908 1.0058476 
MCEE -5.1848197 0.001996 0.0213908 1.0100899 AP1G2 -5.5104565 0.001996 0.0213908 1.0130205 
SENP7 -5.1850107 0.001996 0.0213908 1.0275093 R3HDM2 -5.5115249 0.001996 0.0213908 1.016695 
MKNK1 -5.1918004 0.001996 0.0213908 1.0091249 CPXM1 -5.5127324 0.001996 0.0213908 1.0182301 
FANCG -5.1942241 0.001996 0.0213908 1.0081454 SIAE -5.5218902 0.001996 0.0213908 1.0172075 
RNF135 -5.2135789 0.001996 0.0213908 1.0125179 PGBD4 -5.5267291 0.001996 0.0213908 1.0141141 
TBC1D9B -5.2220827 0.001996 0.0213908 1.0015709 TLR5 -5.5323434 0.001996 0.0213908 1.0103357 
PMF1 -5.2295818 0.001996 0.0213908 1.0009549 SRD5A3 -5.5335277 0.001996 0.0213908 1.0117739 
PIGM -5.233058 0.001996 0.0213908 1.011047 PCDHB1 -5.5359425 0.001996 0.0213908 1.0605676 
CCNI -5.2354383 0.001996 0.0213908 1.0022692 C4orf33 -5.5481222 0.001996 0.0213908 1.0207379 
NS3BP -5.2359986 0.001996 0.0213908 1.0073605 GRM4 -5.5481246 0.001996 0.0213908 1.0311708 
COMMD8 -5.2390438 0.001996 0.0213908 1.0144937 APOBEC3G -5.5547258 0.001996 0.0213908 1.0614988 
CREB3L4 -5.2413853 0.001996 0.0213908 1.0170349 KATNAL1 -5.5611615 0.001996 0.0213908 1.0112428 
BNIP3P1 -5.2451768 0.001996 0.0213908 1.0392967 SUN2 -5.5632299 0.001996 0.0213908 1.0134869 
ITPKB -5.248981 0.001996 0.0213908 1.0229628 ZNF518A -5.5789652 0.001996 0.0213908 1.0114684 
NMRAL1 -5.2492408 0.001996 0.0213908 1.0072554 PPP1R16A -5.58915 0.001996 0.0213908 1.0082481 
CAMK1D -5.257156 0.001996 0.0213908 1.0151285 STRA6 -5.5972477 0.001996 0.0213908 1.015022 
LRRTM1 -5.258899 0.001996 0.0213908 1.025266 CPEB4 -5.6005874 0.001996 0.0213908 1.010418 
FBXW4P1 -5.2633575 0.001996 0.0213908 1.0064698 LPAR6 -5.6036369 0.001996 0.0213908 1.0715982 
C14orf93 -5.2672501 0.001996 0.0213908 1.0073117 ARGLU1 -5.6050067 0.001996 0.0213908 1.0075909 
SERAC1 -5.2818615 0.001996 0.0213908 1.0173053 HERC2P4 -5.6124903 0.001996 0.0213908 1.0080545 
AKD1 -5.2820657 0.001996 0.0213908 1.0085687 C5 -5.6307231 0.001996 0.0213908 1.1057837 
DCAF12 -5.2995159 0.001996 0.0213908 1.0035627 DCTN4 -5.6349525 0.001996 0.0213908 1.0055283 
GRAP -5.302618 0.001996 0.0213908 1.0186508 ARHGAP26 -5.6746948 0.001996 0.0213908 1.0083889 
NBPF12 -5.3140816 0.001996 0.0213908 1.0053077 BTN3A1 -5.6883209 0.001996 0.0213908 1.027363 
TNC -5.3218874 0.001996 0.0213908 1.0410567 RCAN3 -5.6923149 0.001996 0.0213908 1.0057244 
C20orf194 -5.3248367 0.001996 0.0213908 1.0114502 DOPEY2 -5.712081 0.001996 0.0213908 1.0178907 
ZNF638 -5.3304555 0.001996 0.0213908 1.0073891 GUSBP11 -5.7148005 0.001996 0.0213908 1.006042 
HBP1 -5.3654116 0.001996 0.0213908 1.0118801 RCBTB2 -5.7166644 0.001996 0.0213908 1.0112435 
PQLC3 -5.3750308 0.001996 0.0213908 1.0069816 DKFZP686I15217 -5.7266578 0.001996 0.0213908 1.0109473 
N4BP2L2 -5.3784205 0.001996 0.0213908 1.0033527 PMP22 -5.7390459 0.001996 0.0213908 1.0240351 
APBB1 -5.3787165 0.001996 0.0213908 1.0057237 SUPT7L -5.7483588 0.001996 0.0213908 1.0072957 
 
213 
 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
Gene 
Symbol Score Feature P FDR (BH) 
Fold 
Change 
CRYZL1 -5.7583099 0.001996 0.0213908 1.0125772 LTA4H -6.2096408 0.001996 0.0213908 1.0023755 
SLC16A9 -5.7621406 0.001996 0.0213908 1.0073555 C22orf40 -6.2188435 0.001996 0.0213908 1.0136813 
RPP25L -5.7762057 0.001996 0.0213908 1.0069534 OGDHL -6.2435582 0.001996 0.0213908 1.0103209 
IL23A -5.778009 0.001996 0.0213908 1.0298833 NAGK -6.2567458 0.001996 0.0213908 1.0139553 
DMRT3 -5.7821332 0.001996 0.0213908 1.0094458 ENPP5 -6.2573689 0.001996 0.0213908 1.0117057 
NECAP2 -5.7999738 0.001996 0.0213908 1.0058794 CLEC6A -6.277395 0.001996 0.0213908 1.0310508 
ADAMTS6 -5.8024918 0.001996 0.0213908 1.0263552 DUSP10 -6.2847652 0.001996 0.0213908 1.0323026 
SLC10A7 -5.8082535 0.001996 0.0213908 1.0166965 EPG5 -6.2869049 0.001996 0.0213908 1.0125229 
RETSAT -5.8177157 0.001996 0.0213908 1.0074847 TEP1 -6.2968136 0.001996 0.0213908 1.0233379 
LDB2 -5.8303147 0.001996 0.0213908 1.0204909 GBF1 -6.2977325 0.001996 0.0213908 1.00527 
GABBR1 -5.8486527 0.001996 0.0213908 1.0076366 TTLL1 -6.3107859 0.001996 0.0213908 1.0133646 
ZBTB26 -5.8502179 0.001996 0.0213908 1.0168768 LEPREL1 -6.3152329 0.001996 0.0213908 1.0288409 
DOCK8 -5.8512302 0.001996 0.0213908 1.0172222 PINK1 -6.3207651 0.001996 0.0213908 1.0329763 
TSPAN5 -5.8590589 0.001996 0.0213908 1.0081435 KIAA1107 -6.321009 0.001996 0.0213908 1.0399074 
MIXL1 -5.8740661 0.001996 0.0213908 1.1246946 IGSF1 -6.32877 0.001996 0.0213908 1.0098029 
POLL -5.899571 0.001996 0.0213908 1.0162974 SGK494 -6.341087 0.001996 0.0213908 1.0124155 
C15orf57 -5.9465688 0.001996 0.0213908 1.008121 PCSK9 -6.3530142 0.001996 0.0213908 1.0098845 
NBPF10 -5.9515782 0.001996 0.0213908 1.0050467 ATXN1 -6.355711 0.001996 0.0213908 1.0267574 
CDNF -5.964275 0.001996 0.0213908 1.0257097 PARP12 -6.3695905 0.001996 0.0213908 1.0206462 
CMKLR1 -5.9647618 0.001996 0.0213908 1.0543557 BBS10 -6.3787513 0.001996 0.0213908 1.0238258 
SYNE1 -5.9656972 0.001996 0.0213908 1.010136 SLC22A15 -6.397113 0.001996 0.0213908 1.0225883 
PTGR2 -5.9665455 0.001996 0.0213908 1.0108443 LSMD1 -6.4034304 0.001996 0.0213908 1.011214 
TLN2 -5.968371 0.001996 0.0213908 1.013012 SEMA4G -6.4208372 0.001996 0.0213908 1.0111831 
COL6A1 -5.968718 0.001996 0.0213908 1.0145212 RAB19 -6.4599269 0.001996 0.0213908 1.0073259 
CYP4V2 -5.9994252 0.001996 0.0213908 1.0325584 CCDC14 -6.4738275 0.001996 0.0213908 1.0078323 
DDIT4 -6.0046819 0.001996 0.0213908 1.0304614 TROAP -6.50564 0.001996 0.0213908 1.0104448 
PTPN18 -6.0046891 0.001996 0.0213908 1.0068963 
ZNRD1-
AS1 -6.5200957 0.001996 0.0213908 1.0318545 
PGM1 -6.0107409 0.001996 0.0213908 1.0121444 HELZ -6.5263434 0.001996 0.0213908 1.0040928 
VPS26B -6.0209142 0.001996 0.0213908 1.0057304 KLHL24 -6.5270657 0.001996 0.0213908 1.0097981 
MAML2 -6.0232128 0.001996 0.0213908 1.013374 SNX9 -6.5370678 0.001996 0.0213908 1.0083389 
WDFY3 -6.036662 0.001996 0.0213908 1.0056093 FTO -6.5630217 0.001996 0.0213908 1.0048053 
AP4M1 -6.0437991 0.001996 0.0213908 1.0059149 NLRX1 -6.5693373 0.001996 0.0213908 1.0155203 
SNRNP200 -6.053102 0.001996 0.0213908 1.0034278 SLC9A9 -6.5713641 0.001996 0.0213908 1.0915002 
HDAC6 -6.0547109 0.001996 0.0213908 1.0111765 TP53BP1 -6.58435 0.001996 0.0213908 1.0073387 
EYA1 -6.0575135 0.001996 0.0213908 1.0178322 PPOX -6.6038875 0.001996 0.0213908 1.0177472 
OXSM -6.0580489 0.001996 0.0213908 1.0245953 KLHL9 -6.6112099 0.001996 0.0213908 1.0103998 
PRKAG1 -6.0584701 0.001996 0.0213908 1.0078941 PMS2P4 -6.6133854 0.001996 0.0213908 1.0058011 
MARCH3 -6.059689 0.001996 0.0213908 1.0097099 NBPF8 -6.6180398 0.001996 0.0213908 1.0052526 
ALS2CR8 -6.0723321 0.001996 0.0213908 1.0423831 ENOSF1 -6.6208283 0.001996 0.0213908 1.0147079 
ASCC1 -6.0819753 0.001996 0.0213908 1.0054338 GSDMD -6.6318657 0.001996 0.0213908 1.0039931 
CYP2C8 -6.0844083 0.001996 0.0213908 1.0379163 SEC31B -6.6417835 0.001996 0.0213908 1.0171753 
FBP1 -6.0863872 0.001996 0.0213908 1.0191153 BBS1 -6.654126 0.001996 0.0213908 1.0038918 
MALAT1 -6.0878125 0.001996 0.0213908 1.005487 TRIM52 -6.6953697 0.001996 0.0213908 1.0091708 
PMS2P6 -6.0998912 0.001996 0.0213908 1.0082616 NCAPD2 -6.7033504 0.001996 0.0213908 1.0044218 
OR51T1 -6.110794 0.001996 0.0213908 1.0224434 COL6A2 -6.7221847 0.001996 0.0213908 1.0102154 
CCNG2 -6.1284131 0.001996 0.0213908 1.0154356 FGF10 -6.7357912 0.001996 0.0213908 1.0220856 
CTSL1 -6.1407509 0.001996 0.0213908 1.0096872 CPT1A -6.7445011 0.001996 0.0213908 1.0461119 
LPAR1 -6.1717765 0.001996 0.0213908 1.0185823 TBCK -6.7596295 0.001996 0.0213908 1.0116935 
PMS2P5 -6.1829235 0.001996 0.0213908 1.0074686 RNF14 -6.7640311 0.001996 0.0213908 1.0136365 
MSH5 -6.1946535 0.001996 0.0213908 1.0226191 CTC1 -6.8026302 0.001996 0.0213908 1.0110192 
 
214 
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Symbol Score Feature P FDR (BH) 
Fold 
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Symbol Score Feature P FDR (BH) 
Fold 
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ZNF780A -6.8203534 0.001996 0.0213908 1.0198257 PCDHGC5 -7.60633 0.001996 0.0213908 1.0135791 
LRRK2 -6.8251211 0.001996 0.0213908 1.0120889 RTKN -7.6406832 0.001996 0.0213908 1.010845 
BTBD8 -6.8379752 0.001996 0.0213908 1.039614 PAAF1 -7.704145 0.001996 0.0213908 1.0212825 
RGL2 -6.8467386 0.001996 0.0213908 1.006915 OR5BB1P -7.7092229 0.001996 0.0213908 1.0133493 
H1FX -6.8717564 0.001996 0.0213908 1.0066605 ELP4 -7.7127593 0.001996 0.0213908 1.0072173 
CPNE1 -6.8789632 0.001996 0.0213908 1.0065941 GNAL -7.7147281 0.001996 0.0213908 1.0144457 
ATXN7L3B -6.8805017 0.001996 0.0213908 1.0078618 PLAG1 -7.7226229 0.001996 0.0213908 1.0134185 
TTC14 -6.894903 0.001996 0.0213908 1.0104663 ASB11 -7.7337011 0.001996 0.0213908 1.0050931 
ZSCAN30 -6.9036443 0.001996 0.0213908 1.0286459 N6AMT1 -7.760891 0.001996 0.0213908 1.0141682 
MKS1 -6.904772 0.001996 0.0213908 1.0118545 BEX4 -7.780978 0.001996 0.0213908 1.0094665 
DPAGT1 -6.9067276 0.001996 0.0213908 1.0042365 PDZD2 -7.7910886 0.001996 0.0213908 1.0125668 
GTF3C3 -6.9201383 0.001996 0.0213908 1.0076056 UBE3B -7.7999708 0.001996 0.0213908 1.0140684 
KDM5D -6.9364615 0.001996 0.0213908 1.011044 HSPA1L -7.8002439 0.001996 0.0213908 1.0202218 
DTNBP1 -6.9393123 0.001996 0.0213908 1.0073761 TRMT1L -7.8203208 0.001996 0.0213908 1.0118037 
MBNL3 -6.9482239 0.001996 0.0213908 1.0330621 FAM47C -7.830081 0.001996 0.0213908 1.0084473 
NARFL -6.9710759 0.001996 0.0213908 1.008163 SMARCA2 -7.8654215 0.001996 0.0213908 1.030897 
ZNF738 -6.9815044 0.001996 0.0213908 1.0116053 CNOT3 -7.8675605 0.001996 0.0213908 1.0014691 
ATP6V0D1 -6.9975344 0.001996 0.0213908 1.007703 FBXW4 -7.8678944 0.001996 0.0213908 1.0158653 
OR2T8 -7.0279945 0.001996 0.0213908 1.0219167 VPS11 -7.875959 0.001996 0.0213908 1.0085609 
CAMKK2 -7.0388473 0.001996 0.0213908 1.0105632 PRSS3P2 -7.8833193 0.001996 0.0213908 1.0374144 
APOBEC3D -7.0581189 0.001996 0.0213908 1.021927 ENTPD5 -7.8852634 0.001996 0.0213908 1.0140382 
KLHDC9 -7.063413 0.001996 0.0213908 1.0173316 SLC16A13 -7.8919061 0.001996 0.0213908 1.025727 
PREX1 -7.1037629 0.001996 0.0213908 1.0283352 CAPRIN2 -7.9082943 0.001996 0.0213908 1.0165459 
PTGR1 -7.1192104 0.001996 0.0213908 1.0106408 LMO1 -7.9100107 0.001996 0.0213908 1.0253746 
SLC25A35 -7.1308651 0.001996 0.0213908 1.0166699 C20orf94 -7.9270821 0.001996 0.0213908 1.0108004 
NCR1 -7.1381442 0.001996 0.0213908 1.0108386 
PPT2-
EGFL8 -7.9337182 0.001996 0.0213908 1.007765 
TIAM1 -7.1588596 0.001996 0.0213908 1.0090368 PLA2G16 -7.9615979 0.001996 0.0213908 1.0088071 
APBB3 -7.1624921 0.001996 0.0213908 1.0196872 SLC16A12 -7.9810232 0.001996 0.0213908 1.0512863 
SRGAP1 -7.2323208 0.001996 0.0213908 1.0141602 PAFAH2 -7.9851788 0.001996 0.0213908 1.0152099 
MGST2 -7.2508129 0.001996 0.0213908 1.0366003 ZNF827 -7.9936053 0.001996 0.0213908 1.0140477 
CXorf22 -7.2911331 0.001996 0.0213908 1.0423064 FOXP4 -8.0965315 0.001996 0.0213908 1.0077353 
PMS2L2 -7.2935853 0.001996 0.0213908 1.0076842 NBPF1 -8.0993942 0.001996 0.0213908 1.0052265 
MED12 -7.3179864 0.001996 0.0213908 1.0119546 CHTF8 -8.1109178 0.001996 0.0213908 1.0082099 
TDRKH -7.3208918 0.001996 0.0213908 1.0069643 ITSN2 -8.1400592 0.001996 0.0213908 1.0084864 
AB067525 -7.3303437 0.001996 0.0213908 1.0072393 ZSWIM5 -8.1827985 0.001996 0.0213908 1.0137577 
SV2A -7.3455087 0.001996 0.0213908 1.0053008 C1orf56 -8.2110879 0.001996 0.0213908 1.011313 
CYP2B7P1 -7.3670052 0.001996 0.0213908 1.014175 DDX26B -8.2123131 0.001996 0.0213908 1.0143506 
C5orf54 -7.4146723 0.001996 0.0213908 1.0298981 GAD1 -8.2337551 0.001996 0.0213908 1.0848196 
TUBB2B -7.4150767 0.001996 0.0213908 1.0065717 MDM4 -8.2997959 0.001996 0.0213908 1.011044 
CST1 -7.4175501 0.001996 0.0213908 1.1314613 GPRASP1 -8.3228972 0.001996 0.0213908 1.0183566 
STRADA -7.426592 0.001996 0.0213908 1.0121332 COMMD7 -8.3433356 0.001996 0.0213908 1.011247 
ATF6B -7.4366202 0.001996 0.0213908 1.0100357 FBXO25 -8.3956263 0.001996 0.0213908 1.0147133 
ZMAT1 -7.4411535 0.001996 0.0213908 1.0465816 MARCH11 -8.4016406 0.001996 0.0213908 1.0119423 
HSDL1 -7.4522162 0.001996 0.0213908 1.0048042 CXorf24 -8.4119368 0.001996 0.0213908 1.0132279 
KCNT2 -7.4795759 0.001996 0.0213908 1.0105633 ADCK1 -8.4682679 0.001996 0.0213908 1.0119605 
KIF6 -7.5191915 0.001996 0.0213908 1.0175677 TIGD4 -8.4707371 0.001996 0.0213908 1.0175841 
NCSTN -7.5210694 0.001996 0.0213908 1.0087905 ZNF608 -8.473945 0.001996 0.0213908 1.0138703 
KLF10 -7.532847 0.001996 0.0213908 1.0136684 HERC3 -8.5316734 0.001996 0.0213908 1.0222669 
RALYL -7.5503483 0.001996 0.0213908 1.0384504 SRSF7 -8.5384209 0.001996 0.0213908 1.0040691 
AFF1 -7.6042106 0.001996 0.0213908 1.0053923 CNPY4 -8.5457915 0.001996 0.0213908 1.0151007 
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IQGAP3 -8.5855723 0.001996 0.0213908 1.0163604 
C11orf71 -8.603748 0.001996 0.0213908 1.0264958 
FAM100B -8.6802277 0.001996 0.0213908 1.0151502 
PPAPDC1B -8.6882102 0.001996 0.0213908 1.0078017 
ZNF70 -8.7305134 0.001996 0.0213908 1.0140972 
DTX3L -8.7426248 0.001996 0.0213908 1.02818 
MSH5-SAPCD1 -8.7523786 0.001996 0.0213908 1.0176554 
HERC2P2 -8.8056669 0.001996 0.0213908 1.0088492 
INTS3 -8.8665774 0.001996 0.0213908 1.0053616 
CLVS2 -8.8750339 0.001996 0.0213908 1.036194 
BRD8 -8.8859292 0.001996 0.0213908 1.007403 
TMX4 -8.8912818 0.001996 0.0213908 1.0019127 
PARP15 -8.9081506 0.001996 0.0213908 1.0239857 
RABGGTA -8.9672209 0.001996 0.0213908 1.0047702 
TCP11L2 -9.0927091 0.001996 0.0213908 1.0558479 
DRD1 -9.1245135 0.001996 0.0213908 1.0344994 
VPS36 -9.1479002 0.001996 0.0213908 1.0120461 
RAB7L1 -9.1546481 0.001996 0.0213908 1.0149167 
LMBR1L -9.1766946 0.001996 0.0213908 1.011401 
ARHGEF2 -9.2464331 0.001996 0.0213908 1.0116702 
C21orf59 -9.3698631 0.001996 0.0213908 1.0026706 
MTL5 -9.379902 0.001996 0.0213908 1.0174982 
TTLL4 -9.3944922 0.001996 0.0213908 1.0016988 
MUC3B -9.4368042 0.001996 0.0213908 1.0131157 
KLF8 -9.4489356 0.001996 0.0213908 1.0155101 
ANKRD20A11P -9.481308 0.001996 0.0213908 1.0236418 
CALCOCO1 -9.5782684 0.001996 0.0213908 1.0112989 
BNIP3 -9.6010714 0.001996 0.0213908 1.0200455 
VPS52 -9.7167898 0.001996 0.0213908 1.0089596 
DNAJC28 -9.7592289 0.001996 0.0213908 1.0308906 
SLC38A7 -9.8729415 0.001996 0.0213908 1.0083526 
SLC16A14 -9.9345222 0.001996 0.0213908 1.0272934 
FAM122C -10.187996 0.001996 0.0213908 1.0357442 
LINC00526 -10.213373 0.001996 0.0213908 1.0086617 
STAT2 -10.547114 0.001996 0.0213908 1.0206233 
CCDC50 -10.891381 0.001996 0.0213908 1.0116598 
HEMK1 -11.066724 0.001996 0.0213908 1.0162138 
CXCR7 -11.251905 0.001996 0.0213908 1.0320491 
ARRDC3 -11.506191 0.001996 0.0213908 1.0467913 
WDSUB1 -11.518339 0.001996 0.0213908 1.0193503 
TUG1 -11.786437 0.001996 0.0213908 1.0029582 
SURF1 -11.90916 0.001996 0.0213908 1.005738 
ORAI3 -11.974893 0.001996 0.0213908 1.0160472 
MCCC1 -12.552318 0.001996 0.0213908 1.0081205 
NEK8 -13.070066 0.001996 0.0213908 1.0092931 
KIAA0895 -13.277734 0.001996 0.0213908 1.0256696 
CRTC3 -13.495518 0.001996 0.0213908 1.0219474 
PNPO -14.319965 0.001996 0.0213908 1.0168687 
GALT -14.383633 0.001996 0.0213908 1.0107884 
LIN7A -14.743146 0.001996 0.0213908 1.016246 
NSUN3 -15.969391 0.001996 0.0213908 1.010991 
CCDC122 -17.135958 0.001996 0.0213908 1.0196309 
APOBEC3F -19.348266 0.001996 0.0213908 1.0393252 
 
